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Abstract 
Atrial fibrillation (AF) affects 2-3% of the European and North-American population, 
whereas ventricular tachyarrhythmia (VT) is related to an important risk of sudden death. AF 
and VT originate from dysfunctional electrical activity in cardiac tissues and can be treated 
with drug therapy, tissue ablation or a combination of both. Minimally-invasive approaches 
such as Radio-Frequency Catheter Ablation (RFCA) have revolutionized the treatment of 
these diseases; however the success rate of RFCA is currently limited by the lack of 
monitoring techniques to precisely control the extent of thermally ablated tissue. 
The aim of this thesis is to propose novel ultrasound-based approaches for minimally 
invasive cardiac ablation under guidance of ultrasound imaging: a dual-mode imaging/therapy 
intracardiac approach, and a second approach based on transesophageal ultrasound-guided-
High-Intensity-Focused-Ultrasound (USgHIFU) through a collaboration with LabTau (Inserm 
U1032).  
In this thesis, we first validated the accuracy and clinical viability of Shear-Wave 
Elastography (SWE) as a real-time quantitative imaging modality for thermal ablation 
monitoring in vivo. An excellent sensitivity to detect the change of stiffness during the lesion 
formation was demonstrated during radiofrequency ablation of the liver on a large animal 
model. Second we implemented SWE on an intracardiac transducer and validated the 
feasibility of evaluating thermal ablation in vitro and in vivo on beating hearts of a large 
animal model. Myocardial stiffness maps were performed after RFCA demonstrating the 
sensitivity of intracardiac SWE to detect thermal lesions in the atrium and the ventricles. Two 
novel imaging techniques were also developed and assessed on cardiac tissues: ultrafast 
Doppler imaging to detect small vessels and ultrafast acoustoelectric imaging to map acousto-
electrical properties of cardiac tissues. Third a dual mode intracardiac transducer was 
developed to perform both ultrasound therapy and imaging with the same elements, on the 
same device. SWE-controlled HIFU thermal lesions were successfully performed in vivo in 
the atria as well as in the ventricles of a large animal model. At last, SWE was implemented 
on a transesophageal ultrasound imaging and therapy device and the feasibility of 
transesophagial approach was demonstrated in vitro and in vivo. These novel approaches may 
lead to new clinical devices for a safer and controlled treatment of a wide variety of cardiac 
arrhythmias and diseases. 
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Résumé de la thèse 
Chapitre 1 : Introduction 
Les troubles du rythme cardiaque sont associés à des risques pour la santé à court et à 
long terme. La fibrillation atriale (AF), l’arythmie la plus fréquente, qui affecte 2-3% de la 
population européenne et nord-américaine1, est associée à un risque accru 5 fois d’avoir un 
accident vasculaire-cérébral, à une incidence d’insuffisance cardiaque de 40% 2, 3 et en 
général à un taux de mortalité doublé 4, 5. L’AF est causée par une activité électrique 
dysfonctionnelle qui survient autour des veines pulmonaires 6 ou dans les oreillettes 7. Les 
tachycardies ventriculaires (VT) sont liées à un risque important de mort subite 2. Les VT 
peuvent prendre origine dans des circuits de réentrées électriques autour de cicatrices du 
myocarde ou des points d’activation précoce dans le muscle ventriculaire 8. Alors que les VT 
nécessitent souvent d’implanter un défibrillateur automatique implantable, l’AF et les VT 
peuvent être traitées avec des médicaments, de l’ablation tissulaire ou une combinaison des 
deux. 
Les approches minimalement invasives comme l’Ablation par Cathéter 
Radiofréquence (RFCA) ont révolutionné le traitement de l’AF et représentent une nouvelle 
possibilité pour les traitements des VT. La RFCA consiste à isoler les sources de réentrées 
communes 6, 9 ou des foyers locaux 10, 11 par le biais d’une coagulation thermique des tissus 
réalisée avec un cathéter radiofréquence (RF) intracardiaque. Cependant, malgré l’utilisation 
de différentes techniques de guidage et d’imagerie, la RFCA souffre du manque d’une 
imagerie de suivi d’ablation précise pour évaluer la transmuralité des lésions thermiques 8, 12 
qui constitue un aspect crucial pour l’efficacité des procédures d’ablation 13. En effet, le dépôt 
de chaleur réel et donc l’extension de la lésion dans les tissus sont difficiles à évaluer. En 
conséquence le taux de réussite des procédures uniques de la RFCA reste relativement faible 
(~60%) pour tous les types d’AF 14. Une autre limite importante de la RFCA est la difficulté 
de créer des lésions transmurales ou à mi-paroi dans les ventricules. En conséquence une 
ablation additionnelle à l’épicarde 8, 15 est parfois nécessaire. Pour cette raison la RFCA n’est 
pas parfaitement adaptée pour l’ablation des VT et un taux de réussite limité de 35% est 
rapporté dans la littérature 15. 
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 Le but de cette thèse est de proposer de nouvelles approches ultrasonores pour des 
traitements cardiaques minimalement invasifs guidés par échographie : une approche dual-
mode de thérapie et imagerie intracardiaque et une deuxième, basée sur les Ultrasons 
Focalisés à Haute Intensité (HIFU) guidés par ultrasons, par voie transœsophagienne au 
travers d’une collaboration avec le laboratoire LabTau (INSERM U1032). 
Pour cela nous avons d’abord validé la précision et la viabilité clinique de 
l’Élastographie par Ondes de Cisaillement (SWE) en tant que modalité d’imagerie 
quantitative et temps réel pour l’ablation thermique in vivo. Ensuite nous avons implémenté la 
SWE sur un transducteur intracardiaque et validé la faisabilité d’évaluer l’ablation thermique 
in vitro et in vivo sur cœur battant de gros animal. La possibilité d’imager la vascularisation 
cardiaque aussi été étudiée, grâce à l’imagerie Doppler ultrarapide. Puis nous avons 
développé un transducteur intracardiaque dual-mode pour effectuer l’ablation et l’imagerie 
ultrasonores avec les mêmes éléments, sur le même dispositif. Les lésions thermiques induites 
par HIFU et contrôlées par la SWE ont été réalisées avec succès in vivo dans les oreillettes et 
les ventricules chez le gros animal. Enfin la SWE a été implémentée sur un dispositif 
d’imagerie et thérapie ultrasonores transœsophagien et la faisabilité de cette approche a été 
démontrée in vitro et in vivo. Pour finir, la perspective d’une imagerie acoustoélectrique 
ultrarapide est aussi étudiée. 
Chapitre 2 : Suivi temps-réel de l’ablation thermique par Élastographie par 
Ondes de Cisaillement 
Introduction  
L’intérêt pour l’ablation thermique est grandissant ces dernières années, en particulier 
dans le domaine du traitement des tumeurs 16, 17. Les techniques d’ablation thermique 
minimalement invasives comme la radiofréquence ou l’ablation par HIFU 18, présentent de 
nombreux avantages par rapport à la chirurgie classique. Dans certains cas l’ablation 
thermique est devenue une alternative standard à la chirurgie19–21. 
Dans ce chapitre nous nous concentrons sur le cas spécifique du traitement par 
ablation thermique dans le foie. Dans cet organe la sécurité et l’efficacité des thérapies 
thermiques, en particulier la radiofréquence, ont été largement étudiées 22 et d’importants taux 
de récidive tumorales ont été signalées 23. Parmi les causes les plus importantes de 
 8
l’inefficacité d’ablation se trouve l’incapacité à contrôler précisément l’extension de 
l’ablation 24. 
Il existe un besoin considérable pour une technique d’imagerie de suivi pour 
l’ablation. Actuellement le gold-standard pour un suivi non-invasif à l’aide de l’imagerie de 
température est l’imagerie par résonance magnétique (MRI). Cependant le MRI est associé 
avec plusieurs obstacles techniques (compatibilité des matériaux, espace limité pour 
l’intervention) et est coûteux. De plus la résolution temporelle est limitée et des mouvements 
rapides détériorent fortement les images. 
Les effets induits thermiquement peuvent être quantifies par les changements des 
propriétés élastiques des tissus. Il a été montré que la cartographie quantitative de l’élasticité 
est d’une importance majeure car la dureté des tissus pendant la coagulation est directement 
liée à la dose thermique 25. L’Élastographie par Ondes de Cisaillement 26 permet de fournir 
une visualisation objective, opérateur indépendante, des lésions thermiques 27, 28 en donnant le 
module d’Young local des tissus. De plus, grâce à l’imagerie ultrarapide par ondes planes, 
elle est peu affectée par les mouvements naturels présents in-vivo. À notre connaissance c’est 
la seule imagerie temps-réel pouvant satisfaire ces conditions. 
Afin d’évaluer la faisabilité et la précision d’un suivi quantitatif de l’élasticité pendant 
les thérapies thermiques et pour déterminer le seuil de dureté qui prédirait la formation d’une 
nécrose par coagulation, nous avons mené une étude préclinique in-vivo dans laquelle la SWE 
a été utilisée pour cartographier les nécroses par coagulation induites thermiquement 
produites dans les foies de proc avec les systèmes de RFA et de HIFU. 
Matériel et Méthodes 
Au total quarante (n=36; n= 26 par RFA and n= 10 par HIFU) lésions thermiques ont 
été effectuées dans les foies de huit (n=8; RFA: n=5 et HIFU: n=3) porcs en utilisant une 
approche par chirurgie ouverte. Deux systèmes fixes d’ablation ont été utilisés, avec 
l’imagerie avec la thérapie parfaitement alignées. 
Pour la RFA, deux électrodes ont été insérées dans le foie sous guidage par ultrasons 
et la nécrose par coagulation était produite par un système bipolaire radiofréquence connecté à 
un générateur électrochirurgical. La lésion thermique était créée 1.5-2.5 cm sous la surface du 
foie en environ 5min. 
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La thérapie par HIFU était effectuée avec un mono-élément par une procédure point 
par point. Les ultrasons étaient appliqués 20s à chaque point à raison de 9 à 20 points espacés 
de 1 à 2mm selon un motif rectangulaire, 20-30mm sous la surface du foie du point de vue du 
plan d’imagerie. 
Les images de SWE et B-mode étaient acquises avec un échographe ultrarapide 
(Aixplorer, SuperSonic Imagine, France) en utilisant deux sondes linéaires. Les images 
étaient prises avant, pendant et après la procédure d’ablation. Après la procédure le foie était 
excisé et une analyse macro de chaque lésion était effectuée en profondeur à la même position 
et orientation que celle des images. 
Les images de lésions sur les photos macros étaient automatiquement segmentées en 
utilisant le changement de couleur du à la nécrose. Les cartes d’élasticité étaient segmentées 
en utilisant des seuils de module d’Young progressifs. La justesse des cartes d’élasticité de 
lésions RF était estimée en termes de vrai positif (TP), faux positif (FP) et faux négatif (FN) 
par superposition avec les photos macro. Les cartes de lésions par HIFU étaient estimées en 
comparant les surfaces trouvées avec les deux techniques. 
Résultats 
Les 26 régions des lésions thermiques induites par RFA et les 10 par HIFU ont eu une 
élasticité moyenne de  6.4 ± 0.3 kPa (RFA) et 7.5 ± 1.2 kPa (HIFU) avant la chauffe et une 
élasticité moyenne de 38.1 ± 2.5 kPa (RFA, p<0.0001) et 26.6 ± 4.7 kPa (HIFU, p<0.0001) 
après la procédure qui a induit la nécrose par coagulation. 
Au-dessus de 30 kPa la valeur prédictive positive (PPV) était au-dessus de 0.93 mais 
était associée à une faible sensibilité (Se) de 0.5. 20 kPa donnent le meilleur compromis entre 
la Se et la PPV  (0.8 and 0.83, respectivement). 
Pour les lésions induites par HIFU, le meilleur seuil du module d’Young a été de 
21kPa, ce qui est en accord avec la RFA. La surface d’ablation estimée sur les cartes 
d’élasticité était très proche des surfaces trouvées par macro (RFA: 0.022 ± 0.22 cm2 pour 
biais ± déviation standard; HIFU : 0.086 ± 0.20 cm2) avec un intervalle de confiance entre -
0.413 cm2 et +0.459 cm2 (RFA) and -0.483 cm2 and +0.310 cm2 comparé avec la surface 
moyenne des lésions (RFA: 0.751 cm2; HIFU : 0.382 cm2). 
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Conclusion 
Dans cette étude nous avons démontré que l’Élastographie par Ondes de Cisaillement 
quantitative est capable de suivre en temps-réel l’ablation thermique in-vivo avec un fort 
contraste et une cartographie précise. La dureté quantifiée par la SWE était 2 à 6-8 fois plus 
grande (dans le cœur de la lésion) que dans les tissus sains environnants. Un seuil de dureté 
déterminé avec précision pourrait aider à visualiser les bords des lésions thermiques créées. 
En effet, en utilisant un seuil de d’élasticité de 20 kPa (deux fois plus grand que l’élasticité de 
base), nous avons pu prédire la nécrose avec une valeur prédictive positive de 0.83 et une 
sensibilité de 0.8. Le seuil très proche trouvé pour le HIFU a pu confirmer la robustesse de ce 
résultat. Nous pensons que ce travail peut constituer une base solide pour pousser le suivi 
d’ablation thermique par SWE plus loin. 
Chapitre 3: Imagerie intracardiaque ultrasonore ultrarapide pour 
l’évaluation de l’ablation thermique 
Introduction 
Dans ce chapitre nous avons développé une approche intracardiaque d’imagerie 
ultrarapide pour l’évaluation de la thérapie par ablation thermique. Ce développement répond 
à un besoin clinique spécifique : le manque de contrôle et de suivi par imagerie des thérapies 
thermiques dans le cœur et plus spécifiquement dans le contexte de la RFCA. Le principal 
défi de l’imagerie intracardiaque consiste en la miniaturisation d’un transducteur d’imagerie 
pour pouvoir l’insérer dans les chambres cardiaque à travers le système veineux. Cette 
approche est déjà largement répandue dans les centres d'électrophysiologie 12. L’objectif 
précis de ce travail a été de développer des outils d’imagerie originaux pour l’évaluation du 
traitement par RFCA. Pour atteindre cet objectif deux nouvelles modalités d’imagerie ont été 
testées et implémentées sur un transducteur d’imagerie ultrasonore intracardiaque : 
l’Élastographie par Ondes de Cisaillement (SWE) et le Doppler ultrarapide. Ce chapitre 
présente la faisabilité in-vitro et in-vivo de l’évaluation par la SWE de la dureté du myocarde 
pendant la RFCA ainsi que, pour la première fois, de la variation temporelle de la dureté des 
oreillettes dans un  modèle in-vivo normal. Enfin nous présentons des résultats préliminaires 
du Doppler ultrarapide intracardiaque pour cartographier la micro-vascularisation du 
myocarde. 
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SWE : Matériel et méthodes 
Un échographe ultrarapide (Aixplorer®, SuperSonic Imagine, France) a été utilisé 
pour exécuter les séquences de SWE avec un cathéter ultrasonore intracardiaque (6 MHz, 50-
% de bande passante, 64 éléments, 0.2-mm pitch, 9F, Vermon, France). 
La SWE a été d’abord validée dans des échantillons de ventricules porcins ex-vivo (N 
= 5). L’imagerie B-mode et la SWE ont été effectuées sur les tissus cardiaques avant et après 
la RFCA. Les surfaces des lésions ont été déterminées avec les changements de couleur des 
tissus pendant une étude marco et confrontées aux cartes de dureté données par la SWE. 
L’imagerie par SWE a été ensuite effectuée in-vivo dans trois moutons (N = 3) avec 
au total six ablations cartographiées (N = 6). L’accès au cœur a été fait par la veine fémorale 
sous fluoroscopie. D’abord la dureté des tissus auriculaires normaux a été évaluée 
quantitativement ainsi que sa variation pendant le cycle cardiaque. La SWE a été ensuite 
effectuée après la RFCA sur les mêmes tissus.  
SWE : Résultats  
Une forte augmentation de dureté a été observée dans les régions traitées ex-vivo 
(module de cisaillement moyen parmi les échantillons avant ablation : 22±5 kPa, vitesse de 
l’onde de cisaillement moyenne (ct): 4.5±0.4 m s−1 et dans les zones d’ablation après 
traitement: 99±17 kPa, ct moyenne: 9.0±0.5 m s−1 pour un ratio d’augmentation moyen de 
4.5±0.9). 
In-vivo l’extension de la lésion était clairement visible sur les cartes de dureté. Au 
centre des lésions la vitesse de l’onde de cisaillement moyenne parmi les échantillons a 
augmenté de 1.8±0.3 m.s-1 (module de cisaillement moyen : 3.3±1.0 kPa) avant ablation à 
3.1±0.3 m.s-1 (module de cisaillement moyen : 10±2 kPa) après ablation. Un ratio 
d’augmentation moyenne de la ct de 1.8±0.3 a été trouvé (ratio d’augmentation moyenne du 
module de cisaillement: 3.1±0.9). 
Parmi les échantillons une vitesse de l’onde de cisaillement moyenne de 1.4±0.2 m.s-1 
(2.3±0.7 kPa) a été mesurée sur tout le cycle cardiaque. La vitesse moyenne minimale de 
1.0±0.1 m.s-1 (1.0±0.2 kPa) a été mesurée après la décontraction auriculaire, alors que la 
vitesse moyenne maximale de 1.9±0.4 m.s-1 (4.1±1.8 kPa) a été atteinte pendant la contraction 
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auriculaire. Après l’ablation la vitesse de l’onde de cisaillement moyenne des régions ablatées 
a augmenté significativement, cependant un repère temporel dans le cycle cardiaque a été 
nécessaire pour comparer le changement de dureté avant et après ablation. 
Doppler ultrarapide 
Les acquisitions ont été effectuées pendant le même protocole, avant et après la 
RFCA. Le traitement des données était basé sur le filtrage par décomposition en valeurs 
singulières (SVD) 29, pour filtrer les sources de signal énergétiques comme le mouvement 
tissulaire et garder les sources moins énergétiques provenant de la vascularisation du cœur. 
Les données sont présentées sous forme de Doppler Puissance, dans les ventricules, et ont été 
acquises pendant la diastole quand le flux coronarien est le plus important. 
Des coronaires perpendiculaires et parallèles au plan d’imagerie ont été détectées dans 
le septum interventriculaire. Des résultats préliminaires mais prometteurs sont montrés. 
Conclusion 
Par ses capacités quantitatives et temps-réel, la SWE intracardiaque est une technique 
d’imagerie intra opérative prometteuse pour l’évaluation de l’ablation thermique pendant la 
RFCA. L’utilisation d’une barrette d’imagerie à l’intérieur du cœur, avec un scanner 
ultrarapide, donne l’accès à des modalités d’imagerie nouvelles et très intéressantes. 
Chapitre 4: Approche intracardiaque de thérapie et imagerie dual-mode  
Introduction 
Dans ce chapitre une approche intracardiaque originale est proposée pour les 
traitements d’ablation cardiaque, basée sur la combinaison de la thérapie et imagerie par 
ultrasons sur un même dispositif intracardiaque dual-mode. Ce travail a été motivé par 
plusieurs raisons. Premièrement, les résultats d’imagerie intracardiaque obtenus dans le 
chapitre 3 sont prometteurs pour cartographier les lésions induites par RFCA, cependant la 
séparation de la thérapie et de l’imagerie sur deux systèmes nécessite l’usage de multiples 
cathéters et de systèmes de navigation complexes. Deuxièmement la thérapie par HIFU 
présente de nombreux avantages potentiels par rapport à la RFCA, qui pourraient bénéficier à 
l’ablation cardiaque, surtout dans le contexte des tachycardies ventriculaires (VT). 
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Dans ce travail, d’abord, un nouveau transducteur intracardiaque dual-mode a été 
conçu en collaboration avec Vermon (Tours, France). Nous avons caractérisé l’intensité en 
émission en parallèle avec la chauffe interne de la sonde pour plusieurs paramètres 
d’émission. Ensuite nous avons validé in-vitro les séquences de HIFU optimales adaptées à 
notre système, avec des conditions mimant celles du cœur. Enfin nous avons effectué une 
étude de faisabilité in-vivo pour le cathéter dual-mode dans quatre moutons (N = 4), avec une 
installation intracardiaque classique, et nous avons réalisé des ablations guidées par imagerie 
dans les oreillettes droites, les ventricules droits et les septums interventriculaires (IVS). 
Matériel et méthodes 
Le transducteur dual-mode est basé sur un cathéter d’échocardiographie intracardiaque 
standard (voir Chapitre 3) et a été modifié par Vermon pour supporter les émissions HIFU. Il 
est commandé par une électronique prototype programmable, constituée d’un échographe 
ultrarapide (Aixplorer®, SuperSonic Imagine, France) pour l’imagerie et d’une alimentation 
de haute puissance. 
Premièrement, les meilleurs paramètres d’émission ont été évalués en termes de 
d’efficacité thermique, définie comme l’intensité en émission (W/cm2) divisée par la chauffe 
interne du cathéter (°C). Deuxièmement, les séquences HIFU optimales ont été testées pour 
accroître la chauffe des tissus, tout en refroidissant le cathéter seulement avec des conditions 
mimant celles du cœur (un flux d’eau de 50mL/s). 
Enfin, le HIFU a été exécuté in-vivo, sous guidage B-mode temps-réel du cathéter, 
dans les oreillettes droites (n = 6), dans les ventricules droits (n = 5) et dans le septum 
interventriculaire (n = 5) dans quatre moutons (N = 4). Parmi ces échantillons, l’évaluation 
des lésions par SWE a été effectuée dans deux moutons (N = 2, oreillette n  = 3, ventricule n = 
3, septum n = 3). Le cathéter a été inséré par la veine fémorale sous fluoroscopie. Après la 
procédure les lésions ont été marquées au TTC (2,3,5-triphenyl tetrazolium chloride) et le 
cœur était excisé pour une étude macro. 
Résultats 
La meilleure fréquence en émission s’est avérée d’être autour de 5.5MHz avec un 
signal d’excitation des éléments qui contient le moins d’harmoniques possible. Des intensités 
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jusqu’à 21.5 W/cm2 (correspondant à une puissance acoustique totale de 4.6W) ont pu être 
atteintes. 
Cinq (n = 5) lésions ont pu être obtenues avec succès dans les oreillettes. Quatre 
étaient transmurales. Les lésions avaient une longueur moyenne en grand axe de 7.5mm (4 à 
10mm). Dans les ventricules trois lésions (n = 3) ont été réalisées dans la paroi libre. Une 
lésion était transmurale, une sur l’endocarde et une sur l’épicarde, alors toutes les procédures 
ont été effectuées à partir des chambres cardiaques. Toutes ces lésions avaient une profondeur 
approximative de 4mm. Dans le septum quatre lésions (n = 4) ont été réalisées : deux du côté 
du ventricule droit et deux du côté gauche alors que le cathéter se trouvait dans le ventricule 
droit. 
Au total trois lésions (n = 3) auriculaires ont été évaluées avec succès avec la SWE, 
deux dans le ventricule droit (n = 2) et une dans le septum (n = 1). 
Conclusion 
Dans cette étude nous avons développé un nouveau système intracardiaque tout-
ultrason, capable faire de la thérapie et de l’imagerie avec la même barrette. Le dispositif est 
une adaptation directe d’un cathéter d’imagerie et le réseau multiélément qui en résulte 
permet d’effectuer une thérapie par HIFU flexible couplée avec une imagerie de haute qualité, 
qui sont parfaitement alignées. In-vivo de nombreux types de tissus cardiaques (oreillettes, 
ventricules) ont été ablatés avec succès tout en étant contrôlés avec la SWE et l’imagerie B-
mode temps-réel. 
Ce système theranostique présente de nombreux potentiels avantages par rapport à la 
RFCA pour la thérapie dans les oreillettes mais aussi dans les ventricules où la RFCA et 
d’autres modalités de thérapie par contact sont limitées. En implémentant de nouvelles 
modalités d’imagerie ce système pourrait devenir un puissant outil pour le traitement des 
arythmies cardiaques. 
Chapitre 5 : Imagerie de suivi par l’Élastographie par Ondes de 
Cisaillement transœsophagienne 
Introduction 
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Dans ce chapitre nous proposons une deuxième approche basée sur les ultrasons par 
voie transoesophagienne. Ce travail a été motivé par l’approche transoesophagienne 
développée au laboratoire LabTau (INSERM 1032). Elle consiste à utiliser un dispositif 
transoesophagien d’imagerie-thérapie développé par Constanciel et al. 30, 31. Dans ce système 
un transducteur transoesophagien conventionnel a été intégré à l’intérieur d’une sonde HIFU. 
Dans cette étude nous étudions la faisabilité d’une approche de thérapie et imagerie 
duale sur le même dispositif transoesophagien. Nous montrons in-vivo que la SWE cardiaque 
quantitative peut être effectuée avec le système et nous montrons sur des échantillons ex-vivo 
que la SWE transoesophagienne peut cartographier l’étendue des lésions HIFU. 
Matériel et méthodes 
Un endoscope d’imagerie-thérapie conçu pour le HIFU guidé par ultrasons par voie 
transoesophagienne a été utilisé dans cette étude (Vermon, Tours, France). La partie active de 
ce système est faite transducteur HIFU de 8 anneaux tirant à 3MHz et d’un réseau circulaire 
d’imagerie de 64 éléments à 5MHz pour l’échocardiographie transoesophagienne classique 
intégré en son centre. L’imagerie était effectuée avec un Aixplorer. 
Premièrement, la SWE était validée avec l’endoscope transoesophagien dans un moton 
in-vivo. La dureté d’oreillettes normales et de ventricules a été évaluée pendant le cycle 
cardiaque (n=11) et cartographiée (n=7). Deuxièmement, l’ablation par HIFU a été réalisée 
avec le dispositif d’imagerie-thérapie transoesophagienne dans des échantillons ex-vivo de 
poitrine de poulet (n=3), puis d’oreillettes (n=2) et de ventricules (n=2) de cœur de porc. La 
SWE a fourni des images de dureté des tissus avant et après ablation. Les surfaces des lésions 
ont été obtenues avec le changement de couleur des tissus à l’étude macro et ont ensuite été 
comparées à celles obtenues avec la SWE. La SWE a été effectuée avec la nouvelle imagerie 
ultrarapide par ondes divergentes 32. 
Résultats 
Pendant le cycle cardiaque la dureté a varié entre 0.5±0.1kPa et 6.0±0.3kPa dans les 
oreillettes et de 1.3±0.3kPa à 13.5±9.1kPa dans les ventricules. Il était possible de mesurer la 
dureté des tissus à tout moment du cycle cardiaque. 
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Les lésions thermiques étaient visibles sur toutes les cartes de SWE effectuées après 
ablation. Le module de cisaillement des zones traitées a augmenté jusqu’à 16.3±5.5kPa (vs. 
4.4±1.6kPa avant l’ablation) dans la poitrine de poulet, jusqu’à 30.3±10.3kPa (vs. 
12.2±4.3kPa) dans les oreillettes et jusqu’à 73.8±13.9kPa (vs. 21.2±3.3kPa) dans les 
ventricules. A l’étude macro, la surface des lésions a varié entre 0.1 et 1.5cm2 dans la région 
du plan d’imagerie. Les profondeurs et largeurs des lésions estimées par SWE a été différente 
en moyenne de 0.8±2.3mm et -0.2±3.4mm respectivement par rapport à l’étude macro. 
Conclusion 
Nous avons montré la faisabilité du suivi d’ablation thermique par HIFU en utilisant 
un dispositif transoesophagien dual de thérapie et imagerie. La combinaison du HIFU, de 
l’imagerie ultrasonore et de la SWE sur le même système transoesophagien pourrait mener à 
un nouveau dispositif clinique pour un traitement plus sûr et contrôlé d’une large variété 
d’arythmies cardiaques. 
Chapitre 6 : Autres perspectives en imagerie et conclusion générale. 
Autres perspectives : la tomographie acoustoélectrique ultrarapide 
Dans le contexte de la RFCA pour les arythmies auriculaires et ventriculaires, 
l’imagerie des courants électriques et des potentiels d’action dans le cœur sont effectués avec 
des systèmes intracardiaques mono ou multi-électrodes 12 ; de nouveaux systèmes non-
invasifs sont aussi implémentés en clinique 33. Malgré l’indéniable utilité et fonctionnalité de 
ces systèmes il n’est pas possible de cartographier la densité de courant électrique avec une 
résolution spatiale en-dessous de 5mm 34, 35, ce qui pourrait aider à d’identifier des régions 
conductrices non-ablatées ou d’autres sources de dépolarisation, qui participeraient ou 
donneraient origine aux arythmies.  
Il a récemment été montré que l’effet acoustoélectrique 36, 37 peut fournir du contraste 
directement à partir des densités de courant en mesurant l’impédance électrique modulée par 
ultrasons 38. La technique consiste à insonifier un tissu avec un faisceau d’ultrasons focalisés 
en mesurant simultanément les différences haute-fréquence des potentiels. Quand l’onde 
ultrasonore atteint une région dans laquelle le courant circule, une différence haute-fréquence 
du potentiel peut être détectée. 
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Dans ce travail, premièrement, une étude de preuve de concept expérimentale a été 
conduite dans une configuration simple, pour montrer l’interaction acoustoélectrique dans des 
solutions ioniques, en commençant par un transducteur focalisé, puis en focalisant les 
ultrasons avec une sonde d’imagerie. Cette parie souligne la faiblesse de l’imagerie 
acoustoélectrique focale, même si une solution pour augment le ratio signal-à-bruit (SNR) est 
proposée. 
Deuxièmement, nous avons développé la Tomographie Acoustoélectrique Ultrarapide 
(UAT), basée sur les émissions d’ondes planes. Les stratégies de reconstruction basées sur la 
transformée de Radon ont été conçues pour augmenter la cadence d’imagerie et fournir de 
hautes résolutions uniformes en spatial et temporel, tout en respectant les standards de la FDA 
pour les applications humaines. La validation dans des fantômes a été effectuée, montrant la 
viabilité de l’approche avec une sonde d’imagerie standard. 
En utilisant une approche intracardiaque, cette technique pourrait potentiellement 
fournir des images de courants électriques cardiaques avec une résolution submillimétrique 
inégalée, qui pourrait aider à trouver ou diagnostiquer des circuits électriques arythmogènes 
ou anormaux dans le cœur. 
Conclusion générale 
Cette thèse a été l’opportunité de prendre avantage des possibilités de plus en plus 
nombreuses que les ultrasons peuvent offrir dans le domaine de l’imagerie médicale et de la 
thérapie et de les appliquer à un besoin particulier : le traitement des arythmies cardiaques. En 
choisissant une approche tout-ultrason pour la thérapie et pour l’imagerie, nos collaborateurs 
et nous avons développé deux dispositifs interstitiels, un cathéter intracardiaque dual-mode et 
un endoscope transoesophagien de HIFU guidé par ultrasons, tous les deux adaptés à 
l’environnement cardiaque. 
Tout d’abord, nous avons validé la précision de la SWE à suivre les thérapies 
thermiques, comme la RFA ou le HIFU, in-vivo dans le foie. Les résultats obtenus sont très 
prometteurs et donnent des hautes valeurs de sensibilité et de valeur prédictive positive pour 
la détection des tissus ablatés et confirment les résultats précédents sur le lien des tissus 
coagulés thermiquement et des images d’élasticité. 
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Deuxièmement, nous avons implémenté la SWE et d’autres modalités d’imagerie sur 
un transducteur intracardiaque et avons testé le système in-vivo. En particulier nous avons 
validé la faisabilité de la SWE à pouvoir évaluer la RFCA classique dans le cœur et nous 
avons montré le potentiel d’autres imageries diagnostiques (par exemple la détection des 
coronaires par le Doppler ultrarapide).  
Troisièmement, nous avons implémenté la thérapie HIFU sur le même transducteur 
pour obtenir un système capable d’effectuer de la thérapie contrôlée par image avec le même 
réseau d’éléments. Un tel système dual-mode présente une flexibilité très intéressante pour les 
procédures d’ablation pour la fibrillation auriculaire ainsi que pour les tachycardies 
ventriculaires. Grâce aux nombreuses possibilités d’imagerie et de thérapie que ce système 
offre, ses applications pourraient être diverses dans le cœur comme dans d’autres organes.  
Enfin, nous avons participé au développement d’un second système ultrasonore dédié 
au cœur, en implémentant et validant la SWE pour l’évaluation de l’ablation par HIFU. Pour 
cela nous avons testé la SWE basée sur l’imagerie ultrarapide par ondes divergentes, 
développée précédemment, avec une sonde transoesophagienne. Nous avons montré la 
faisabilité de cartographier la dureté des tissus avec ce système in-vivo dans un cœur battant 
normal et in-vitro sur des tissus cardiaques avec des lésions induites par HIFU avec la même 
sonde. Au-delà du contrôle de l’ablation thermique, la SWE par approche transoesophagienne 
pourrait être montrée comme une modalité d’élastographie prometteuse pour les diagnoses 
cardiaques. 
Mots-clefs : Ultrasons, Imagerie médicale, Échographie, Thérapies non-invasives, 
Arythmies cardiaques, Élastographie par ondes de cisaillement, Ultrasons Focalisés à Haute 
Intensité, Suivi d’ablation thermique, Échocardiographie intracardiaque, Échocardiographie 
transœsophagienne, Imagerie de Doppler ultrarapide, Imagerie acoustoélectrique 
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Chapter 1. Introduction 
 
1 Clinical context: cardiac arrhythmias 
1.1 Cardiac anatomy 
The heart is the blood pump of the body. The function of this organ is vital; a partial 
dysfunction can immediately severely affect the whole body.  
The heart is located at the center of the chest, most of the time (during the respiratory 
cycle) ahead of the lungs. It is composed of four chambers, left and right atria and left and 
right ventricles (Figure 1-1a). The atria, anterooms of the ventricles, help filling these during 
the cardiac cycle and the final pumping effort is performed by the ventricles. The right part of 
the heart receives deoxygenated blood from the body and sends it to the lungs. The left part 
receives oxygenated blood from the lungs and sends it to whole body, the left ventricle thus 
has to provide much more effort and encounters more resistance than the right. In 
consequence its volume and thickness is more important (Figure 1-1b). 
 
Figure 1-1 : Anatomical structure of the heart. (a) Global view showing, the four cardiac 
chambers and the schematic blood circulation (blue: deoxygenated blood; red: oxygenated).  
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(b) Cross section of the heart showing the muscular thickness and anatomy of the ventricles. 
RA: right atrium; LA: left atrium; RV: right ventricle; LV: left ventricle; IVS: interventricular 
septum; PVs: pulmonary veins. (CC for b: Patrick J. Lynch, medical illustrator; C. Carl Jaffe, 
MD, cardiologist). 
The heart is a muscular, fibrous organ; the cardiac wall is composed of the inner 
endocardium, middle myocardium and the outer epicardium. The whole organ is surrounded 
by a sac called the pericardium. The cardiac cycle is composed a complete heart beat which 
covers the contraction (systole) and the relaxation (diastole). It begins on atrial systole (Figure 
1-2): first, the atrio-ventricular (AV) valves open leading to a passive ventricular filling from 
the full of blood atria, second, atria contract and propel the remaining 20-30% volume of 
blood to the ventricles. Then AV valves close and ventricular systole begins leading to an 
isovolumic contraction. Pulmonary and aortic valve opening follows and the blood is ejected 
from the heart. Finally the valves close and isovolumic relaxation begins while the atria fill 
with blood. 
 
Figure 1-2 : Diagram of principal cardiac cycle events (contraction, relaxation), confronted to 
the electrocardiogram, ventricular volume, and ventricular and atrial pressures. (adapted from: 
http://en.wikipedia.org/wiki/Cardiac_cycle#/media/File:Wiggers_Diagram.png) 
Heart rythmics are controlled with the sinoatrial node on the right atrium. This self-
contracting node is connected in turn to the atrioventricular node, which constitutes the 
electrical junction between atria and ventricles. The electrical signal is propagated then to the 
ventricles by specialized tissue called the Purkinje fibres. Finally the whole organ contracts by 
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a successive chemical signal transmission from cardiac cell to cell. Both atria then both 
ventricles contract simultaneously. As a result variations of an electrical signal, the 
electrocardiogram (ECG), can be observed during the cardiac cycle which corresponds 
exactly to the different events of the cycle. The ECG is composed of a P-wave, which 
corresponds to the atrial contraction, followed by the QRS complex, the ventricular systole 
and ended by the T-wave, the ventricular diastole. 
In average a human heart contracts 60 to 100 times per minute, with an output of 4 to 
8 L.min-1 (average 5.25 L.min-1). 
1.2 Cardiac arrhythmias 
Heart rhythm disorders are associated with severe short and long term health risks. 
Atrial fibrillation (AF), the most frequent arrhythmia, which affects 2-3% of the European 
and North-American population 1, is associated with a 5 fold increased risk of stroke, with a 
40% incidence of congestive heart failure2, 3 and in general a doubled death rate4, 5. AF is 
caused by dysfunctional electrical activity that initially occurs in the pulmonary veins (PV) 6 
or in the atria 7. Ventricular tachycardias (VT) are related to an important risk of sudden 
cardiac death 2. VTs can originate from electrical reentries within myocardial scar or early 
activation point sources in the ventricular muscle8. While VTs often require the implantation 
of an implantable cardioverter-defibrillator, both AF and VT can be treated with drug therapy, 
tissue ablation, or a combination of both. 
Depending on the duration of arrhythmic episodes, AF is distinguished in few types. 
Paroxysmal AF is a self-terminating arrhythmia, usually under 48h. When AF lasts for more 
than 7 days or requires drug or electrical cardioversion for termination, it is called persistent. 
A long-standing persistent AF lasts for more than 1 year and requires a rhythm control 
strategy. 
VT classification can be simplified to: premature ventricular complexes (less than 3 
beats arising with a cycle length of < 600ms), non-sustained VT (duration of >3 beats and < 
30s with a cycle length of < 600ms), sustained monomorphic VT (>30s duration or requiring 
earlier intervention due to hemodynamic instability; similar QRS configuration from beat to 
beat), sustained polymorphic VT (the same but with a continuously changing QRS). 
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1.3 Treatment of arrhythmia 
1.3.1 Drug administration 
A standard management strategy of AF is a first-line drug therapy4, 9. Depending on 
the symptoms, risks (thromboembolism) and structural heart diseases, drugs can be 
anticoagulative, rate controlling and antiarrhythmic. In parallel a drug or electrical 
cardioversion can be performed to acutely restore a sinus rhythm. Antiarrhythmic drugs 
(AAD) interfere with various types of ionic channels in cardiac tissues (sodium, potassium, 
calcium) or the sympathetic nervous system. However, the general success rate of AAD has 
been reported to be around 50% 10. Moreover this kind of therapy is related to a variety of 
adverse effects encountered among approximately 30% of treated patients10. 
Depending on the nature of the VT and e.g. the presence of structural heart disease, 
priority management of this arrhythmia can be an implantation of an implantable 
cardiovereter-defibrillator or a pacemaker, AAD administration or ablation 8, 11. 
1.3.2 Ablation 
Cardiac ablation is settled as a second-line therapy for AF (i.e. when the AF is one or 
more drug refractory). It can be performed either by invasive surgery or by a minimally-
invasive catheter ablation.  
Surgical 
Established by Cox et al. 12 surgical ablation strategy consists of the electrical isolation 
of all possible macro-reentrant circuits that may potentially develop in the atria. The isolation 
was performed with traditional surgical cut-and-sew incisions in the right and left atria, placed 
in a pattern letting most of the atrial myocardium to be still activated with the sinus node 
(Cox-Maze III procedure). Very high success rates were reported13, however the complexity, 
technical difficulty and risks related to the procedure hampered a widespread application. The 
surgical incisions have then been replaced by linear ablation with Radio-Frequency (RF) 
energy, cryoablation and High-Intensity Focused Ultrasound (HIFU) (Cox-Maze IV). The 
largest study, reported on a success rate of 89% with or without AAD parallel administration 
and of 78% without AAD after 12months. Still, this procedure remains invasive and an 
incidence of major complications of 11% was reported (2% of deaths and approx. 2% of 
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stroke during operations). Today, the great majority of cardiac ablation is thus performed with 
catheter-based minimally-invasive procedures. 
Minimally-invasive therapy 
Minimally-invasive Radio-Frequency Catheter Ablation (RFCA) is a well-established 
alternative to surgery for the management of AF and a new therapeutic approach to treat VT 
occurrences. RFCA consists in the electrical isolation of common reentry sources 6, 14 or 
identified and localized foci 15, 16 through tissue thermal coagulation performed with an 
intracardiac RF catheter. For AF, the ablation pattern is frequently a simplified Cox-Maze 
procedure, called mini-Maze.  
However, while RFCA is often monitored with electromapping17–20, electrical 
impedance measurement 21, fluoroscopy 22, and intracardiac echocardiography 23, it suffers 
from a lack of precise ablation monitoring to assess the transmurality of the thermal lesion 8, 9, 
which is a crucial aspect for ensuring effective ablation procedures 24. The actual heat 
deposition and thus the lesion extent in the tissues are indeed difficult to assess.  
Another important limitation of RFCA is the difficulty of creating transmural or mid-
wall lesions in the ventricles. As a consequence an additional epicardial ablation8, 25 is 
sometimes needed. Therefore, RFCA is not perfectly adapted for VTs ablation, and a limited 
success rate of 35% is reported in the literature 25. In parallel, the single-procedure success 
rate of RFCA remains relatively low (~ 60%) for all types of treated AF 10. This rate is 
improved by repeating the procedures, with an average number of 1.3 procedures per patient a 
success rate of approx. 72% has been reported, increasing finally to 80% with additional AAD 
administration (refractory prior RFCA) 26. Nonetheless the procedure remains time-
consuming and still sometimes technically difficult: ablation lines are performed with a dot-
by-dot strategy possibly leaving difficult to detect conducting gaps. New balloon-catheter-
based systems with other energy sources than RF have been developed. Those include 
cryoenergy27, 28, laser29 or HIFU30 (but was withdrawn from the market). Balloon-based 
systems are adapted for quick, single-to-several ablations, pulmonary vein isolation. Success 
rates approaching RFCA have been reported.   
In summary, first, an imaging modality that could provide, in real-time, the spatial 
extent and the transmurality of ablated tissue could potentially reduce the procedure duration 
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and difficulty, and improve the effectiveness of existing ablation techniques. Second, a 
therapy modality that could overcome the local, contact-based energy deposition (RFCA, 
cryoablation and laser) and easily ablate large zones could also simplify the procedure and 
significantly improve VT ablation efficiency. 
2 Ultrasound therapies 
The possibility for ultrasound to produce lasting changes in biological systems has 
been revealed in 1927 by Wood and Loomis 31. The therapies presented in this part, can be 
divided into three parts, thermal therapies, shockwave therapies and cavitation mediated 
therapies. 
2.1 Therapy with ultrasound: history and concepts 
2.1.1 HIFU: a thermal therapy 
History and concept 
Thermal therapies rely on the mechanism of absorption of the mechanical energy by 
the tissues and its conversion to heat. Two types of those therapies can be distinguished: 
hyperthermia and ablation. The principle of the first relies on raising the tissue temperature on 
a 43-50°C range for few minutes to an hour 32, 33. While the procedure itself leads only to 
reversible damage 33, 34 it can be used as an adjuvant to radiation therapy 35 or to locally 
enhance drug- or chemotherapy 36–38.  
Ablation relies on applying a local and intense beam in a tissue in order to reach 
temperatures above 50-55°C 33, 39 and create coagulation necrosis 34 usually within several 
seconds. The ultrasonic beam is usually highly focused 40 (HIFU, for: High Intensity Focused 
Ultrasound) leaving surrounding tissue unharmed, which constitutes one of the major 
advantages of this technique over radio-,curie- or proton therapy. Moreover it is a non-contact 
therapy, with the potential of being completely non-invasive (unlike RF-, cryo- or laser 
ablation). One of the actual limitations is that with most systems the ultrasonic beam is very 
localized and the ablation of large volumes necessitates long-treatment time. However, 
depending on the target it can also be an advantage. Thus, usually the lesion is first created 
within a small volume, then the beam is moved nearby and the process repeated. Formerly all 
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HIFU devices were composed of a single element and were mechanically moved 40. To ablate 
larger volumes without movement the transducer’s geometry can be altered 41 or the device’s 
architecture can be a multielement transducer allowing for an electronic beam steering or a 
production of multiple simultaneous foci 42–44. 
Lynn et al. 45 were the first to produce highly localized biological effects in tissues and 
were followed by the Fry brothers in the 1950s who treated over 100 patients for various 
neurological disorders 46, 47. Early therapeutic systems were limited by a small choice of 
imaging techniques (Fry brothers were treating under X-ray imaging) and until the 1990s only 
one new noticeable system has been designed, for ophthalmological applications 48 (it was the 
first Food and Drugs Administration approved HIFU system, in 1988). Starting from the 
1990s and the emergence of new sophisticated imaging techniques (good quality echography, 
MRI) HIFU experienced an important renewal of interest.  
Today’s HIFU patient treatments include (approximate number of treated patients up 
to 2012 49) prostate cancer50 (45000), uterine fibroids51 (20000), liver cancer (15000), bone 
metastases (1000), breast cancer (500) and brain, bone non-metastases, breast fibro-adenoma, 
kidney, thyroid, pancreas (approx. 500 in total). In total HIFU clinical trials or commercial 
treatments have been performed for more than 20 different applications, with an exponential 
growing since the 1990s 49. Targeted tissues can be tumorous 33, 49, 52, 53, or not 33, 49, 53, 54. 
HIFU dosimetry: the thermal dose 
As for today no official thermal therapy dosimetry has been instituted. However a 
recent survey among physicists and engineers working in the field of ultrasound 55 indicated 
that the most popular and accepted dosimetry for ultrasound thermal therapies is the thermal 
dose. This in-situ quantification has been introduced by Sapareto and Dewey 56. It relies on 
the principle of a thermally equivalent time exposition. The concept originates from the 
observation that there is an empirical relationship between exposure time and temperature for 
a biological tissue to exhibit cellular death. Given a time temperature profile T(i) the thermal 
dose (or CEM: cumulative equivalent minutes) is expressed as the equivalent cumulative time 
a tissue has been exposed to a 43°C temperature :  
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temperature between time ti-1 and ti. In other words this equation signifies that above 43°C a 
gain of 1°C on tissue temperature divides the needed exposure time by 2. The threshold of a 
CEM43°C to obtain a nearly 100% necrosis varies among different types of tissues and has 
been widely investigated. The typical CEM43°C threshold for muscular or myocardial tissue is 
240min but only 30min for liver.  
The concept of the thermal dose is directly used in MR or ultrasound thermometry to 
predict the extension of thermally induced lesions. 
2.1.2 The other side: non-thermal therapies 
Compared to HIFU, which reposes on long continuous emissions, shock-wave uses 
short but very high pressure pulses (for lithotripsy, typically a 1µs spike of approx. 50MPa 
followed by a 4µs -10MPa relaxation, with a pulse repetition frequency (PRF) of 1-2Hz at 
150-300 kHz). Such a shock produces no-thermal effect but a high stress on the tissue at the 
focus, which disrupts the target. One of the most common usages of this modality is called 
lithotripsy, destined to dissolute kidney stones 57, 58. Lithotripsy has been introduced in the 
1980s and has since rapidly gained a very large acceptance to become the dominant treatment 
method. Shock-wave therapy is also widely used in physiotherapy 59 and with lower power 
for cardiac angiogenesis (see 2.2.2). 
Histotripsy60 is a second possible non-thermal modality. Similarly to shock-wave 
lithotripsy, this therapy relies on short but very energetic pulses. It is based on the local 
generation then mechanical excitation of a bubble cloud within the tissues. More specifically 
a burst of a few to 10-20 cycles at very high pressures (in order of +100 / -15 to -20 MPa) 
with frequencies in the range of 200kHz to 3MHz is sent and first few bubbles are generated 
in the tissue within the focal spot with the inertial cavitation mechanism. For a high 
probability to generate the bubbles, a peak negative pressure threshold, combined with other 
parameters has to be reached 61–63. With a PRF high enough (between 20 Hz and 1kHz) a new 
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ultrasonic pulse arrives before the bubbles dissolves and a whole bubble cloud is generated. 
This cloud is then excited at every next pulse and the collapsing bubbles generate enough 
mechanical stress to disrupt and liquefy the tissue. The resulting fractionation can be used to 
create cavities, communications and mechanical ablation within the tissues with therapeutic 
purposes 64. This mechanism has been applied in-vivo in the heart (see part 2.2.2), the 
kidney65, the prostate 66, the liver 67. Histotripsy has the advantage of being easily controllable 
with standard B-mode imaging as the bubble cloud appears as a very echogenic region and 
corresponds exactly to the treated area. 
Very analogous to histotripsy, boiling histotripsy is a modality of tissue disruption 
mixing thermal and mechanical effects 64, 68. Compared to histotripsy, longer shock-wave 
pulses are sent (millisecond range) which are strongly attenuated and absorbed by the tissue. 
The resulting heating generates rapidly a boiling bubble cloud, which in turn is mechanically 
excited by the ultrasonic pulses and disintegrates the tissue. An interesting possibility for this 
technique is to decellularize tissue, while the tissue is disrupted, the vascularization can be left 
behind 64.  
Another usage of ultrasound for therapeutic purposes is ultrasound mediated drug 
delivery 38, by droplet vaporization, sonopration (increase of vascular permeability for drugs), 
sonophoresis (increase the permeability of the skin) or other. Sonothrombolysis is used to 
dissolute intravascular thrombuses 69, low-intensity pulsed ultrasound is recognized to 
enhance bone fracture healing 70 and finally ultrasound for cosmetics and adipose tissue 
removal 71. 
2.2 Cardiac ultrasound therapy 
Cardiac ultrasound therapy is challenging. The heart is deeply located behind the ribs 
at distances up to 15mm and is subject to rapid motion. Moreover possible fat layers in the 
vicinity of the rib cage can have a strongly aberrating and attenuating effect. A 
straightforward transthoracic approach is thus particularly demanding. 
Despite those obstacles various ultrasound therapeutic systems have been developed in 
the last two decades 54, 72. To overcome the ribs and distance issue a particular interest has 
been focused on endoscopic, interstitial and also surgical approaches. Yet, as the rib cage is 
an obstacle principally for thermal ablation, there is a gain of interest for other, non-thermal 
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ultrasound modalities, such as extracorporeal shock-wave therapy (ECWT) and histotripsy. 
To date only one surgical HIFU device (Epicor, St Jude Medical, Saint Paul, MN) is FDA 
approved and two ECWT systems (Storz Medical, Switzerland; Medispec, USA) are CE 
marked. 
2.2.1 HIFU-based therapy 
Open-chest and transthoracic studies 
HIFU epicardial approaches were the first to be tested in the heart. Two studies from 
the same group73, 74 reported first in-vivo cardiac ablation by using an open-chest surgery, 
with few additional trials with an intracardiac but invasive approach. With the same surgical 
method using additional B-mode guidance Strickberg et al. 75 reported on successful in-vivo 
atrioventricular junction ablation and another group performed lesions in the interventricular 
septum 76. Finally by using a large aperture (22cm diameter) HIFU transducer, formerly 
dedicated for tumor ablation, Rong et al. 77 reported on first in-vivo transthoracic ablation in 
the interventricular septum in dogs. Yet the procedure required preparation (skin degassing, 
artificial hydrothorax) and the chosen cardiac zone was the less affected by motion.   
The most advanced HIFU epicardial approach has been the Epicor Medical Cardiac 
Ablation System78 (Saint Jude Medical, St. Paul, MN) performing linear lesions on the left 
atrium. The transducer was inserted through thoracoscopic approach and wrapped around the 
pulmonary veins along the epicardium. However, despite positive results 78, 79, the necessity 
of invasive surgery combined with similar results to the classical RFCA and the limitation, by 
its design, to the treatment of AF led Saint Jude Medical to stop the production of this system. 
Many studies have been dedicated to overcome the rib barrier 80–84, principally for 
liver applications, by using large multi-element apertures. This obstacle can also be bypassed 
by performing ablation from inside of the body, with interstitial devices. 
Interstitial devices 
For cardiac ablation two approaches were investigated: transesophageal and 
intracardiac devices. The first report of an interstitial setup, without open-chest surgery has 
been reported by Ohkubo et al. 85, where an intracardiac HIFU catheter has been used with a 
classical femoral vein approach. The most promising intracardiac results were obtained with 
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balloon-based systems 30 dedicated for pulmonary vein isolation for atrial fibrillation ablation 
but the usage of those systems is definitively stopped. The reader is invited to consult 
Chapter4 part 1.2 for a more detailed historical on intracardiac systems. 
Transesophageal approaches have also been proposed for cardiac HIFU ablation 86–89 
and first animal in-vivo 90, 91 studies have been performed. In this original approach, less 
invasive than procedures involving catheter insertion into the heart, cardiac thermal lesions 
are performed through the esophagus with a HIFU endoscope. 
Thermal ablation strategies have principally targeted atrial fibrillation and ventricular 
tachycardia disorders as well as the atrioventricular node ablation. Because of the different 
nature of the lesions or of effects they produce, non-thermal therapies have been dedicated to 
other cardiac pathologies. 
2.2.2 Other, non-thermal therapies 
Cardiac non-thermal therapies are divided into two modalities: ECWT and histotripsy. 
Extra-corporeal shock-wave therapy 
ECWT relies on sending the same individual shocked-pulses than for lithotripsy. For 
cardiac application the total power of energy is however ten-times smaller than for kidney 
stone lithotripsy. The first application for cardiac ECWT was the promotion of angiogenesis 
92
 to treat ischemic heart disease. Fukumoto et al. performed first successful trials on patients 
affected by artery coronary disease 93 and was followed by other larger studies 94. Other 
groups used the same phenomenon to treat ischemic heart failure prior 95, 96 or not 97 to cardiac 
cell therapies . No complications were reported during those studies and no cardiac injuries 
have been reported in randomized trials 98. ECWT has the advantage to be performed with a 
simple non-invasive transcostal approach. 
Histotripsy 
To our knowledge the first to report on in-vivo cardiac tissue disruption were Smith et 
al. 99. The cardiac use of histotripsy has then been extensively studied by the University of 
Michigan group (Ann Arbor, Michigan). Atrial septal defects were achieved in vivo with an 
open chest approach 100 then in-vivo lesions were in fetal hearts in-utero 101 and in neonatal 
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pigs without surgery 102. Finally a motion correction has been developed and successfully 
tested in-vivo on open-chest animals improving therapy targeting 103. Another study 
performed cavitational microlesions by targeting contrast microbubbles in the heart104 for 
tissue reduction with potential applications for hypertropic cardiomyopathy. No cardiac 
transcostal study on big adult animal has been reported however Kim et al. 67 successfully 
performed liver lesions with a straightforward transcostal approach. Compared to ECWT, 
histotripsy still has to overcome some technical obstacles and necessitates further safety 
studies before any first human studies. 
2.3 Ultrasound-guided therapy 
Every therapeutic modality has a substantial need for guidance, target imaging, 
therapy control and monitoring. Many ultrasound and non-ultrasound imaging techniques 
have been developed to address this demand. Chapter 2 part 1.1.2 describes in detail most of 
those modalities. In this thesis a particular focus is made on ultrasound imaging for therapy 
guidance and monitoring. 
3 Introduction to echography 
3.1 Conventional imaging 
In conventional B-mode ultrasound imaging an image is acquired by a line-by-line 
successive beam focusing in front of the probe. For each focus, scatterers on the line reflect a 
part of the beam which is received and electronically adapted on reception (focusing in 
reception) to create an image, retrieve the scatterers’ positions, on the line. The acquisition 
time is set by the go and return of the wave and the process is repeated a hundred times to 
create a whole image. Using linear arrays the beams are focused in front of the probe, using 
phased arrays (element pitch ≤ λ/2) the beams can be steered outside of the frontal view. 
Typical frame rates can reach 50-100Hz with this technique. 
3.2 Ultrafast imaging 
To overcome the limited frame rate of focus-based imaging Tanter et al. 105 proposed 
to insonify the whole medium with one plane wave to create an image within a single 
emission-reception time. The beam was only focused on reception and thus the quality of the 
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image was lower. However the frame rate increased by a factor of a hundred, attaining up to 
20000 images per second. This opened completely new perspectives in ultrasound imaging 106 
by giving the possibility to observe transient effects which were too rapid before or by 
significantly increasing the sensitivity of already existing ultrasonic imaging modalities. 
Moreover Montaldo et al. 107 demonstrated that by sending tilted plane waves (several 
degrees) and coherently summing them in reception, it is possible to recreate synthetic focal 
spots within the medium and finally attain to the same quality of image with around 40 
emissions than with focused imaging. Even though only few emissions are sufficient to 
improve the image significantly. 
Recently Papadacci et al. 108 demonstrated, with the same rationale, that it is possible 
to recreate synthetic focuses by sending diverging waves with different virtual sources (virtual 
centre of the wide-beam diverging wave) with a phased array.  
3.3 Shear-wave Elastography 
The principle of SWE109 relies on the synergetic combination of the acoustic radiation 
force 110 and ultrafast ultrasound imaging 106 leading to real time and quantitative imaging of 
stiffness. The acoustic radiation force obtained by focusing ultrasound using the imaging 
probe remotely generates push impulse, which results in the propagation of a shear-wave in 
the surrounding region that can be imaged with the same probe in real time using plane wave 
ultrafast imaging. It is possible then to derive visco-elastic properties of the tissue from the 
induced shear-wave propagation. When assuming the medium to be semi-infinite, the group 
velocity ct of the shear-wave is proportional to the shear modulus µ of the examined tissue 
according to: 
µ = ρ ct 2  (1.1) 
where ρ is the local density. 
To create a plane shear-wave rather than a cylindrical in deep tissues, it is possible to 
generate in a row 2-3 push impulses on a column pattern and create an elastic Cerenkov effect 
111
. The advantage of this is that the whole depth of the image can be covered with a shear-
wave and it is also much easier to calculate its speed. On the other side, it is profitable to 
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induce and acquire separately a few pushes in width to finally cover the whole image with 
shear-waves and average the acquisitions if the SNR is low 112. 
To calculate the shear-wave speed locally a time-of-flight algorithm 109, 113 is used to 
track the shear-wave group velocity ct and the shear modulus map is obtained from (1.1) for 
each acquisition. Corresponding quality maps are obtained from the algorithm’s temporal 1-D 
cross-correlation. The final ‘stiffness map’ is obtained with a quality weighted average (least-
squares mean) of the acquisitions. 
4 Thesis overview 
The goal of the thesis is to bring new solutions for cardiac therapy and imaging with 
minimally-invasive ultrasonic approaches. The privileged solutions are High-Intensity-
Focused-Ultrasound (HIFU) for therapy and Shear-Wave Elastography for imaging and 
therapy evaluation. 
In this purpose, first, we evaluated the accuracy and clinical viability of Shear-Wave 
Elastography (SWE) as a real-time quantitative imaging modality for thermal ablation 
monitoring in vivo.  
Second we implemented SWE on an intracardiac transducer and validated the 
feasibility of evaluating thermal ablation in vitro and in vivo on beating hearts of a large 
animal model. Two novel imaging techniques were also developed and assessed on cardiac 
tissues: ultrafast Doppler imaging to detect small vessels and ultrafast acoustoelectric imaging 
to map acousto-electrical properties of cardiac tissues.  
Third a dual mode intracardiac transducer was developed to perform both ultrasound 
therapy and imaging with the same elements, on the same device. 
At last, SWE was implemented on a transesophageal ultrasound imaging and therapy 
device and the feasibility of transesophagial approach was demonstrated in vitro and in vivo. 
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Chapter 2. Real-time monitoring of 
thermal ablation using Shear-Wave 
Elastography 
1 Introduction  
This chapter introduces the concept of thermal ablation monitoring using Shear-Wave 
Elastography in vivo and will focus on its application in liver thermal therapy. 
First the problematic of thermal ablation control is introduced and a state-of-the art 
among ultrasonic and other imaging modalities is provided, showing the unmet need of a real-
time monitoring technique with good temporal and spatial resolution, flexible and objectively 
reliable. 
Second, an in-vivo study is presented in porcine liver using Radio-Frequency Ablation 
(RFA) as well as High-Intensity Focused Ultrasound (HIFU). The results demonstrate that 
quantitative and real-time SWE stiffness mapping can be reliably linked to tissue coagulation 
and can precisely map the thermal ablation extension.  
1.1 Control and monitoring of thermal ablation: overview 
1.1.1 Thermal ablation 
Recent years have witnessed a growing interest for thermal ablation, especially in the 
field of tumor treatment34, 114. Thermoablative minimally invasive techniques, such as 
radiofrequency115, laser116, microwave117, cryoablation118 and HIFU33 ablation, present many 
advantages over classical surgery and resection. Tumors being treated are present in many 
organs including the liver115, the breast119, the lungs120, the esophagus121, the bones122 and 
others. In some cases thermo-ablation has become a standard alternative to surgical resection 
123–125
. All these minimally invasive therapies, except HIFU, consist in applying thermal 
energy to a probe inserted into the tumor mass to produce coagulation necrosis 126, 127.  
In this chapter we will focus the attention to the specific case of thermal ablation 
treatment in the liver. In this organ the safety and effectiveness of thermal therapies, 
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especially radiofrequency, have been widely investigated128, and high local tumor recurrence 
rates have been reported129. Among most important causes of ablative inefficiency pointed by 
meta-analysis studies is the inability to predict or control precisely the thermal ablation’s 
extension130. This is induced by the fact that the ablative volume is predicted empirically 
without taking into account the actual anatomy and tissue properties, especially the effects of 
vascularization, in the direct vicinity and within the targeted area130, 131. Existing monitoring 
relies on target temperature and electrical properties measurement directly in contact with the 
ablation devices and has been proven of very limited efficiency.  
Consequently a substantial need still exists for a precise monitoring technique of the 
ablation. Such monitoring technique would help, first, guiding the treatment and targeting the 
tissue, second, discriminating ablated from viable tissue, within and at the borders of the 
treated volume. Many imaging techniques have been developed in this direction but they have 
encountered several important limitations. 
1.1.2 Ablation monitoring: state-of-the-art 
 Non-ultrasonic modalities 
Current non-invasive monitoring gold standard for temperature mapping is magnetic 
resonance imaging (MRI). Temperature and by extension thermal dose deposition can be 
monitored with near real-time MRI sequences. This technique can accurately delineate the 
treated area and lower the risk of local recurrence132–134. In the research field, Magnetic 
Resonance Elastography (MRE)135, 136 is another possibility to assess the extension of 
thermally ablated tissue. 
However MR imaging is associated with several technical obstacles (MR compatible 
materials, limited space for intervention) and is expensive. The temporal and spatial 
resolutions are also limited and rapid motion affects strongly the imaging quality. 
Computed-Tomography (CT) techniques for thermometry have also been investigated 
137, 138
. This imaging modality has the potential to provide a good spatial resolution; on the 
other hand the obtained temperature-related contrast is limited. This technique also offers the 
possibility to map local vascularization and its absence or reduction due to thermal 
ablation139. Nonetheless the ionizing nature of this modality, with the related dangers and 
constraints for the physician, limits significantly the interest for its development. 
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Ultrasound imaging 
Because of its low cost and wide availability for surgeons and interventional 
radiologists during laparotomy or laparoscopy, ultrasonography is one of the preferred 
modality for image guidance119, 130, 140. Moreover, thermal ablation effects are usually visible 
in real-time in ultrasound images. Indeed, the heating process during thermal ablation leads to 
the production of steam bubbles that are seen on the ultrasound images as a transient 
hyperechoic zone, and these artifacts are commonly used as a surrogate marker of target 
destruction141–143. Such clinical usage of ultrasound is however principally dedicated to tissue 
targeting and provides only qualitative and very incomplete information on target destruction. 
Furthermore, this hyperechoic zone disappears within several tens of minutes, and cannot be 
used afterwards to localize the treated zone. A robust and specific real-time imaging method 
to detect coagulation and precisely monitor the thermal ablation procedure is required. 
Extensive work has been performed in the field of ultrasound to monitor various 
effects of thermal ablation on tissue. Several mechanisms are principally at stake: bubble 
formation, temperature dependence of the speed of sound, tissue thermal expansion and tissue 
coagulation. The first three points are transient effects dependent of temperature (speed of 
sound and thermal expansion) or of an empiric combination of acoustic power (for HIFU 
ablation) and temperature (bubbles), thereby they are suitable for ablation monitoring during 
the procedure. Final ablation size can be derived by accumulating such information e.g. by 
computing the thermal dose. On the other hand the final ablation effect is marked with tissue 
coagulation34. It can be observed during the treatment, but also after tissue’s thermal 
relaxation, as the final physiological effect of the ablation. 
Already observed on classical B-mode imaging, bubbles from boiling appear when the 
100°C temperature threshold of tissue is reached. However another bubble formation 
mechanism, inertial cavitation144, can occur below this temperature depending on ultrasound 
pressure. A passive detection of such created bubbles has been proposed by Mast et al.145, 
where bubble detection is performed with a separated imaging array without any emission 
pulses. Based on this work, Coussios et al. proposed the Passive Acoustic Mapping (PAM) 
technique to map the formation of bubbles in real-time in ex-vivo tissue146. This type of 
mapping is very efficient in the detection of a HIFU beam in presence of cavitation, however 
it does not provide quantitative information on the necrosis and on the progression of the 
treatment. Moreover it is not capable of evaluating the thermal effect around the focal spot, 
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where tissue damage comes from non-cavitating thermal diffusion and thus not capable of 
predicting the whole area of ablation. 
The speed of sound dependence in tissue and tissue thermal expansion has been 
widely investigated in order to map the local temperature147–152. Both effects generates an 
effective strain on ultrasound images that can be quantified precisely. The combination of 
these two effects is linear in the temperature range up to 50°C and temperature can be directly 
derived from the time shifts observed within the ultrasonic RF data or by B-mode speckle 
decorrelation. Above this threshold, the dependence becomes non-linear and temperature 
cannot be determined easily any more. At this point though tissue coagulation occurs rapidly 
and within certain conditions the strain generated by the change of tissue properties can be 
quantified with this technique153. One major limitation, however, of strain temperature 
imaging is its lack of robustness, as temperature is derived from time shifts occurring within 
successive frames and is thus very sensitive to motion153. In this field the most advanced 
developments are achieved by Ebbini et al. reporting real-time, up to 500Hz temperature 
monitoring 154, 155. Such induced variations are also strongly tissue-dependent and sensitive to 
the fat content within the tissue 156. This type of imaging, as well as bubble and cavitation 
detection, relies on transient effects that cannot provide information once the treatment is 
finished. Thus the final evaluation of the whole area or volume of treatment may be 
problematic.  
Finally it has been also shown that thermal coagulation modulates tissue attenuation 
152, 157–159
 and the backscattered energy 160. Yet such obtained contrast remains low, is also 
very tissue dependent and is based on relative changes, with all the limitations mentioned 
above. 
Ultrasound elastography 
Alternatively, thermally induced effects can be quantified by the changes in elastic 
properties of the tissues. Two phenomena are known and have been reported by many groups: 
the temperature dependence of tissue elasticity and the observed link between stiffening and 
thermal coagulation. This first effect has first been reported by Apter161. The link between 
structural collagen denaturation, its irreversibility above 60°C and stiffness changes was 
shown by 162–164. Subsequently Wu et al.135 completed an MR elastography study of thermally 
induced elasticity variations that highlighted inter alia a first reversible effect of elasticity 
 41
decrease between 20 and 60°C and a second of elasticity increase around 60°C and above. In 
the field of ultrasound, temperature dependence of soft tissue elasticity has been quantified 
only recently 165–167. On the other hand tissue elasticity changes after coagulation have been 
measured using various US elastography techniques. These include static elastography168–170 
and acoustic radiation force based techniques171–173.  
Static elastography is a direct implementation of the Hooke’s law. A static constraint 
is applied on the tissue, generally with the ultrasonic probe or a mechanical piece integrated 
within, that induces a deformation of the tissue which is measurable on standard B-mode 
images. This deformation is proportional to the tissue’s Young modulus. However, in 
practice, it is very difficult to control and measure such applied force; thereby the technique 
provides only qualitative elastic information, which is consequently operator dependent. 
Moreover because of the time-consuming compression operation this technique is not easily 
implementable for a real-time in-vivo monitoring.  
A similar issue is encountered with the acoustic radiation force based techniques 
which do not rely on shear-wave propagation. Acoustic Radiation Force Imaging171, 174 
(ARFI) and Harmonic Motion Imaging172, 175 (HMI) remotely and locally induce a force that 
generates a vibration of the tissue. The amplitude of this vibration is again proportional to the 
elastic properties of the tissue, but it is not possible to measure such applied force and thus not 
possible to provide a quantitative assessment of the local stiffness. 
Quantitative mapping of stiffness has been shown of major importance because tissue 
stiffness during tissue coagulation is directly linked to the thermal dose 176. To our knowledge 
Shear-Wave Elastography 109 is the only real-time modality satisfying these conditions. This 
technique can provide an objective, operator independent, visualization of the thermal lesion 
boundaries173, 177. Moreover thanks to the Ultrafast plane wave imaging, it is relatively not 
affected by motion naturally present in-vivo. 
To assess the feasibility and accuracy of quantitative elasticity monitoring during 
thermal therapy and to determine the elasticity threshold that predicts the formation of 
coagulation necrosis, we carried out an in vivo preclinical study in which SWE was used to 
map thermally induced coagulation necrosis areas produced in pig livers with an RFA and 
HIFU system.  
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2 In vivo experiences 
In this study two types of thermal ablation systems were used: one composed of 
bipolar radiofrequency needles, the other using an ultrasonic HIFU transducer. As the two 
systems present many similarities, the evaluation of SWE to monitor ablation was analogous.   
2.1 Materials and methods 
All procedures were approved by the University Committee for animal research of the 
“Ecole de Chirurgie, Assistance Publique-Hôpitaux de Paris” and are in accordance with the 
guidelines issued by the National Institutes of Health for care of laboratory animals. 
2.1.1 Animals and surgery 
In total forty (n=40; n= 29 with RFA and n= 11 with HIFU) thermal lesions were 
carried out in the liver of eight (n=8; RFA: n=5 and HIFU: n=3) Landrace pigs (weight range: 
30-35 kg) using an open surgery approach in a surgical suite dedicated to large animals. 
Anesthesia was induced by ear vein intubation with a mixture of morphine hydrochloride (0.5 
mg/kg; Morphine Lavoisier, France) and propofol (4 mg/kg; Fresenius, France) and 
maintained with isoflurane (1.5%-2.5% for 1 L/min oxygen inhalation; Forene, Abbott, 
France). The anesthetized animal was in dorsal recumbency on a warming blanket to preserve 
the body temperature, and then the abdomen was shaved for laparotomy. Vital parameters 
were monitored throughout the surgery.  
2.1.2 Thermal lesions 
For both RFA and HIFU approaches a ventral midline laparotomy was performed for 
all the ablation and imaging protocol. Both systems were fixed on a mechanical arm, which 
remained immobile during the procedures. 
RFA 
Two electrodes were inserted in the liver under US guidance, and coagulation necrosis 
was produced with a bipolar radiofrequency system connected to an electrosurgical generator 
(Force FX-8C electrosurgical generator; Valleylab, Tyco Healthcare, Switzerland). The 
generator power was 4 W, the radiofrequency was 470 kHz, and the distance between the two 
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electrodes was always set to 7mm. To ensure a good imaging reproducibility, we created a 
self-maintained therapy-imaging device that kept the imaging probe fixed while a 
translational mechanism allowed the insertion of the electrodes at the focal plane of the probe 
(Figure 2-1a). A thermal “coagulation necrosis” lesion was created 1.5-2.5 cm beneath the 
liver surface in approximately 5 min without water vaporization or bubble formation. 
HIFU 
A similar setup was used for HIFU. A focused single element (2.25MHz, 38mm 
diameter, focused at 38mm, Imasonic, France) was fixed at the end of a confocal and 
motorized disposal (Figure 2-1b). The signal was generated with a function generator (AFG 
3101, Tektronix, USA) and amplified (BT00100-AlphaS-CW, Tomco, Australia) to 35W of 
effective electric power, resulting in a pic positive pressure of 7.8±0.2MPa (measured in 
water) at the ultrasonic focus. The HIFU transducer was angled at 60° to the imaging plane of 
the imaging probe. The imaging probe remained fixed while the HIFU transducer was 
motorized with two translational stages (25mm travel range, PI, Germany) in directions 
parallel to the imaging plane. The dimensions of the HIFU focal spot at -6dB were 0.6mm in 
diameter and 4.3mm in depth, but as the transducer was angled, it resulted in an approximate 
ellipsoidal cross-section of 0.6mm by 1mm in the imaging (Figure 2-2).  
During the HIFU procedure therapy was applied at one point for 20s then the 
transducer was moved parallel to the imaging plane: typically with steps of 1mm along its 
lateral axis and 2mm along depth totaling 9 to 20 positions in a rectangular pattern (Figure 
2-2). Lesions were created 20-30mm deep in the liver from the imaging plane point of view.  
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Figure 2-1 : Schematic and photograph of the RFA (a) and HIFU (b) imaging-therapy 
systems. Both imaging arrays are integral of the immobile mechanical arm (not represented). 
(a) The RFA system is composed of ablation needles that are inserted in tissue with the 
translation stage (green) that ensures a perfect alignment of the needles’ tips with the imaging 
plane (15mm away from the transducer). (b) The HIFU probe is fixed on two motorized 
platines (black) and angles at 60° with the imaging plane. The possible translational range is 
25*25mm2 in parallel to the imaging plane. 
 
Figure 2-2 : Representations of the HIFU beam relative to the imaging plane. (a) Typical 
pattern of the performed therapy. HIFU focuses are seen as ellipsoidal cross-sections. (b) 3D 
representation of the imaging-therapy system. 
2.1.3 Image collection 
SWE and B-mode images were acquired with an ultrafast ultrasound scanner 
(Aixplorer, SuperSonic Imagine, France) using two linear probes (for RFA: 8MHz, 256 
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elements, 0.2mm pitch; for HIFU: 6MHz, 192elements, 0.2mm pitch, Vermon, France). 
Images were taken before the procedure for reference, every 30s during RFA thermal ablation 
and at the end of each HIFU focal position (i.e every 20s). At the end of the procedure an 
image was also taken every minute for 5 min. All images were taken in the focal plane. The 
imaging plane was used as the reference for sample dissection.  
First, B-mode images were used for therapy guidance. Then, SWE images were 
recorded using the SonicSoftware tool (Supersonic Imagine, Aix-en-Provence, France), under 
the clinical mode of the scanner, as 2-D Young’s modulus maps. Elastographic images and 
the corresponding B-mode images were acquired simultaneously and saved as static maps. To 
compare always the same area, images were acquired at the end of the expiratory phase of the 
respiratory cycle. 
2.1.4 Exclusion criteria 
An initial liver elasticity value >10 kPa was an exclusion criterion because such high 
value before any treatment revealed an artifact due to liver compression by the probe. When 
compression for technical reasons occurred, SWE measures cannot be considered reliable, and 
we chose to readjust probe and retake a reading. If not recognized during thermal procedure, 
we excluded lesion from the analysis. 
2.1.5 Gross pathology 
After in vivo US imaging, animals were euthanized by intravenous injection of 100 
mg/kg sodium pentobarbital. The livers were resected and sliced in the focal plane. Gross 
examination of each lesion was performed in the same position and orientation in which it 
was previously imaged. Specimens were photographed beside a millimeter ruler. In 
accordance with previous reports178, 179, typical macroscopic thermal lesions with a central 
“white zone” (Wz) of coagulation necrosis surrounded by a peripheral, hyperemic “red zone” 
(Rz) within the native liver tissue were found (Figure 2-3). A pathologist examined each 
region of interest to macroscopically differentiate the Wz and Rz areas. Specimens were then 
preserved in 10% formalin solution for microscopic analysis. Representative tissue samples 
were embedded in paraffin and stained with hematoxylin-eosin-safran. 
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Figure 2-3 : pathological standard features of a thermal lesion in macro specimen, with 
segmented “white zone” (Wz) of necrosis coagulation, “red zone” (Rz) with red blood cells 
and untreated (U) healthy tissue. 
2.1.6 Image analysis 
For both RFA and HIFU, SWE and gross pathology images were analysed using a 
homemade software program written in Matlab (Mathworks, Natick, MA). For pathology 
photographs, the K-means180 clustering was used to automatically segment the Wz only. The 
Rz contained a large amount of red blood cells and did not always correspond to complete 
coagulation necrosis. The same elastographic data as displayed on the scanner were used. A 
region of interest was manually positioned at the lesion location; then, the area corresponding 
to the lesion was automatically segmented, tissue stiffness was calculated before and after 
thermal ablation, and the mean elasticity values compared.  
RFA specific data analysis 
A new contour elastographic map (Figure 2-4) was built by dividing the pixels in 
zones corresponding to 5 kPa of elasticity, from 15 to 60 kPa. The contours of such created 
elasticity zones were considered as potential thresholds and tested in correlation with the in 
vivo findings. Indeed, after semiautomatic rigid registration of the elastographic and 
pathology image segmentation, the validity of the elastographic prediction was assessed by 
using a pixel-by-pixel analysis and by classifying the pixels in true positive (TP), false 
positive (FP) and false negative (FN), according to Figure 2-5. Areas that were classified as 
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stiff (i.e., above each threshold in kilopascals) and that overlapped with the coagulation 
necrosis were considered as true positive. Segmented coagulation areas that were not covered 
by the elastographic map were considered as false negative. Areas above each threshold in 
kilopascal without necrosis were considered as false positive. The positive predictive value 
(PPV) and sensitivity (Se) were calculated for each threshold.  
 
 
Figure 2-4 : Elastographic map of a thermal lesion obtained by AixplorerR and pixel-by-pixel 
rebuilt contour map in Matlab (Young’s modulus in kPa). The core of this lesion did not 
exceed 45 kPa. 
 
 
Figure 2-5 : Scheme of data analysis for Radio-Frequency Ablation data. 
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A radiologist with 20 y of experience interpreted blindly the B-mode images that 
corresponded to the studied SWE images and tried to outline the lesion boundaries, without 
knowledge of the elastographic maps. He knew a thermal ablative procedure had been 
performed following a protocol that avoided water vaporization and steam bubble formation. 
His mapping was estimated by using the NIH ImageJ software (National Institutes of Health) 
and compared with the surgical specimens. 
This specific SWE data analysis was possible thanks to the physical markers left by 
the RFA needles. The needles were clearly seen on B-mode images during the procedure, as 
well as the inclusions they left in the tissue. By matching their position on the ultrasound 
images and on gross pathology, pixel-by-pixel comparisons were possible. This type of 
analysis was not possible with HIFU due to the absence of such markers. 
HIFU specific data analysis 
In the case of HIFU, segmentation of the elastographic maps was performed every 
1kPa from 10kPa to 60kPa. As no viable markers were present on all ultrasonic and gross 
pathology images, no pixel-to-pixel comparison was possible. The best matching surface was 
the criterion to find the best threshold for SWE to delineate the boundaries of the lesions. 
2.1.7 Statistical analysis 
Statistical analyses were performed using Matlab. The mean elasticity values of the 
thermal lesion areas and their respective standard deviations were calculated. Elasticity values 
before and after ablation were compared with the two-sided Student t-test. The Bland-Altman 
graphical method was used to detect the presence of systematic bias and measurements 
outside of the 95% confidence interval. P < 0.05 was considered statistically significant. 
2.2 Results 
Three RFA and one HIFU lesions were excluded because of a pretreatment liver 
elasticity value >10 kPa. Figure 2-6 shows examples of SWE maps of thermal lesions 
performed (a) with the RFA setup, (b) with the HIFU setup. The remaining 26 areas of RFA 
and 10 HIFU thermal lesions had a mean elasticity value of 6.4 ± 0.3 kPa (RFA) and 7.5 ± 1.2 
kPa (HIFU) before heating and a mean elasticity of 38.1 ± 2.5 kPa (RFA, p<0.0001) and 26.6 
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± 4.7 kPa (HIFU, p<0.0001) after the procedure that induced coagulation necrosis (Figure 
2-7). 
 
Figure 2-6 : Examples of (top) SWE maps of areas of liver ablated with (a) the RFA system, 
(b) the HIFU system and (bottom) the corresponding B-mode images. The boundaries of the 
lesions can be clearly delineated with SWE while they appear less contrasted and incomplete 
on B-mode. 
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Figure 2-7 : Box plot representation of liver elasticity (Young’s modulus [kPa]) calculated 
before and after ablation with RFA (a) and HIFU (b), in the areas identified as lesions. (a) The 
elasticity significantly increases (p<0.0001) from 6.4 ± 0.3 kPa to 38.1 ± 2.5 kPa. (b) The 
elasticity significantly increases (p<0.0001) from 7.5 ± 1.2 kPa to 26.6 ± 4.7 kPa. 
 
2.2.1 Pathologic analysis 
All thermal lesions showed the expected pathologic features, and the Wz and Rz could 
be clearly differentiated in all cases. For RFA lesions the Rz thickness was 0.8-1.5 mm and 
the mean measured Wz area was 75.1 ± 20 mm2 (40.5 - 131.3 mm2). For HIFU induced 
lesions the mean Wz area was 38.2 ± 11 mm2 (18.2 - 55.8 mm2). 
2.2.2 Microscopic analysis 
At low magnification (*5), the cell architecture of the Wz, Rz, and normal untreated 
tissue was clearly different (Figure 2-8). At higher magnification (*40), conventional 
hematoxylin-eosin-safran staining did not show prominent changes in the Wz other than a 
lighter staining of the tissue with faintly stained nuclei and distortion of the sinusoidal 
architecture181. The Rz appeared as congestive tissue with a large amount of red blood cells. 
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Figure 2-8 : Microscopic analysis of an RFA thermal lesion. Hematoxylin-eosin-safran 
staining, original magnification x5. Histopathological examination revealed a clear difference 
between the cellular architecture within the white zone (Wz), the right zone (Rz) and normal 
untreated tissue (U). X corresponds to a classical electrocautery lesion. 
2.2.3 RFA lesions B-mode image analysis 
The expert radiologist did not detect any lesion in three cases (11.5%), could 
determine only incompletely the lesion boundaries in 16 cases (61.5%) and completely 
outlined what he considered to be the lesions in seven cases (27%). The mean surface 
difference between the Wz in the gross specimens and the lesion area delimited by the 
radiologist in B-mode images was 42.5%. 
2.2.4 Prediction of accurate visualization of coagulation 
necrosis 
Se and PPV were calculated for different elasticity thresholds as described previously. 
Figure 2-9 shows the Se - PPV couples for the different studied elasticity thresholds of RFA 
lesions. Above 30 kPa, PPV was higher than 0.93 but was associated with Se values as low as 
0.5. The curves showed that a 20 kPa threshold gave the best compromise between Se and 
PPV (0.8 and 0.83, respectively).  
For HIFU induced lesions the best Young’s modulus threshold was found to be 21kPa, 
which is in agreement with RFA. The Bland-Altman method (Figure 2-10) showed no bias on 
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RFA lesions estimation and a limited one for HIFU. The estimated ablation area size on 
elastographic maps was very close to the Wz size (RFA: 0.022 ± 0.22 cm2 for bias ± standard 
deviation; HIFU : 0.086 ± 0.20 cm2) with a confidence interval between -0.413 cm2 and 
+0.459 cm2 (RFA) and -0.483 cm2 and +0.310 cm2 compared with the mean size of the 
lesions (RFA: 0.751 cm2; HIFU : 0.382 cm2). 
 
Figure 2-9 : RFA lesions: Sensitivity (Se) and positive predictive value (PPV) analysis of 
different quantitative elasticity thresholds. The 20kPa threshold is chosen as the best 
compromise between Se and PPV. 
 
 
Figure 2-10 : Bland and Altman representation of the agreement between the surfaces of the 
SWE map (E) and the surfaces of macro specimen (M). Mean and limits of the confidence 
interval (CI) are represented by dot lines. 
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2.3 Discussion 
In this study we have demonstrated that quantitative Shear-Wave Elastography is 
capable of a real-time monitoring of thermal ablation in-vivo with a high-contrast and good-
accuracy mapping. The stiffness quantified by SWE was 2 to 6-8 times higher (in the core of 
the lesion) than in the surrounding healthy tissue, because of protein coagulation. An 
accurately determined elasticity threshold might help visualizing the boundaries of the created 
thermal lesion. Indeed, using an elasticity threshold of 20 kPa (two times higher than the 
native liver elasticity), we could predict cell necrosis with a Positive Predictive Value of 0.83 
and Sensibility of 0.8. The very close threshold found for HIFU confirms the robustness of 
these results. The possibility of such an absolute threshold means that no preliminary 
acquisition would be needed before the ablation procedure and the determination of ablated 
tissue would be very straightforward.  
In this study we mainly focalized on the precision and universality aspect of SWE to 
map, in-vivo, thermally coagulated tissue. As our reference was gross pathology investigation 
of excised tissue, it was not possible to confront it to the mapping acquired before the end of a 
procedure. Nevertheless, as mentioned in the Materials & Methods section, each procedure 
was also monitored during the ablation. Figure 2-11 shows an example of such monitoring of 
a HIFU ablation. In this case 20 successive spatially distributed (6*4mm2 translation area) 
ablations were performed and the progressive appearance of the lesion is clearly visible, 
already after the second ablation (approximate ablated area: 2*2mm2).  
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Figure 2-11 : Example of SWE monitoring of a HIFU ablation. Up right is represented the 
scheme of successive ablations performed in the tissue. In total HIFU was performed on 20 
focal positions (15s per position), each separated of 1mm within a line and 2mm within a 
column. A selection of successive SWE maps with the scheme of the completed focal 
positions (in red) is represented from the up left to bottom right. A photograph of the excised 
tissue, cut along the imaging plane, is shown at bottom right (same spatial scale as for SWE). 
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Satisfactory clinical results using MR temperature mapping have also been reported 
132, 133
, but they are associated with the classical MR drawbacks in terms of costs and 
increased technical complexity. An ultrasonic technique is potentially less expensive and 
directly available in the operative room for surgeons or radiologists, as it is already the most 
used imaging modality for such procedures. Moreover, with MR temperature imaging, 
coagulation maps were estimated indirectly by computing the thermal dose. In contrast, tissue 
stiffness is an intrinsic property, which reflects the tissue organization at cellular and 
macroscopic level, and thus pathophysiological, potentially permanent, changes that occur 
during coagulation. 
On the other hand a radiologist with experience in liver US imaging and liver 
radiofrequency procedures under B-mode guidance in humans could not clearly delineate 
thermal ablative lesions in 70% of the cases even in the absence of artifacts (gas bubble 
formation) that can alter US imaging and real-time estimation of the size of the thermal 
lesion. Although B-mode ultrasonography is the most commonly used guidance method for 
liver thermal ablative procedures, it is not precise enough for real-time monitoring of thermal 
ablation and prediction of the extent of coagulation necrosis139. 
Automatic segmentation of the liver specimens was used to avoid inter-individual 
differences. The pathologic findings showed a classical Wz of coagulation necrosis 
surrounded by a peripheral congestive Rz with a large amount of red blood cells. Like in 
previous reports 178, 179, 182, we defined as “coagulation necrosis” only areas with macroscopic 
features that were highly predictive of irreversible thermal cell damage. Histologic evidence 
of necrosis is commonly found in vivo 24-36 h after hepatocyte ischemic injury, and 
mitochondrial abnormalities are the earliest finding 183. At the early stage analyzed in this 
study, only immunohistochemical vital dyes could clearly demonstrate loss of vitality 
immediately after thermal ablation 184–186. 
This study has several limitations. First, because of the small sample size and the 
creation of standardized lesion, the findings should be cautiously interpreted. Nevertheless it 
demonstrates the capability of revealing millimetric lesions, which should be seen as an 
advantage. Second, healthy livers were treated because no pig liver cancer cell lines are 
currently available. Thus, the effectiveness and accuracy of elastography mapping remains to 
be evaluated using pseudotumor models131 or cirrhotic liver. SWE might confirm MR 
Elastography findings that malignant tumors were stiffer than human healthy liver with 
 56
elasticity around 10 kPa 187 and 2 kPa 188, respectively. Thanks to this contrast, it could be 
possible to apprehend coagulation necrosis at the margin of the tumor 131. Third, results were 
confronted to gross pathology macroscopic investigation, with possible small variations 
between the positions of the imaging plane and the excised tissue section. This variation was 
more important for HIFU induced lesions, because, no physical markers were present within 
the tissue. Fourth, this study was designed to monitor thermal procedures during open 
abdominal surgery; however, as SWE can assess and measure deep tissue stiffness, it might 
be also used for percutaneous radiofrequency ablation. Further studies need to be performed 
to test this specific assumption, but as suggested by Figure 2-12, that shows the map of a 
thermal ablation performed percutaneously (the ablation and the image), it is feasible.  
 
Figure 2-12 : SWE map performed in-vivo, percutaneously, of a RFA performed 
percutaneously as well. The different fat and muscular layers can be seen above the 
elastographic map. 
Finally in this work we were limited to a two-dimensional (2D) monitoring of the 
thermal ablation. While such an imaging provides already a consequent amount of 
information, the treated volume can only be evaluated by a manual scanning of the tissue 
along the third dimension. This kind of operation could be a source of errors, of incorrect or 
insufficient volume evaluation and finally treatment. A simple way would be to motorize the 
two-dimensional probe and recreate a volume by successive scanning. Such a solution has 
been developed by Vermon (Tours, France) as the wobbling probes. These probes are 
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constituted of a 2D transducer, mounted on a rotating motor. By successive scans, within few 
seconds, a whole B-mode and SWE volume can be recreated on the Aixplorer scanner. 
Recently Athanasiou et al. 189 published very interesting results on the evaluation of breast 
tumor volumes with such obtained 3D SWE. We have performed acquisitions with the same 
system on RFA induced lesions from the study presented previously. Figure 2-13 represents 
examples of these acquisitions. By segmenting elasticity on all planes, the volume of ablation 
could be evaluated very easily. However the disadvantage of this system, in the case of 
thermal ablation monitoring, is the loss of the real-time aspect and also the big size of the 
probe. A perfectly suitable solution would be a 3D real-time SWE imaging with small probes. 
First promising results on the development of such novel systems have recently been 
published by Provost et al. 190opening a new world for ultrasound imaging. 
 
Figure 2-13 : Examples of a multi-plane representation of a 3D-SWE volume in in-vivo sheep 
liver that underwent RFA. Hard inclusions of thermal ablation are clearly visible. 
3 Conclusions 
The development of new imaging strategies to provide real-time assessment of the 
effectiveness of thermal procedures is an important issue for mini-invasive treatments, such as 
open or percutaneous ablative therapies. Completeness of a thermal ablation procedure is 
particularly difficult to determine in real time with the risk of leaving behind viable tumor 
cells. SWE is a new imaging modality that quantifies tissue stiffness and that is mostly used 
for diagnosis 191, 192. Here, we confirm that areas of coagulation necrosis are significantly 
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stiffer than the surrounding tissue and we demonstrate that their boundaries can be predicted 
with effectiveness and reproducibility using SWE, preclinically. In previous studies 131, 193, 
US elastography has proven its interest and superiority compared with standard B-mode 
ultrasonography. 
The major advantage of elastographic modalities to monitor and evaluate thermal 
ablation is that it quantifies both transient and non-transient tissue alterations. Changes linked 
to thermal coagulation appear during the ablation and remain within the tissue a long time 
after the procedure 168, it then possible to monitor them at the moment of the procedure and 
potentially perform a global evaluation at the end of a series of ablations.  
As described in the introduction, SWE can be also used for local temperature 
monitoring, in the range of normal body temperature to 45°C. Thus when temperature in 
tissue is elevated, two effects interfere for elasticity estimation: stiffening due to thermal 
coagulation and softening due to temperature elevation167. As a consequence the area of 
ablated tissue may be underestimated during the ablation. However, as clinical thermal 
ablation is systematically over-performed to ensure a total elimination of targeted tissue 130, 
this might not be an issue. An intraoperative quantification of the combination of both 
contributions could be an interesting solution. In this study, as SWE thermometry was not in 
consideration, all final lesion surface quantification was performed after thermal relaxation to 
overcome a possible interference and simply to let the coagulation process end.  
Finally we believe this work can constitute a solid basis to push SWE monitoring of 
thermal ablation forward. All data acquisition was performed with the clinical version of the 
Aixplorer Ultrafast scanner (SuperSonic Imagine, Aix-en-Provence, France), thus showing 
the maturity of the technique. As an important next step additional preclinical studies with 
pseudotumor models 194 are needed to validate this technique. 
In this chapter we presented results, in the context of an existing clinical need, 
obtained for thermal ablation monitoring in the liver. This organ presents a homogeneous 
structure and is affected by motion, mostly respiratory, in a limited extent. In the following 
chapters SWE evaluation of thermal ablation will be presented in another part of the body: the 
heart. In this environment, motion, access and tissue structure imply a certain dose of 
adaptation. 
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Chapter 3. Intracardiac ultrafast 
ultrasound imaging for the evaluation 
of thermal ablation 
1 Introduction 
This chapter is the first of a series dealing about therapy and imaging of the heart. As 
presented in the introduction of this manuscript, cardiac ultrasound imaging and therapy are 
challenging to perform in a transthoracic approach because the heart is deeply located behind 
the ribs at distances up to 15 cm, and is subject to rapid motion. 
In this chapter we develop an intracardiac ultrafast imaging approach for the 
assessment of thermal ablation therapy. This development addresses a specific clinical need: 
the lack of control and monitoring of thermal therapies in the heart and more specifically in 
the context of Radio-Frequency Catheter Ablation (RFCA) (see Chapter 1 part 1.3 for more 
details). The main challenge of intracardiac imaging approach consists in miniaturizing an 
imaging transducer to insert it in the cardiac chambers through the venous system. As it will 
be introduced in the following parts, this approach is already widespread in electrophysiology 
labs. The specific aim of this work is to develop novel imaging tools for the assessment of 
RFCA treatment. To achieve this objective, two novel imaging modalities have been 
investigated and implemented on an intracardiac ultrasound imaging transducer: Shear-Wave 
Elastography (SWE) and Ultrafast Doppler. This chapter will present the in-vitro and in-vivo 
feasibility of SWE evaluation of myocardial stiffness during RFCA and will present 
preliminary results of intracardiac Ultrafast Doppler to map the micro-vascularization of the 
myocardium. 
2 Evaluation of atrial Radio-Frequency Ablation using 
intracardiac Shear-Wave Elastography 
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2.1 Introduction 
2.1.1 RFCA ablation monitoring: state-of-the-art 
Several techniques have been proposed for RFCA monitoring. Magnetic Resonance 
(MR) Temperature imaging 195 can provide the temperature elevation of the ablated region in 
quasi real time but is limited by its cost, complexity and the need of non-magnetic RF 
catheter. Intracardiac echocardiography (ICE) is being used routinely for the guidance of 
catheter ablation 196. The placement of ICE and ablation catheters can be performed under 
fluoroscopy or with recent navigation systems that track in 3D the catheters using magnetic 
sensors placed on their tip 197. Intracardiac ultrasound imaging can also provide qualitative 
information on the ablated zone by observing microbubble formation 196 or speckle variation 
198
 during ablation but those techniques cannot be used to assess the viability of the cardiac 
tissue. Intracardiac strain and strain rate imaging have been used to quantify myocardial 
deformation 199 but these techniques remained limited to the evaluation of myocardial 
function and cannot provide information on the atrial tissue viability after thermal ablation. 
Thermal strain imaging 200 quantifies also the strain induced by heat to provide temperature 
elevation during RFCA but does not provide information on the physical properties of tissues 
and thus is not capable of evaluating the lesions after thermal relaxation.  
2.1.2 Intracardiac elastography 
State-of-the-art 
In order to visualize the thermal lesion with ultrasound, evaluation of tissue stiffness 
has recently been introduced as an effective means to map ablated regions173, 177, 201, 202, 
providing stiffness contrasts between normal and ablated tissues of more than a factor of 2. As 
it has already been mentioned in the previous chapters, it was shown in vivo that the 
stiffening of a thermally ablated tissue is linked to the applied thermal dose 176, and thus, to its 
viability. Acoustic Radiation force imaging (ARFI), an ultrasound technique that provide 
images of relative tissue elasticity202, 203, was recently shown capable to visualize intracardiac 
thermal lesions in canines in vivo 204 and in humans 205. However, ARFI, as a relative stiffness 
imaging, requires the acquisition of a baseline, the tissue response before ablation, which is 
problematic during AF episodes. 
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In the field of cardiac imaging, Shear-Wave Elastography has already been 
successfully implemented to measure quantitatively the temporal variation of stiffness 
occurring in the myocardium in vivo during the cardiac cycle 206 and the fiber orientation of 
the different layers of the cardiac muscle 207. An intracardiac ultrasound approach was 
proposed by Hollender et al.208 in vivo to assess the stiffness the interventricular septum using 
a shear wave velocimetry technique and acoustic radiation force imaging (ARFI) for the 
characterization of infarcts in porcine heart in vivo 209.  
New contribution 
In this study, we have developed a novel, intracardiac, ultrasound-catheter-based SWE 
technique to image the extent of ablation lesions in vivo. First, we demonstrated the feasibility 
of SWE using an intracardiac ultrasound catheter by mapping the well-known increase in 
stiffness associated with radio-frequency ablation in ex vivo ventricular myocardial tissue. 
Second, we imaged, for the first time, the temporal variation of the stiffness of the atrial tissue 
in a normal, in vivo model, in order to determine the moment within the cardiac cycle at 
which the contrast between ablated and normal tissue is maximum. Finally, we demonstrate 
the feasibility of mapping the extent of radiofrequency ablation lesions in a beating heart, in 
vivo. 
2.2 Materials and methods 
2.2.1 Intracardiac Shear-Wave Elastography 
In this study, an ultrafast ultrasound scanner (Aixplorer®, SuperSonic Imagine, 
France) was used to perform SWE sequences with an intracardiac ultrasound catheter (6 
MHz, 50-% bandwidth, 64 elements, 0.2-mm pitch, 9F, Vermon, France), which consist in a 
radiation "push" ,i.e., the ultrasound focused emission used to generate a shear-wave defined 
by its duration and frequency (300 µs at 6 MHz in this study), followed by an ultrafast plane 
wave imaging sequence. The push parameters used in this study resulted in a peak positive 
pressure of 5MPa (measured in water) and a Mechanical Index of 1.0 at a 15-mm focus. The 
temperature elevation was below 1°C both in the focal region and at transducer face.  
Ultrafast imaging was performed using either one or three compounded (-1°, 0°, +1°) plane 
wave emissions at 7 MHz. The resulting imaging frame rate depended on the imaging depth – 
one compressional wave transmit and return time, and on the number of compounded plane 
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waves 107.  Up to 5 push and imaging sequences were used in order to increase the field of 
view and the signal-to-noise ratio of the shear modulus maps 112. A time-of-flight algorithm 
109, 113
 was used to track the shear-wave group velocity ct and the shear modulus map was 
obtained from (1) for each acquisition. Corresponding quality maps were obtained from the 
algorithm’s temporal 1-D cross-correlation. The final ‘stiffness map’ was obtained with a 
quality weighted average (least-squares mean) of all five acquisitions.  
The time-of-flight algorithm estimates the shear-wave group velocity locally. It is 
based on a sliding window estimator for each pixel within a lateral line. In our study all 
imaging acquisitions were laterally resolved at 100µm; the velocity was averaged on 
millimetric distances: 0.8mm for ex-vivo acquisitions, 1.1mm and 1.5mm for in-vivo 
compounded and non-compounded acquisitions respectively. Those values do not give but are 
related to the lateral resolution 210. 
For in vivo acquisitions, additional post-processing was performed. More specifically, 
the curvature of the sample was manually delineated in post-processing and the shear wave 
velocity was measured along the direction parallel to the delineated boundary. 
2.2.2 Ex-vivo experimental setup 
Shear-Wave Elastography and Radio-Frequency Catheter Ablation were performed in 
freshly excised and degassed porcine heart samples. The five 10x30x30 mm3 left ventricle 
samples obtained from two hearts (n = 5) were embedded in Agar gel (Figure 3-1). An 
acoustic absorber was fixed at the bottom of the plastic container containing the samples to 
avoid reflections. The container was placed in a tank filled with degassed and thermostatic 
(37°C) water. The ultrasound (US) transducer was positioned in water such that the imaging 
plane was perpendicular to the surface of the samples. The catheter was positioned using a 3-
D motorized motion system. During ablation, the US catheter was moved away using the 
motors and the Radio-Frequency Ablation (RFA) catheter (Saint Jude and EPTechnology, 
EPT-1000XP) was positioned on the center of the zone previously imaged by the US 
transducer. A ground plate fixed at the bottom of the container collected the current delivered 
by RFCA. 
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Figure 3-1 : Ex-vivo experiments setup. Heart samples were fixed in Agar gel and immersed 
in degassed water. The US imaging catheter was placed mechanically on the transverse plane 
and distance to the samples was controlled with a motor. The US catheter was precisely put 
away and back to perform SWE before and after RFA. The RFA catheter was mechanically 
positioned in the center of the US image to perform ablation and then driven away. 
2.2.3 Ex-vivo sequences 
The US catheter was placed approximately 4 mm away from the sample’s surface. A 
B-mode image was acquired and then SWE was performed – pushes were generated at a 
depth of 6 mm. Imaging depth was fixed at 12 mm which resulted in a PRF of 27.8 kHz and a 
final frame rate of 9300 images/s after compounding. The total sequence duration was 18 ms. 
The catheter underwent motion resulting from a kick-back in response to the generated 
radiation force, which appeared in the images as a global motion undergone by the entire 
image (i.e. with a low spatial frequency) and was corrected by applying a spatial high-pass 
filter (fc = 60m-1) onto the tissue velocity maps. A Butterworth temporal low-pass filter (cut-
off frequency: 1400Hz) was also applied to each pixel to remove high frequency noise. 
The RFA catheter was positioned in the center of the imaged zone to perform the 
ablation and the ultrasound catheter was then driven away. A heating of 2*2min with 8 Watts 
of electrical power was performed. After ablation the RFA catheter was removed and the 
imaging catheter was precisely driven to its initial position. 
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SWE was performed again and a new stiffness map was obtained. SWE was 
performed several minutes after ablation in order to insure that the tissue temperature was 
back to 37 degrees, hence avoiding any potential false positives caused by the variation of the 
shear modulus with temperature when the necrosis threshold is not reached 166. 
A gross pathology study was performed at the end of the study. More specifically, the 
heart samples were cut along the imaging plane of the ultrasound transducer, under control of 
the B-mode imaging, removed from the gel and photographed. Depth and size of the lesion 
were estimated by identifying the boundary of the variation in tissue color using a k-means 
clustering algorithm 180, by discriminating viable tissue (red) from ablated (white). According 
to the results obtained by Sapin-de Brosses et al.176 and Mariani et al.201 (Chapter2), a shear 
modulus increase ratio of 2 to 3 between normal and ablated tissue can be used to 
discriminate ablated from non-ablated tissue. In this study, a 60-kPa threshold was used to 
determine lesions’ boundaries. 
2.2.4 In-vivo experimental setup 
The study was approved by the University of Bordeaux guidelines on the use and care 
of animals. Three 40 to 50 kg sheep were studied. The animals were pre-anesthetized by 
injecting 10–20 mg/kg of ketamine hydrochloride, and general anesthesia was maintained 
with an infusion of sodium pentobarbital (2.5 mg/kg/hour) and ketamine hydrochloride (2 
mg/kg/hour). The sheep were ventilated with 25% humidified oxygen via a tracheostomy. 
After the in-vivo procedure the animals were euthanized.  Treated hearts were collected and 
placed in a formaldehyde solution. Gross pathology was performed to assess the presence of a 
lesion, although co-registration with SWE was not performed. 
An incision was performed in the thigh of the animal to access the femoral vein. The 
RFA catheter and the ultrasound imaging transducer were inserted into steerable sheaths 
(12F) and introduced via the femoral vein into the right atrium, under fluoroscopy (Figure 
3-2a). The alignment of the ablation and monitoring devices was performed using the 
ultrasound catheter B-mode imaging. Figure 3-2b shows such an alignment as seen under 
fluoroscopy. Automated R-wave detection was used to precisely start acquisitions at a 
specific cardiac event on the ECG.  Note however that all acquisitions were performed in a 
single cardiac cycle. 
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Figure 3-2 : (a) Example of US and RFA catheters placement in the right atrium. The 
catheters are inserted through the jugular vein. (b) Example of US and RFA catheters 
alignment monitored under fluoroscopy. 
2.2.5 In-vivo sequences 
Two types of acquisitions were performed in vivo: the time variation of stiffness 
during the cardiac cycle was measured quantitatively and stiffness maps were performed 
before and after RFCA. Because of potential guided-waves effect occurring in vivo in the atria 
which consist of a thin layer of several mm, shear-wave speed is provided instead of shear 
modulus as the principal quantification result.  
In vivo stiffness maps of ablated atrium 
The ablation and imaging catheters were first aimed at a normal region of the right 
atrium under fluoroscopy. The tip of the ablation device was put in contact with the tissue 
using electrical impedance monitoring. The ultrasound transducer was positioned at a distance 
of approximately 8 mm from the tissue under B-mode imaging guidance while insuring that 
the RFA catheter was located at the center of the ultrasound imaging plane. 
The ablation catheter tip was then removed from the image by manually steering the 
sheath and a stiffness mapping was performed on the normal tissue. The acquisitions were 
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triggered at the R-wave of the ECG, which corresponds to the beginning of atrial diastole. 
Depending on the acquisition, the push focal distance was set at a depth varying between 6 
and 12 mm while the imaging depth was fixed at 20 mm for an imaging PRF of 18.9 kHz. 
Either 30 compounded images at a 6.3-kHz frame rate or 100 images at the 18.9-kHz frame 
rate were obtained, for a total acquisition time of 28ms. A temporal Butterworth band-pass 
filter (cutoff frequencies for compounded images: 100-600Hz; cutoff frequencies for non-
compounded images: 100-1000Hz) was used to isolate the shear-wave. For each frame the 
spatial mean tissue velocity, resulting from the catheter-tissue relative movement, was also 
removed. Total automated time of beamforming and processing data for the final map was 
typically 7.5s using a laptop computer, with manual delineation requiring 3 supplementary 
seconds. 
The RF catheter was then positioned back onto the tissue in the center of the imaging 
plane and ablation was performed. Temperature and electrical impedance of the tip of the 
catheter were monitored to control tissue heating and avoid boiling. 
After ablation, the RFA catheter was removed and a stiffness mapping was performed 
again with the same parameters. 
Time variation of stiffness driven by cardiac contraction 
To investigate the temporal pattern of atrial stiffening in normal tissue (N = 5, sheep N 
= 3), we performed ten 4-ms-long single-push SWE acquisitions during a single cardiac cycle 
(sinus rhythm) at a rate of one every 60 ms, with the first acquisition triggered on the R-wave 
peak of the ECG. The entire single cycle was sampled by 10 SWE acquisitions. 
Spatiotemporal representations of the shear wave were obtained by averaging the tissue 
velocity along the thickness (i.e., axially) of the tissue. The slope of a linear least-squares fit 
of the lateral position of the maxima of the waveform as a function of time provided the mean 
shear-wave group velocity estimates.  
The same acquisition was performed at the same position in the tissue (N = 4, sheep = 
3) after ablation. 
Statistical analysis 
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All results are given with their standard deviation (SD) within or across samples. 
Changes in myocardial stiffness were analyzed using a paired two-tailed t-test to evaluate the 
significance of difference between individual values before and after ablation. Statistical 
significance was inferred for p<0.05. 
2.3 Results  
2.3.1 Ex vivo study 
Figure 3-3 shows the variation of the shear modulus in an ex vivo sample before and 
after ablation. Before ablation (Figure 3-3a), the shear modulus is homogeneous throughout 
the sample and is approximately 21±9kPa (corresponding shear wave velocity: ct = 
4.4±0.9m.s-1) within the sample, with a small number of artifacts, most likely attributable to 
remaining air bubbles in the sample. Figure 3-3b shows the resulting stiffness map in the 
same sample after RFCA. The mean shear modulus increased from 21±9kPa (ct = 4.4±0.9m.s-
1) to 109±82kPa (ct = 9.7±2.9m.s-1) in the lesion. 
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Figure 3-3 : Shear modulus maps (a) before and (b) after ablation in a left ventricular ex vivo 
sample. The mean shear modulus before ablation was 21±9 kPa. After a 2*2min 8W heating 
with the RFA catheter and a 5 min thermal relaxation, the mean shear modulus increased to 
109±82kPa in the region identified as the lesion (shear modulus threshold of 60 kPa), 
corresponding to an increase factor of 5.2. 
Mean lesion depths were measured with gross pathology and with SWE at the center 
line of the lesion and were found to be in good agreement with an approximate depth of 3 mm 
(Figure 3-4). The average shear modulus across samples obtained in the ablated zones was 
99±17kPa (average ct: 9.0±0.5 m.s-1) for a mean shear modulus across samples before 
ablation of 22±5kPa (average ct: 4.5±0.4 m.s-1, p < 0.005) (Figure 3-5). A mean shear 
modulus increase ratio across samples of 4.5±0.9 was found (mean ct increase ratio: 2.0±0.3), 
which shows the very high contrast that can be obtained with this technique. In contrast, we 
did not observe any significant qualitative changes on the B-mode images. 
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Figure 3-4 : Lesions’ depths determined with SWE with a shear modulus threshold of 60 kPa 
(d1), compared against gross pathology (d2) plotted within 95% limits of agreement (± 1.96 
standard deviation (SD) of the difference). A mean lesion depth of 3mm was found with gross 
pathology and the average absolute difference found with SWE was 0.20mm. Two examples 
of lesion tissue color change are shown. 
 
Figure 3-5 : Average shear modulus across ex-vivo samples (n=5) before and after ablation. 
The mean value increased from 22±5kPa to 99±17kPa, i.e. a ratio of 4.5±0.9 in the lesions’ 
boundaries. 
2.3.2 In vivo study 
Time variation of normal atrial stiffness  
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Intracardiac SWE was first performed in normal atrial tissue. Normal atrial stiffness 
and its variation during the cardiac cycle were measured at a total of five atrial locations in the 
three animals. Figure 3-6a shows an example of shear wave speed measured in normal atrium 
(lateral wall) and its variation with stress (pressure and atrial contraction) during the cardiac 
cycle. The shear wave speed was found to vary from 1.0 m.s-1 to 1.5 m.s-1 (corresponding 
shear modulus: 1.0kPa to 2.4kPa) during the cardiac cycle. The shear-wave speed curve 
presented four main phases depicting the atrial cycle: 1) Atrial filling: from 60ms after the R-
wave to 50 ms after the T-wave, the shear-wave speed increased from 1.0 m.s-1 to 1.5 m.s-1 
(1.0kPa to 2.4kPa); 2) Ventricular filling : from 50 ms after the T wave to the P-wave the 
shear-wave speed decreased from 1.5 m.s-1 to 1.0 m.s-1 (2.4kPa to 1.2kPa); 3) Atrial 
contraction: from the P-wave to 60 ms before the R-wave the shear-wave speed increased to 
1.4 m.s-1 (2.2kPa); and 4) Atrial relaxation: from 60 ms before the R-wave to 60ms after the 
R-wave the shear-wave speed dropped to 1.0 m.s-1 (1.1 kPa). 
Similar time variation was found at the five locations in the three animals. Over the 
samples a mean atrial shear-wave velocity of 1.4±0.2 m.s-1 (2.3±0.7 kPa) was measured over 
the cardiac cycle. The mean minimal velocity of 1.0±0.1 m.s-1 (1.0±0.2 kPa) was measured 
after atrial relaxation, whereas the mean maximal velocity of 1.9±0.4 m.s-1 (4.1±1.8 kPa) was 
reached during atrial contraction. 
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Figure 3-6 : Time variation of stiffness in a right atrium zone (lateral wall) (a) before and (b) 
after ablation. For each sample a total of 15 acquisitions were performed, at a rate of one 
every 60ms, corresponding to 10 acquisitions per heart cycle. Every shear-wave acquisition is 
represented spatiotemporally with a linear fit (white line) on the successive shear-wave 
maxima. The resulting shear-wave speeds are given below with corresponding ECG timings. 
(a) The shear-wave speed of normal atrial tissue varied from 1.0 m.s-1 to 1.5 m.s-1 with a 
mean value of 1.2±0.2 m.s-1. Two peaks are present: one at the end of atrial blood filling, one 
at atrial systole. (b) The shear-wave speed of ablated atrial tissue varied from 2.3 m.s-1 to 4.3 
m.s-1 with a mean value of 2.9±0.7 m.s-1. A very strong peak is visible on atrial systole and a 
relatively low on the blood filling. 
Time variation of ablated atrial stiffness  
The atrial stiffness was then measured after ablation. Figure 3-6b shows the increase 
of shear wave speed for the same location as in Figure 3-6a. Within the cardiac cycle the 
temporal average of the shear wave speed increased to 2.9±0.7 m.s-1 (9.5 ±5.0 kPa) and larger 
temporal variations can be observed. The temporal shape differed slightly from the normal 
tissue, but the atrial contraction and relaxation phases are still visible: a large increase 
appeared (from 2.3 to 4.3 m.s-1; from 5.5 kPa to 19.2 kPa) at the beginning of the atrial 
systole followed by a relaxation. In contrast, the atrial shear-wave speed increased moderately 
during the passive filling (from 2.2 to 2.6 m.s-1; from 5.0 kPa to 7.1 kPa).  
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Figure 3-7 summarizes the average stiffness variations over all the different locations 
in normal and ablated tissues. The minimal, mean and maximal stiffness values within one 
cardiac cycle are shown. All these values were found to increase significantly in ablated 
tissues. The mean shear-wave speed of ablated atrium was found to increase significantly to 
2.4±0.4 m.s-1 (6.3±2.0 kPa, p<0.002), the mean minimal velocity increased to 1.7±0.4 m.s-1 
(3.1±1.6 kPa, p<0.05) and the mean maximal value to 3.5±0.5 m.s-1 (13±4kPa, p<.001). 
 
Figure 3-7 : Minimal/Mean/Maximal shear-wave speed (a) and shear modulus (b) measured 
in the right atrium, within one cardiac cycle, before (averaged across n=5 samples) and after 
ablation (n=4). Shear-wave speed in normal tissue varied across samples from 1.0±0.1 m.s-1 
to 1.9±0.4 m.s-1 (corresponding shear modulus:  1.0±0.2kPa to 4.1±1.8kPa) with an average 
of 1.4±0.2 m.s-1 (2.3±0.7kPa) and from 1.7±0.4 m.s-1 to 3.5±0.5 m.s-1 (3.1±1.6kPa to 
13±4kPa) with an average of 2.4±0.4 m.s-1 (6.3±2.0kPa) in ablated tissue. 
Stiffness mapping of ablated atrium  
The R-wave was chosen as a time reference point for stiffness mapping of normal and 
ablated tissues. Figure 3-8 shows several examples of stiffness maps obtained before and after 
ablation at different locations of the right atrium. In Figure 3-8a, the lesion is visible as a 
region of high shear wave speed. The mean shear-wave speed increased from 1.6±0.3 m.s-1 to 
3.3±0.4 m.s-1 (2.9±1.0 kPa to 12±3 kPa) in the central region of the lesion. The border of the 
lesion seems to be visible on the left side of the lesion. At this location the stiffness remained 
unchanged compared to the normal stiffness. The lesion observed on gross pathology showed 
a good agreement in dimensions (approximate diameter of 5mm) and transmurality of the 
same ablation area found with SWE. Figure 3-8b and Figure 3-8c show other examples of 
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RFCA lesions with variations respectively of 1.8±0.2 m.s-1 to 3.4±0.4 m.s-1 (3.3±0.7 kPa to 
12±3 kPa) and from 1.4±0.2 m.s-1 to 2.6±0.2 m.s-1 (2.3±0.7 kPa to 7.3±1.3 kPa).  
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Figure 3-8 : Shear-wave speed maps in normal (middle), ablated (right) right atrial tissue, 
with Bmode images taken before ablation (left). The mean shear-wave speed value varied in 
the central region of the sample from 1.6±0.3 m.s-1 in normal tissue to 3.3±0.4 m.s-1 in the 
ablated zone (a), from 1.8±0.2 m.s-1 to 3.4±0.4 m.s-1 (b), from 1.4±0.2 m.s-1 to 2.6±0.2 m.s-
1 (c). Maps acquired after ablation clearly reveal the presence of lesions. Validation against 
gross pathology (a) shows a good agreement between width and depth (transmurality) found 
with SWE of the presented lesion. 
A total of 6 ablation locations were mapped with SWE in the three animals. A 
significant increase of atrial stiffness was found for 5 lesions. One lesion exhibited no 
significant change, but this lesion was not found after the heart was explanted. For each of the 
5 lesions with stiffness increase, the mean stiffness was calculated in a 3mm-diameter area in 
the center of the lesion (average shear-wave speed across samples: 3.1±0.3 m.s-1, average 
shear modulus: 10±2 kPa) and compared against the mean stiffness before ablation in the 
same 3mm-diameter area (average ct across samples: 1.8±0.3 m.s-1, average shear modulus: 
3.3±1.0 kPa) (Figure 3-9). A mean ct increase ratio of 1.8±0.3 was found (mean shear 
modulus increase ratio: 3.1±0.9).  
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Figure 3-9 : Average shear-wave speed (a) and shear modulus (b) across in-vivo samples 
(n=5) before and after ablation. The mean shear-wave speed increased from 1.8±0.3 m.s-1 
(mean shear modulus: 3.3±1.0 kPa) to 3.1±0.3 m.s-1(mean shear modulus: 10±2 kPa), i.e. a 
ratio of 1.8±0.3 (mean shear modulus increase ratio: 3.1±0.9) in the considered 3mm-diameter 
lesion’s centers. 
2.4 Discussion 
In this study, Shear-Wave Elastography was implemented on a standard intracardiac 
imaging transducer to map the thermal lesions induced with RFCA in cardiac tissue ex vivo 
and in vivo. Intracardiac SWE was first investigated in ex-vivo heart samples (N = 5). Lesions 
were induced with a clinical RFA catheter and stiffness mapping was performed before and 
after ablation in the same plane. A large shear modulus ratio was obtained (2 to 5 folds) 
between healthy and ablated tissue and provided a reliable quantity to determine lesions’ 
boundaries, as validated against gross pathology. 
The feasibility of intracardiac SWE was then demonstrated in vivo in sheep (N = 3).  
At first, as atrial tissue – as well as ventricles – is active during the cardiac cycle, we 
investigated its normal stiffness’ temporal profile during the entire cardiac cycle. Little 
attention has been given previously to the time variation of atrial stiffness, and there is 
currently no data in our knowledge that could be used to determine at what time of the cardiac 
cycle the stiffness mapping should be performed. By measuring the variation of normal atrial 
stiffness within one cardiac cycle, we found that this variation was approximately 50% during 
the whole cardiac cycle, which is lower than the variation observed in the ventricles 206, 208, 211, 
212
. More important variations of atrial stiffness were found after ablation. Therefore, a time 
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point was required to compare stiffness before and after. The R-wave was found as a good 
reference time point: the R-wave is easy to detect and the atrial stiffness of ablated and 
normal tissues is relatively low at this time point which is better to provide shear velocity 
estimates 210. The time variation profile of those variations was found consistent with passive 
and active cardiac events of the right atrium. The shear-wave speed curve presents a first 
increase of 50% during the passive filling of the atrium. The opening of the tricuspid valve 
then leads to the passive emptying of the chamber, which is associated with a decrease in the 
shear-wave speed. The P-wave corresponds to the atrial systole – an increase of pressure and 
also active stiffening (40% increase of the shear-wave-speed). Finally, before the R-wave – 
i.e., the onset ventricular contraction – the atrium has a smaller volume, is relaxed and has a 
low stiffness. 
Based on these measurements, the R-wave was chosen as a reference time point for 
mapping the atrial tissue. Indeed, any time point of the cardiac cycle could have been chosen 
because the stiffness in normal tissue does not vary strongly during the cardiac cycle. 
Nevertheless, in order to compare the different acquisitions, it is important to compare the 
stiffness at the same time point, and the R-wave presented a practical reference time point. 
N=6 RFCA lesions were mapped with SWE in the right atrium. The stiffness in the 
lesion increased significantly in 5 lesions. Based on the in vitro results, a 2 fold increase of 
the shear wave speed was determined as a threshold for the lesion detection. If this threshold 
is applied on the in vivo results, the boundary of the lesion can be determined on the SWE 
maps. However, further work is necessary to confirm that this threshold can discriminate 
ablated tissue from viable tissues. 
Atrial stiffness measured in vivo by SWE was in good agreement with values reported 
in the literature on mechanical testing measurements of excised atrial tissues. Bellini et al. 213 
reported a shear modulus between 1.56 and 8.84 kPa in 9 excised human right atrial samples. 
In right atrial in vivo sheep tissues, we found a shear modulus between 1.0 and 4.1 kPa. In 
contrast, because of myocardium contracture and rigor mortis stiffening several hours after 
excision, ex-vivo ventricular samples exhibited much higher values of shear modulus. 
An advantage of SWE is its real time capability due to ultrafast imaging that permits 
the acquisition a stiffness map within a single heartbeat. Thanks to this use of plane wave 
imaging, SWE satisfies the ALARA principle ("As low as reasonably acceptable"). Stiffness 
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maps were acquired within 20ms for a single cardiac cycle and could be processed in quasi-
real time.  
Motion artifacts due to cardiac contraction remain very limited and do not affect the 
tracking of the shear wave within cardiac tissues. Indeed since the heart wall motion has a 
lower frequency content 214, 215 than the shear wave tissue velocity (temporal frequency 
content from 100 to 400Hz) it can be removed using spatial and temporal filters 206, 212. 
These results suggest that SWE could be used in a clinical setting for the monitoring 
of atrial stiffness in patients even during arrhythmia and is the subject of on-going studies in 
our group. 
The time-of-flight algorithm used for shear-wave velocity mapping was originally 
designed and optimized for shear waves propagating in a direction parallel to the probe. As 
our results indicated that shear waves generated using a 6-MHz probe were guided and as 
such propagated following the geometry of the atrial tissue, the algorithm was adapted to take 
into account the varying direction of propagation. While this modification currently requires 
user input, tissue’s curvature was entered manually by selecting several points of its surface 
on B-mode images, the process could be automated in a relatively straightforward manner and 
allow for real-time processing.  
Another advantage of SWE is its capability to provide quantitative values of the shear 
modulus. In vivo, the absolute value of the shear-wave speed increased strongly after ablation 
(the maximal shear modulus reached 13 kPa). As suggested by the results obtained during the 
cardiac cycle (Figure 3-7) one has to be careful when choosing the absolute value of stiffness 
to determine the presence of a lesion in vivo. Systolic (typically maximal) stiffness before 
ablation can be superior to the diastolic (typically minimal) in a lesion. However, when 
considering a specific instant of the cardiac cycle, the post-ablation shear-wave speed was 
always much higher than the pre-ablation shear-wave speed. If a stiffness threshold of ablated 
tissue can be determined experimentally and confirmed in more experiments and in different 
parts of the atria, the post ablation mapping could be sufficient to determine the ablation zone 
without the need for pre-ablation mapping. This is of particular importance for the 
identification of ablated zones in patients with recurring AF.   
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However, current limitations to SWE include the fact that the shear modulus relation 
to shear-wave group velocity as described in Chapter1 was verified under purely elastic and 
semi-infinite assumptions, which may not be correct for atrial tissues as the atrial wall is thin 
and viscoelastic. However, in future work, these effects could be taken into account in the 
shear modulus calculation with appropriate models including visco-elastic 216 and guided 
wave propagation models 212, 217. Guided wave effects need to be carefully addressed in order 
to establish a quantitative threshold of ablated tissue. While including such corrections in 
acquisition sequences using an intracardiac catheter is the object of on-going work, the 
approach used in this study is a simple, first-order approximation to the mapping of the 
stiffness. 
Ex-vivo characterization of shear modulus mapping with SWE was based on gross 
pathology tissue investigation. This technique intrinsically implies variations in the 
measurement of lesions’ boundaries: indeed, after ablation, the tissue was manually cut 
following the US imaging plane with a possible deviation that we estimate to be, based on 
observation, of approximately ±0.5 mm inducing imprecise lesions’ boundaries determination 
with the optical images. 
Another limitation of this study is the small number of animals investigated. The small 
size of the study makes it difficult to draw definite conclusions about the reproducibility of 
the technique.  
Finally, another major limitation we encountered during the in vivo study was the lack 
of navigation system which made very challenging the alignment of the ultrasound and RFA 
catheters. Fluoroscopy was used to identify the position of both devices in the heart and their 
relative approximate position, the alignment of the catheters was made under US B-mode, but 
it was very difficult to precisely ensure that the imaging plane was located at the center of the 
lesion. Additionally the catheters were moving during the procedure, this could explain the 
difference of the tissue’s shape before and after ablation on Figure 3-8b. A precise navigation 
system could be of assistance to locate both catheters, and the accuracy of the alignment will 
be evaluated in a future study.  
Even better, the capability of ultrasound to both image and thermally ablate tissues 
present a great potential for dual mode approaches 218 with intracardiac probes. A single 
catheter system could be developed, capable of both ablation and monitoring with the same 
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transducer elements. Such intracardiac dual mode transducer would provide an intracardiac 
treatment of atrial fibrillation with controlled monitoring of necrosis. The work presented in 
this article corresponds to a first step towards these full ultrasound-based atrial fibrillation 
treatments. 
3 Intracardiac Ultrafast Doppler imaging 
3.1 State-of-the-art and concepts 
Another important effect of thermal ablation, in addition to the change of elastic 
properties of ablated tissues, evaluated with SWE, is the modification of the micro-
vascularization. This effect can be imaged with CT139 (as mentioned in the previous chapter), 
contrast-enhanced MRI 219, contrast-enhanced ultrasound B-mode imaging 220 or more 
generally with ultrasound Doppler imaging 219. 
Cardiac vascular flow imaging is an important tool for the diagnosis of various 
cardiovascular diseases e.g. myocardial infarction or coronary artery stenosis. Gold standard 
techniques are CT 221 and MRI 222 that provide angiographic images with high sensitivity but 
necessitate the injection of contrast agents, suffer from low frame rates and are not real-time. 
On the other hand currently existing ultrasound contrast enhanced real-time imaging 223 
suffers from poor sensitivity resulting in the detection of only main arteries. 
In past several years a new ultrasound imaging technique, Ultrafast Doppler224, has 
been developed. It is based on Ultrafast imaging presented in the first chapter. It has the 
advantage of providing a full blood flow characterization with a high sensitivity and in real-
time. It provides access to completely new imaging modalities such as functional ultrasound 
(fUS) in the brain 225, 226 or high sensitivity cerebral blood flow imaging in the neonates 227 
and has recently been used for cardiac imaging providing the left ventricular hemodynamic 
function with a transthoracic approach 228 as well as the feasibility of coronary flow imaging 
after thoracotomy 229. 
In this work we implemented Ultrafast Doppler imaging on the intracardiac transducer 
in order to investigate the feasibility of coronary mapping with the intracardiac approach to 
assess the possibility of detection of the variation of vasculature after RFCA. We tested the 
technique in-vivo on two sheep (N = 2). 
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3.2 Methods 
3.2.1 Experimental setup 
The acquisitions were performed in sheep (n = 2) during the same protocol described 
in part 2.2.4 of this chapter for RFCA evaluation with intracardiac SWE. Ultrafast Doppler 
was thus performed on the same tissues that were imaged with SWE. Acquisitions were taken 
before ablation in the ventricles to assess the presence of coronaries. Since cardiac perfusion 
occurs during relaxation, the acquisitions were triggered on ventricular diastole. 
3.2.2 Ultrafast Doppler imaging 
Sequences 
In this study two sets of parameters were tested for ultrafast Doppler sequences. In the 
first case a series of 11 tilted plane waves (-5:0:5°) at 6.5MHz were sent with a PRF of 19.6 
kHz for an imaging depth of 16mm. After compounding in total 1400 images were obtained 
for a final frame rate of 1.8 kHz and a total acquisition time of 786ms. In the second case a 
series of 3 plane waves (-2 0 2°) at 5MHz was sent with a PRF of 16.1 kHz for an imaging 
depth of 30mm. After compounding 1200 images were obtained with a final frame rate of 5.4 
kHz and an acquisition time of 223ms. 
Data processing 
The data processing in based on Singular Value Decomposition (SVD) filtering, a 
technique very recently introduced in the field of Ultrafast Doppler imaging 230. Briefly, it is 
based on the hypothesis of a high spatiotemporal coherence of the tissue signal, compared to 
the blood flow. It means that it is possible to separate both sources of signal by carefully 
choosing a rejection threshold of n first singular vectors of the SVD from the total raw signal 
(a rejection of the most energetic sources).   
In this work we performed SVD by choosing sliding temporal windows within the 
final compounded frames. For the first sequence signal was processed within 30 frames 
(corresponding to 17ms of acquisition) every 20 frames (11ms) and first 20 eigenvectors were 
rejected. For the second sequence, signal was processed within 200 frames (37ms of 
acquisition) every 50 frames (9ms) and first 140 eigenvectors were rejected. Finally power 
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Doppler images were calculated by integrating over time the resulting signal on the 
considered temporal window. 
3.3 Results 
Figure 3-10 shows an example of acquisition in an interventricular septum, performed 
with the first set of parameters. SVD filtering revealed localized energetic spots 
corresponding very probably to coronary flow (perpendicular to the imaging plane). 
 
Figure 3-10 : Ultrafast Doppler acquisition in an interventricular septum. (a) Sum of the 30 
Bmode images used for processing. (b) Power Doppler image after SCD filtering revealing 
energetic signals within the tissue. (c) The indicated spots presumably correspond to coronary 
flow. 
Figure 3-11 shows an example of a second acquisition in the interventricular septum, 
with the other set of parameters. After the SVD filtering very thin (few hundreds of microns) 
structures appear within the tissue.  
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Figure 3-11 : Power Doppler acquisition with SVD filtering revealing coronary-like 
structures. (a) B-mode image of the cardiac wall. (b) Power Doppler acquisition within a 
37ms window (200 frames). Two coronaries may be visible. (c) Most probable positions of 
the coronaries. 
3.4 Discussion  
While the examples shown in the results section are promising, consequent work 
needs to be done to confirm the possibilities of the intracardiac Ultrafast Doppler imaging. 
The processing of the coronary mapping necessitates improvement to increase the sensibility 
of the technique in order to make a study on the vascular effect of thermal ablation possible. 
Nevertheless even a simple introduction of the SVD filtering shows new potentials for 
intracardiac Ultrafast Doppler.  
4 Conclusion 
In this chapter we have shown the capability of Shear-Wave Elastography to map 
Radio-Frequency Ablation lesions in ex-vivo myocardial tissues with high contrast (mean 
shear modulus increase ratio of 4.5±0.9) using an intracardiac catheter. In vivo feasibility has 
been demonstrated for lesion evaluation as well as for the estimation of the shear-wave speed 
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and shear modulus time profile of atria. This technique reveals very promising for the 
evaluation of Radio-Frequency Catheter Ablation and more generally intracardiac thermal 
ablations. 
We have also shown other possibilities of imaging with an intracardiac transducer, 
with possible applications for thermal ablation evaluation (Ultrafast Doppler Imaging of 
lesions) but also for other diagnostic imaging (Ultrafast Doppler revealing coronaries). Those 
new approaches are at the stadium of a promise but could become in the near future real new 
imaging modalities for the intracardiac approach. 
Beyond current state of the art, the work presented in this chapter, in particular 
intracardiac SWE, was a first step towards a theranostic intracardiac ultrasound system 
combining monitoring and ablation capabilities on the same probe. Indeed, as discussed 
previously, we think the usage of two independent catheters, one for therapy, one for imaging, 
could be related to an important risk of errors for thermal lesions mapping. In the next chapter 
we present a novel intracardiac system presenting a dual-mode therapy-imaging approach all 
performed with the same elements of the same device. 
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Chapter 4. Intracardiac dual-mode 
therapy and imaging approach 
1 Introduction  
1.1 Motivation 
In this chapter, a novel intracardiac approach is proposed for cardiac ablation 
treatments based on the combination of ultrasound therapy and imaging on the same 
intracardiac dual mode transducer. This work was motivated by several reasons. First, the 
results of intracardiac imaging obtained in Chapter 3 are promising for mapping RFCA 
lesions, however, the separation of therapy and imaging on two separate systems, requires the 
use of multiple catheters and complex navigation systems. Second, as discussed previously 
(Chapter 1), HIFU therapy presents many potential advantages over RFCA that could be 
beneficial for cardiac ablation especially in the context of ventricular tachycardia (VT). The 
idea of catheter-based cardiac HIFU is not new and several systems have already been 
developed and tested even pre-clinically. 
1.2 Intracardiac HIFU: state-of-the-art 
A general overview of cardiac HIFU has been presented previously (Chapter 1). Here 
we will draw attention on catheter-based approaches. Various catheter-based systems and 
designs, dedicated for minimally-invasive cardiac HIFU ablation, have been studied in the last 
two decades.   
In a similar approach than the intraoperative Epicor system, some designs are 
dedicated for an epicardial approach without, however, the need for extensive surgery. Such 
approach is already performed with RFCA to create lesions in the ventricles for VT 
treatement231, trying to overcome the low energy penetration of this technique8. Hynynen et 
al. 74, 232 were first to perform in-vivo epicardial HIFU-induced lesions with catheter-based 
designs obtaining lesions depths up to 8.5mm. More recently Koruth et al.233 tested another 
design capable of creating lesions in the myocardium up to 15mm deep leaving vital coronary 
structures intact. To note, an original system, based on non-thermal shock-wave tissue 
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disruption has also been proposed recently234, but lesion formation was limited only to 3mm. 
Although designed for minimally-invasive usage, all these systems were tested with surgical 
sternotomy. Still, if not performed with surgery, the epicardial approach may be more limited 
for maneuverability and finally the flexibility of the ablation.  
Intracardiac HIFU approaches have also been investigated. A first in-vivo proof of 
concept has been performed by He et al. 73, but with a catheter insertion via the cardiac 
chambers. Ohkubo et al. 85 designed and realized first in-vivo HIFU ablation using a high 
power transducer by the classical femoral vein approach and obtained maximal lesions’ 
depths up to 8-10mm. However, motivated by new anatomical findings in the field of atrial 
fibrillation 6, new balloon-based systems have been designed for an efficient pulmonary vein 
(PV) isolation. As other balloon-based systems, those transducers were capable of creating 
circumferential lesions around PVs with single-up-to-several sonications. A first system, 
conceived by Atrionix (Sunnyvale, CA, USA), underwent pre-clinical tests235, 236 but was 
limited by an architecture unsuitable for a variable PV anatomy. A second system 
(ProRhythm, Ronkonkoma, NY), presenting a more  adapted design to perform PV isolation, 
has also been investigated in humans 30, 237. Despite promising performances and safety 
algorithms the system led unfortunately to two patient deaths and its clinical usage has been 
stopped238, 239. By the nature of the probe design, the circumferential focus was fixed and 
probably too deep, leading to atrio-esophageal fistulas even after focus reduction and with 
esophageal temperature monitoring. 
All those systems presented interesting ablation performances but were not 
accompanied with imaging modalities to control the effective lesion formation. This issue has 
been extensively presented in Chapter 3 and the balloon example may have shown once again 
the importance for such control. 
Only few experimental image-guided HIFU systems, designed for intracardiac usage, 
have been reported. Gentry et al. designed a cylindrical forward looking catheter 240, 241 
composed of a HIFU ablation ring, with in its center a custom 2-D imaging array. The group 
reported first in-vitro ablations and preliminary imaging. Another possibility for image 
guidance is MRI, Carias et al. 242 published recently first achievements on MRI compatible 
intracardiac HIFU catheters with successful in-vitro ablation. On the other side of the wall, to 
complete the therapy-imaging devices list, new systems based on RF ablation, but with 
integrated ultrasound imaging have been successfully tested in-vivo 198–200.  
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This lack of performant ultrasound-based therapy-imaging devices is caused by the 
challenges of the intracardiac environment, principally the combination of miniaturization 
accompanied with the need of sufficient HIFU performances and manoeuvrability, which 
leave very little space for imaging. Therefore a possible solution, satisfying all those 
requirements, is to design a hybrid transducer, combining therapy and imaging on the same 
elements. Such ultrasonic systems are called dual-mode transducers and have already been 
used for other applications. 
1.3 Dual-mode intracardiac catheter 
1.3.1 State-of-the-art 
The concept of dual-mode arrays has been introduced by Ebbini et al. 243, 244 and is 
based on usage of the same elements for imaging and ablation. The first advantage underlined 
for this type of probe was the quick feedback it can provide to control therapy. This feature 
was applied for transcostal therapy in the liver or kidney to avoid an excessive exposure at the 
rib locations 81 and to finally provide a real-time feedback during therapy to enhance ablation 
control 245. However in our concern the main advantage dual-mode arrays offer, is the 
miniaturization of the image-controlled therapy device. 
Few interstitial dual-mode systems have been proposed for liver or biliary 
applications. Two designs are based on single 246 or five-element 247 high-power transducers 
performing sector-imaging by a mechanical rotation of the probe. A third one was composed 
of a 32-element array and has been successfully tested in-vivo on rabbit tumorous liver 
models248, providing high emission intensities (110W/cm2) and good quality B-mode 
imaging. 
1.3.2 Dual-mode intracardiac catheter 
In our case the system relies on a standard intracardiac imaging transducer which 
underwent only few modifications to provide high intensities and thermally support HIFU 
sequences for ablation. The goal is to benefit from all the imaging modalities presented in 
Chapter 3 and in parallel be capable of creating lesions using the same aperture. The 
alignment and devices size issues could be thus easily solved. Moreover thanks to the multi-
element architecture, therapy with this device could be very flexible: with only the electronic 
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steering, large zones of tissue could be ablated without moving the transducer. Even more, 
whereas in atria the transmural aspect of the lesion is desired, in the case of ablation for 
ventricular tachycardia, only certain layers of the cardiac wall need sometimes to be targeted. 
In this work, first, a new dual mode intracardiac transducer was designed in 
collaboration with Vermon (Tours, France). We have characterized the output intensity with 
an acoustic balance setup in parallel with the internal heating of the probe for several 
emission parameters. Second, we validated in vitro optimal HIFU sequences adapted to our 
device with heart-mimicking conditions. Finally we performed an in-vivo feasibility study for 
the dual-mode catheter in four sheep (n = 4) with a standard intracardiac setup and performed 
image guided ablations in right atria, right ventricles and interventricular septa (IVS).  
2 In vitro HIFU performance characterization 
2.1 Materials 
2.1.1 Dual-mode intracardiac transducer 
The dual-mode transducer (Figure 4-1a) was based on a regular intracardiac 
echocardiography (ICE) catheter249 (6 MHz, 50-% bandwidth, 64 elements, 0.2-mm pitch, 9F, 
Vermon, France) and has been customized by Vermon to support HIFU emissions. It was 
driven by fully programmable prototype electronics (256 emission, 128 reception channels, 
SuperSonic Imagine, France) consisting of an ultrafast ultrasound scanner (Aixplorer®, 
SuperSonic Imagine, France) for imaging, combined with a high power supply (up to 10W 
per channel) for therapy. A thermistance set at the basis of the catheter’s tip, before the active 
surface, was monitoring the internal heating of the transducer. 
2.2 Output and thermal characterization 
2.2.1 Methods 
An acoustic balance setup (Sartorius CPA423S) was used to characterize the 
transducer’s output intensity against the internal heating of the catheter in water at ambient 
temperature (22°C) for 2s emissions (Figure 4-1b). The power electronics elements’ 
excitation signal was square-shaped with adjustable central frequency and duty cycle of the 
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active state (percentage of time the signal is ‘on’ during one period) (Figure 4-2). First, 
measures were performed to find the best emission configuration for those two parameters: 
(1) the central emission frequency (range: 4MHz to 7MHz); (2) the duty cycle of the square 
signal (range: 5% to 100%). Results were presented in terms of thermal efficiency defined 
here as the output intensity (W/cm2) divided by the internal heating of the catheter (°C). 
Second, the transducer’s output against internal heating was measured for the best 
configuration that was found. 
 
Figure 4-1 : (a) The intracardiac dual-mode transducer (dark gray) with the dimensions of the 
active surface (light gray). (b) Acoustic balance setup. The catheter (blue wire) was emitting 
plane waves on an acoustic absorber (brown resin) for 2 seconds. The radiation force created 
within the absorber is directly proportional to the output power and can be measured with a 
high precision balance. 
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Figure 4-2 : schematic of the command signal applied on the transducer. The duty cycle 
represents the percentage a signal is ‘ON’ (-1 or 1) over the period time. 
2.2.2 Results 
Figure 4-3a shows the thermal efficiency of the transducer versus the central 
frequency of the emission. Whereas the maximum sensitivity of the transducer was around 
7.1MHz and the central frequency 6.4MHz, the best efficiency measured by the ratio of 
output intensity and internal temperature was found around 5.75MHz.  
The thermally most efficient duty cycle of the command signal was found to be 0.75 
(Figure 4-3b). This is due to the harmonic contents of the square waveform transmitted by the 
electronics. Such waveform contains a large amount of third harmonics which depends on the 
duty cycle. In theory, the lowest content of harmonics is found for a duty cycle of 0.8 which is 
very close to the result found here. This suggests that even if the harmonics are outside of the 
bandwidth of the transducer, they may participate to the heating of the probe. 
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Figure 4-3 : Thermal characterization of the transducer in terms of (a) emission central 
frequency, (b) command signal duty cycle. (a) The thermally most efficient emission was 
found around 5.75MHz. (b) The best excitation duty cycle was found around 0.75. 
Figure 4-4 represents the transducer’s output intensity measured with emissions found 
most efficient in terms of internal heating of the transducer (5.5MHz and duty cycle of 0.75). 
Intensities up to 21.5 W/cm2 (corresponding to a total acoustic power of 4.6W) have been 
reached for a maximal temperature increase inside the catheter of 9.0°C during the 2s 
emissions. The temperature increase was found to be linearly dependent with the output 
intensities.  
 
Figure 4-4 : Intracardiac transducer’s output intensity (W/cm2) against power supply voltage 
for 2s constant emissions. A maximal intensity of 21.5W/cm2 has been characterized. 
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2.2.3 Discussion 
These first measurements were promising, suggesting that the catheter may support 
important emission intensities (nearly 18W/cm2) that could be sufficient to thermally induce 
lesions. Continuous emissions were performed 10s with 11W/cm2 with a good stability of the 
transducer. By emitting during 10s at 11W/cm2 at 10mm, we could observe the formation of 
impacts on a Plexiglas plate (Figure 4-5a), as well as we managed to create in-vitro, a first 
lesion in chicken breast (in a 37°C bath) (Figure 4-5b). The continuous emission strategy is 
the most effective to create thermal lesions but it was not possible exceed those intensities and 
emission time. Thus we had to adapt the HIFU sequences to enhance the cooling of the 
catheter and avoid its destruction and study the cooling effect itself by imitating the 
intracardiac blood flow characteristics. 
 
Figure 4-5 : First thermal effects obtained with 10s continuous emissions at 11W/cm2 with the 
catheter. (a) Three impacts created in a Plexiglas plate, obtained with the electronic steering 
of the array, without movement. (b) Three lesions created in a chicken breast (approx. 
1.5*2.5mm2 total surface) obtained in the same manner. 
2.3 In-vitro thermal tests 
2.3.1 Methods 
An excised 30*30*10mm3 bovine skeletal muscle was placed on an acoustic absorber, 
in a degassed water tank at 22°C. A thermocouple was inserted inside the tissue, 4mm below 
the surface. The ultrasound transducer was placed 5mm above surface of the tissue and 
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parallel to it (Figure 4-6). The water in tank underwent a constant flow of approximately 
50mL/s to imitate cardiac intracavitary blood dynamics.  
 
Figure 4-6 : Schematics of the in-vitro setup. The HIFU beam is focalized near a 
thermocouple inserted in the bovine muscle. A constant water flow is induced to imitate 
intracardiac pumping conditions. 
Transducer’s HIFU emissions were tested by focusing ultrasound 1mm under the tip 
of the thermocouple. The sequences (5.5MHz, output intensity 16.5W/cm2, 0.75 Duty Cycle) 
were composed of 500ms emissions followed by 500ms pauses to enhance the transducer’s 
cooling by the flow. Total sequence durations were increased progressively from 10 to 120s. 
Temperatures in the catheter and in the tissue were monitored simultaneously. 
2.3.2 Results 
Figure 4-7b shows an example of the bovine tissue temperature when focusing with 
the transducer next to the thermocouple. While a strong flow was induced in the bath, 
temperature measured in the tissue was growing during the 2 minutes of ultrasound focusing 
for a maximal ∆T of 8.4°C. In contrast temperature in the catheter was stabilized after 20s of 
emission (Figure 4-7a) for a maximal increase of +16.5°C (39.5°C). 
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Figure 4-7 : Temperatures measured in (a) the catheter, (b) a bovine muscle, during a 2min 
HIFU sequence. A water flow was induced in the environment which stabilized the catheter’s 
internal heating (maximal ∆T of 16.5°C at 20s), while the temperature in the muscle (4mm 
below the surface) was increasing during the whole sequence. 
2.4 Discussion 
In this part we have characterized the transducer’s output within a non-destructive and 
repeatable range. An emission frequency of 5.5MHz has been chosen as it was very close to 
the thermally most efficient frequency for this model of transducer and as emissions at this 
frequency were very stable in time. It is also a good compromise between tissue penetration 
and absorption as both wide (ventricles: up to 2cm - 2.5cm) and thin (some parts of atria are 
under 1mm wide) tissues were targeted in the study. 
The sequence construction of 500ms emission followed by 500ms of pause was found 
as the best compromise to rapidly heat the targeted tissue and take advantage of the natural 
blood cavitary flow in the heart to cool the transducer down. Thanks to the little dimensions 
of the transducer (9F i.e. 3mm of diameter) temperature in the device can be easily controlled, 
while temperature in tissue decreases with much longer constants. Taking advantage of this 
no supplementary cooling was needed even for sequences up to 2 minutes. 
Taking benefit of the results presented in this part as well as in Chapter3 we proceeded 
to the in-vivo feasibility validation of this therapy-imaging system. 
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3 In vivo experiments 
3.1 Materials and methods 
3.1.1 In-vivo experimental setup 
The study was approved by the University of Bordeaux guidelines on the use and care 
of animals. Two 40 to 50 kg sheep were studied. The animals were pre-anesthetized by 
injecting 10–20 mg/kg of ketamine hydrochloride, and general anesthesia was maintained 
with an infusion of sodium pentobarbital (2.5 mg/kg/hour) and ketamine hydrochloride (2 
mg/kg/hour). The sheep were ventilated with 25% humidified oxygen via a tracheostomy.  
An incision was performed in the thigh of the animal to access the femoral vein. The 
ultrasound catheter was inserted into a steerable sheath (12F) and introduced via the femoral 
vein into the right atrium, under fluoroscopy. The positioning of the device was made under 
its real-time B-mode imaging. Automated R-wave detection was used to precisely start SWE 
imaging acquisitions at a specific cardiac event on the ECG. In the right ventricular free wall 
or the IVS SWE mapping was triggered between the T-wave and the QRS complex on the 
ECG, which corresponds to the ventricular diastole. In the atria SWE sequences were 
triggered at the QRS complex which is the beginning of the atrial diastole. All SWE 
acquisitions were performed within a single cardiac cycle. As the duration of the HIFU 
sequences was much longer than one cardiac cycle (1-4min against ~650ms respectively) they 
were not ECG-triggered. 
HIFU has been performed, under the catheter’s real-time B-mode guidance, in right 
atria (n = 6) in right ventricles (n = 5) and in the interventricular septum (n = 5) in four sheep 
(N = 4). Among these SWE lesions’ evaluation has been performed in two sheep (N = 2; 
atrium n = 3, ventricle n = 3, septum n = 3). 
At the end of the in-vivo procedure, a sternotomy was made to access the heart. In 
order to mark the ablated tissue the aorta was clamped and a solution of 2,3,5-triphenyl 
tetrazolium chloride (TTC) at 1% was directly injected into this artery to force a diffusion in 
the right coronary arteries and finally in the right atrium and ventricle (the TTC solution 
marks the living tissue in red and leaves the dead as is). The animals were then euthanized. 
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Treated hearts were collected, lesions identified, photographed and finally frozen for further 
gross pathology evaluation. 
3.1.2 In-vivo HIFU-SWE sequences 
The catheter was inserted in the right atrium and ventricle under fluoroscopy. It was 
then positioned at a distance between 5 and 15mm from tissue under its B-mode imaging. A 
SWE mapping acquisition was performed on normal tissue before HIFU ablation and then 
after the whole therapy sequence. The catheter was not moved during the whole imaging-
therapy procedure, meaning that all final lesions were obtained with only one position of the 
transducer. 
HIFU therapy sequences 
In this study we performed in-vivo ablation with intensities at the transducer’s output 
ranging from 14.5W/cm2 to around 20W/cm2, at a frequency of 5.5MHz (with a Duty Cycle 
of 0.75). Each HIFU sequence was composed of 500ms emission followed by 500ms of 
pause, repeated for a total time of 2 to 4min for one focus. Depending on the sample, the 
focus was electronically moved several times axially and/or laterally for a few millimeters and 
the sequence was repeated (in total: average 4 focuses (2 to 7, mean total time: 8min30s) in 
the atria and 8 focuses (3 to 12, mean time: 20min30s) in the ventricles and IVS). HIFU was 
performed in the range of 5-20mm in depth and centered from element 12 to 52 (-4mm to 
+4mm from the center).  
In general the whole transducer’s surface was active for all sequences. However when 
the cardiac wall was in contact with some elements of the catheter’s tip during contraction 
these elements (5 to 10) were turned off for the whole HIFU sequence to avoid potential 
damage (caused by an insufficient blood-flow-driven cooling). Additionally during each 
sequence, to avoid damaging the probe, the catheter’s temperature was monitored – an 
elevation temperature of 12°C was fixed as a threshold that was stopping the sequence. No 
additional transducer’s cooling was used but the natural cardiac blood flow. 
SWE imaging sequences 
In this study, SWE sequences were performed in the same manner that was described 
in Chapter 3 (part 2.2.1) with some parameters adjusted. In all tissues 5 shear-wave 
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generations (push time of 300µs at 5.5MHz each) and imaging sequences (two compounded 
plane waves (-2°, +2°) at 7MHz) were performed. In the atria the shear-wave generation was 
consisting of one push, performed in average 2mm below the surface (between 5mm and 
15mm). In the ventricles, to cover a larger depth within the tissue and generate a shear plane 
wave, two pushes (150µs each) were generated one after the other (separated of 3mm in 
depth, with the first 2mm below the surface), as explained by Bercoff et al111. Imaging depth 
was fixed at 20mm resulting in a PRF of 18.9 kHz and an imaging frame after compounding 
of 9.4 kHz. Up to 75 final images were obtained for a total acquisition time of 41ms in 
maximum.  
A temporal Butterworth high-pass filter (cutoff frequency: 1000Hz) was applied to 
each pixel to isolate the shear-wave. For each frame the spatial mean tissue velocity, resulting 
from catheter-tissue relative movement, was also removed. Finally a directional filter 250 was 
used to remove regressive shear-waves and improve the SNR. The same time-of-flight 
algorithm as in Chapter 3 was applied to track the shear-waves. All imaging acquisitions were 
laterally resolved at 100µm; the velocity was estimated on a mean 1.2 mm kernel. As already 
mentioned those values do not give but are related to the lateral resolution. Total automated 
time of beamforming and processing data for the final map was typically 7.5s using a laptop 
computer with a 3s manual segmentation of the atrial walls (Chapter 3). 
The same SWE mapping was performed before and after HIFU ablation by carefully 
choosing the same trigger within the cardiac cycle. 
3.2 Results 
3.2.1 HIFU therapy 
Atria 
Five (n = 5) lesions have been successfully achieved in the atria. Four were 
transmural, for a mean wall thickness of 2mm, the last was 8mm deep but for a wall thickness 
(including fat layers) of 12mm. The lesions had a mean long-axis length of 7.5mm (4 to 
10mm). Figure 4-8 shows an example of ablation strategy and result in a right atrial tissue 
(posterior septum). In this case five different positions were targeted, for two minutes each (a) 
and the final lesion exhibited a volume of 10*5*2mm3 (transmural) on gross pathology (b). 
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Figure 4-8 : Example of ablation performed in the right atrium. (a) The successive HIFU focal 
positions are represented on a B-mode image obtained with the catheter. The focal spots were 
fixed while the tissue was moving (the image is acquired at a mean position during the cardiac 
cycle). (b) The final linear lesion had a volume of 10*5*2mm3 and was transmural. Next to 
the HIFU lesion was performed a classical RF catheter ablation for comparison. 
Ventricles and IVS 
In the ventricles three lesions (n = 3) have been successively performed in the free 
wall. One was transmural, one on the endocardium and one on the epicardium, while all the 
procedures were performed from the cardiac chambers. All those lesions were approximately 
4mm deep. Figure 4-9 shows the photographs of the transmural (a) and epicardial (b) lesion. 
The transmural lesion had a volume of 10*6*4mm3 and was achieved with three four-minute 
ablations.  
In the IVS four lesions (n = 4) have been realized: two on the right ventricular side and 
two on the left ventricular side, while targeting from the right ventricles. A mean depth of 
3mm has been obtained (2 to 4mm) with a mean width of 4mm.  
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Figure 4-9 : Examples of lesions achieved in the right ventricular free wall, with their 
schematically represented positions. (a) A 10*6*4mm3 transmural lesion realized with 3 focal 
positions of 4min each. (b) An epicardial lesion (4*3*4mm3) achieved while focusing from 
the interior of the heart. 
Table 4-1 summarizes all the lesions achieved during the procedures. It separates the 
different cardiac walls and the types of ablated layers. 
Table 4-1 : Summary of all the intracardiac HIFU attempts and results. (RV: right ventricle; 
IVS: interventricular septum) 
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3.2.2 SWE imaging 
Among all the 12 lesions achieved in this study only one was slightly visible on the 
real-time B-mode imaging (Figure 4-10). The corresponding lesion found on gross pathology 
was not completely coagulated. This result exhibited the low sensitivity of B-mode imaging 
for lesion imaging and confronted us on the need of other imaging modality. 
 
Figure 4-10 : The only lesion detected on the real-time B-mode imaging of the catheter. (a) B-
mode image before ablation. (b) B-mode image after ablation. (c) Photograph of the lesion on 
gross pathology study. The lesion was not completely coagulated. 
Figure 4-11 displays an example of a HIFU ablation evaluation with SWE in a right 
atrium. The thin wall was targeted with two focal spots in the center (Figure 4-11a). In this 
region the shear modulus increased from 4.5±1.2kPa (before ablation Figure 4-11b) to 
19.0±5.2kPa (after ablation Figure 4-11c). On gross pathology study (Figure 4-11d) the 
presence of the lesion was confirmed and presented dimensions in agreement with those 
suggested by the SWE map. 
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Figure 4-11 : Example of SWE mapping, before and after HIFU ablation in the right atrium, 
all with the dual-mode catheter. (a) The tissue was targeted with two focal spots for 2min 
each (represented on a B-mode image before ablation). (b) The mean shear modulus was 
4.5±1.2kPa before ablation and (c) 19.0±5.2kPa after ablation. (d) The approximate 
dimensions of the lesion exhibited on gross pathology (d) were in agreement with the SWE 
map. 
Figure 4-12 shows an example of identified ablation in the IVS. A little lesion has 
been obtained (Figure 4-12c) but the dimensions seen on SWE map agree well. The shear 
modulus increased from 2.2±0.3kPa (before ablation Figure 4-12a) to 5.7±1.2kPa (after 
ablation Figure 4-12b). 
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Figure 4-12 : Example of a SWE HIFU evaluation in the interventricular septum. The shear 
modulus increased from 2.2±0.3kPa before ablation (a) to 5.7±1.2kPa after ablation, in the 
center of the lesion (b). The dimensions of the lesion on gross pathology photograph (c) were 
in good agreement with the stiffness map. 
Figure 4-13 represents an example of ablation evaluation obtained in the RV free wall. 
HIFU therapy has been targeted following a column shape in the center of the image (Figure 
4-13a). A same stiffening shape can be observed on the SWE after ablation, with a shear 
modulus increase from 2.9±0.8kPa to 8.5±1.7kPa. 
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Figure 4-13 : Example of a SWE stiffness mapping in the right ventricle before and after 
HIFU ablation. (a) The tissue was targeted following a column pattern. The mean shear 
modulus before ablation was 2.9±0.8kPa in the central zone. (b) After ablation the map 
exhibited a stiff region of the same pattern as the ablation, with a mean shear modulus of 
8.5±1.7kPa in its center. 
In total three atrial lesions (n = 3) have been evaluated with SWE, two in the right 
ventricle (n = 2) and one in the IVS (n = 1). The mean shear modulus within atrial tissue 
increased from 4.3±0.4kPa before ablation to 14.0±4.4kPa after ablation and within 
ventricular tissues (RV and IVS) from 2.6±0.4kPa to 8.1±2.2kPa, for final mean stiffness 
(shear modulus) ratios before-after ablation of 3.3±0.8 in the atria and of 3.1±0.7 in the 
ventricles. 
4 Discussion 
In this second part of the validation of a dual-mode intracardiac transducer, we tested 
and successfully validated the in-vivo feasibility of performing both HIFU therapy and its 
evaluation with real-time Bmode and Shear-Wave Elastography (SWE). In total twelve (n = 
12) successful ablations have been performed in the right atria (n = 5), in the right ventricular 
(RV) free wall (n = 3) and the interventricular septum (IVS) (n = 4), in four (N = 4) sheep. 
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Among them three (n = 3) atrial, two (n = 2) RV and one (n = 1) IVS were evaluated with 
SWE by using the same catheter. 
Such a dual-mode intracardiac device presents many advantages. Motivated first by a 
need for intracardiac thermal ablation control and evaluation, second by a lack of performant 
therapy devices for ventricular ablation, this system has the potential to address both issues. 
The problem of therapy and imaging alignment, raised in the previous chapter, is completely 
resolved, as the same transducer is used for both. The advantages of SWE over B-mode 
imaging have already been discussed in the 2nd and 3rd Chapters and were confirmed once 
again in this study: while all ablations were monitored with real-time B-mode, only 1 lesion 
has been identified with this technique. In contrast all atrial lesions monitored with SWE have 
been clearly distinguished.  
HIFU therapy, as well, presents majors advantages over RFCA. It is a non-contact 
therapy meaning that the exact position and distance relative to the tissue are not critical, 
whereas it is an important issue for RF based ablation 251. Moreover, thanks to the multi-
element architecture of the device, HIFU therapy can be very flexible and large zones can be 
targeted without moving the transducer: in this study lesions up to 10mm wide and 4mm deep 
have been created, without intervention, in the atria and the ventricles. Preliminary results 
have shown that it could be possible to target separate layers in the cardiac tissues 
(endocardium, myocardium, epicardium), as epicardium-only lesions have already been 
achieved. This is an important requirement for ventricular ablation where scared tissues can 
artificially create electrical reentry loops and where the ablation need is very local8. Finally 
the novelties of this device are its therapeutic and imaging modalities; while this system is 
directly adapted from a clinically used imaging array and such ultrasonic transducers are 
routinely used during atrial fibrillation ablation9, 23. This suggests that the implementation of 
this apparatus could, in fine, be straightforward as the methodologies would remain similar. 
As the imaging and therapeutic possibilities of this dual-mode catheter are potentially 
multiple, the device could be either used as an only imaging or therapy system or as an all-in 
support for RFCA for example in atrial ablation. 
However, several limitations of this study have to be addressed. Lesions’ depths 
obtained with the device (4mm in maximum) were not bigger than the best performances that 
are reported for RFCA: because of its little aperture (13.2*2mm2 of active surface) the device 
is still limited in power. Maximal emission intensities applied in study were approaching 
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21W/cm2 corresponding to an acoustical power of 5.5W at the transducer’s surface. This was 
sufficient for atrial ablation, but for ventricles a gain could be necessary. Moreover treatment 
times were also longer than for RFCA. Typically a circular 5mm*5mm transmural atrial 
lesion can be created within 1min with RFCA, whereas in this study we performed atrial 
HIFU ablation in average with four 2min-focuses (for final transmural lesions of 
7.5mm*5mm in average). Still, there is much space to improve those performances. First, the 
cardiac wall movement was not addressed during ablation: HIFU focuses remained fixed 
during the 2 and 4min sequences of ablation. At first glance, as the focal spot is small (an 
ellipse of approx. 0.2*1mm in the focal plane when focusing at 10mm), in the atria this wall 
movement may enhance a larger heating and finally ablation, because the movement 
amplitude and also the tissue perfusion are not important. In contrast, in most ventricular 
walls the perfusion and wall movement may be too important to make this phenomenon 
beneficial, thus a tracking of the wall could be profitable. Second, the therapy sequence 
composed of 500ms of emission, followed by 500ms may not be optimal in-vivo. During the 
procedures, we could observe that differences on the cooling of the catheter, with the blood 
flow, were important depending the location of the catheter. A threshold of +12°C on 
catheter’s the temperature rise was fixed as an emergency stop during ablation and the 
intensity was adjusted at each location to maximize the output without exceeding this 
temperature. Nevertheless we did not study whether it would be more profitable to lower the 
output and lower the pause or increase the power and the pause. Finally the advantage of our 
system is that it was using only natural blood flow to cool down, but it could be possible, to 
bring additional  cooling e.g. by the guiding sheath (it was successfully tested in vitro). 
In this study we performed SWE only before and after ablation, yet the pauses within 
the therapy sequences could be used to perform imaging and finally achieve a real-time 
monitoring of the therapy. The imaging itself is limited: only linear and no sector-based 
imaging is possible with this array. This directivity of the elements, however, is beneficial for 
therapy as it allows to maximize the energy, locally, in front of the transducer.  
Finally we did not investigate any possible injuries outside the heart, after excision. As 
it was introduced in this chapter, atrio-esophageal fistulas were the reason of failure of a very 
promising previous HIFU system, however here the ablation could be in fine very well 
controlled. The focal spots are thinner, they can be flexibly positioned and, above all, all the 
therapy is controlled with imaging. 
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An important perspective for this work is to directly investigate the electrical effects of 
the ablation on the cardiac tissue and to validate a local electrical isolation. This is the next 
step of the study, still, we know that the tissues identified as lesions on gross pathology were 
viably dead as a well-recognized tissue marker was used. The HIFU ablation itself is 
thermally induced, in the same way as RFCA. During our procedures no navigation system 
was used, it would be important in the future to implement necessary markers to be able to 
locate precisely our system in the heart. 
5 Conclusion 
In this study we developed a novel intracardiac all-ultrasound system capable to 
perform both therapy and imaging by using the same aperture. The device is a direct 
adaptation of an imaging catheter and the resulting multi-element array allows a flexible 
HIFU therapy coupled with a high-quality imaging which are perfectly aligned. In-vivo many 
types of cardiac tissues (atrial, ventricular) have been successfully ablated and controlled with 
SWE and real-time B-mode imaging. 
This theranostic system presents many potential advantages over RFCA for therapy in 
atria but also in the ventricles where RFCA and other contact-based therapeutic modalities are 
limited. By implementing novel ultrasound imaging modalities it could become a powerful 
tool for cardiac arrhythmias treatment. Finally, as the same type of instruments is already in 
clinical routine usage, the implementation and acceptance of this device could be done 
without consequent efforts. 
In the next chapter an alternative approach for all-ultrasound cardiac arrhythmias 
treatment is proposed: a transesophageal ultrasound-guided HIFU probe. This next system is 
based on the same observation that a viable lesion control coupled with flexible therapy is 
needed for the heart. 
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Chapter 5. Transesophageal shear-
wave elastography monitoring 
 
1 Introduction 
1.1 Transesophageal ultrasound-guided-HIFU device 
In this chapter we propose a second approach based on transesophageal ultrasound. 
This work was motivated by the therapeutic transesophageal approach developed at LabTau 
Inserm U1032 by Cyril Lafon, Jean-Yves Chapelon, Elodie Constanciel, and William 
Apoutou N’djin in collaboration with cardiologists from Lyon Hospital. It consists of a single 
transesophageal imaging-therapy device recently developed by Constanciel et al. 89, 91. In this 
device, a conventional transesophageal imaging transducer was embedded inside a HIFU 
transducer. The position of the HIFU beam can be electronically adjusted, and anatomical 
guidance is done under real-time transesophageal echocardiography (TEE).  
As in systems presented in the previous chapters, the therapeutic procedure requires an 
accurate guidance system of the HIFU beam as well as an imaging modality to control the 
creation of thermal lesion at the targeted tissue. In the context of transesophageal therapy 
Magnetic Resonance Imaging (MRI) has been proposed 90 but is costly, requires specific MR 
compatible ultrasound transducers for per procedural analysis, and suffers from a low imaging 
frame rate which is an important issue in this precise cardiac application.  
Ultrasound imaging has also been proposed for providing treatment guidance and 
lesion monitoring in real time. Indeed TEE is widely used in clinical practice and can be 
integrated relatively easily in the same probe. TEE is commonly used before RFCA 
procedures or cardioversion to detect endocardial thrombi 9, 252. It is sometimes used for 
catheter ablation guidance253, 254 or more generally for guiding interventional cardiac 
procedures 252, 255. However, the monitoring and assessment of HIFU treatment remains 
limited with TEE, because thermal lesions do not appear with sufficiently high contrast on 
conventional B-mode images. 
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1.2 Transesophageal Shear-Wave Elastography 
In this study, we propose the use of TEE shear-wave elastography (SWE) to assess 
quantitatively the HIFU ablation procedure. The evaluation of tissue stiffness with this 
technique in cardiac and non-cardiac organs has already been widely discussed in the previous 
chapters including skeletal muscle 177, liver201 (see Chapter 2) or the myocardium249 (see 
Chapter 3 & 4). Despite a large interest of imaging cardiac elasticity, SWE has not been 
implemented yet in the context of transesophagial echocardiography. This implementation is 
not straightforward as TEE probes are characterized by small apertures while requiring a large 
field of view (FOV). Moreover, SWE assessment of ablated cardiac tissues has not been 
reported in the literature to our knowledge using HIFU treatment. The objectives of this study 
are twofold: first to show in vivo that cardiac SWE can be performed with a TEE probe in 
order to provide a map of myocardial stiffness in a beating heart. Second, to show the 
feasibility of TEE-SWE to map HIFU-induced lesions in vitro with the ultrasound-guided 
HIFU (USgHIFU) probe89, 91. These two steps are required before this technique can be used 
in vivo to generate and image thermal lesions using a single imaging-therapy transesophageal 
ultrasound endoscope. 
2 In-vitro and in-vivo SWE 
2.1 Materials and methods 
2.1.1 Transesophageal ultrasound-guided HIFU probe 
An imaging-therapy endoscope designed for transesophageal USgHIFU ablation has 
been used in this study (Vermon, Tours, France). The active part of the system was made of a 
3-MHz HIFU transducer with a 5-MHz TEE imaging transducer embedded at its center. The 
HIFU transducer is geometrically focused at 40mm and is composed of 8 isosurface 
concentric rings, which allow the focal depth to be varied between 15 to 55 mm by dynamic 
focusing. The active surface (Figure 5-1a) is a portion of a sphere, 30 mm in diameter, 
truncated at 14 mm along the axis of endoscope (18 mm in diameter) and has a total active 
area of 3cm2. It presents a circular opening (12mm diameter) in its center for the TEE 
imaging probe. The prototype was mounted on a flexible and steerable medical endoscope 
and capable of delivering 10W/cm2 for 15s or 15W/cm2 for 3s. 
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The HIFU transducer was driven by a multi-channel amplifier (Image Guided 
Therapy, Pessac, France), which could generate up to 20 W per channel.  
The TEE imaging probe at first independent, then embedded in the USgHIFU 
endoscope, is a circular 1D phased array composed of 64 elements (PA5.0/64, 5MHz, 
0.15mm pitch, Vermon, Tours, France). It is designed for conventional TEE 
echocardiography but for that purpose, the transducer is usually mounted on a rotary motor.   
 
Figure 5-1: (a) Physical configuration of the transesophageal USgHIFU device. The imaging 
probe (red) is inserted at the center of the truncated hemispherical HIFU transducer (orange). 
The whole system is mounted on a steerable endoscope. (b) In vitro experimental setup. A 
balloon, containing circulating cooling water, covers the device. An esophagus is attached 
around the balloon. The device aims a porcine heart positioned at distance of 2 to 3cm from it. 
The setup is immobile and put in a thermostatic 37°C saline tank. 
2.1.2 Diverging-waves Shear-Wave Elastography 
In this study, an ultrafast ultrasound scanner (Aixplorer®, SuperSonic Imagine, 
France) was used to perform SWE sequences with the TEE imaging probe, mounted in the 
center of the HIFU transducer. The sequences consisted in a radiation "push" ,i.e., the 
ultrasound focused emission used to generate a shear-wave defined by its duration and 
frequency (400 µs at 4MHz), followed by an ultrafast divergent waves 108 imaging sequence. 
The push parameters resulted in a peak positive pressure of 6.3MPa (measured in water) and 
peak negative of -4MPa which corresponds to a derated pressure of -1.6MPa with a 
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Mechanical Index of 0.8. Ultrafast imaging was performed using either two divergent waves 
emissions (represented by virtual sources placed at [-1.2;1.2] mm laterally and 8mm axially) 
or three divergent waves emissions (represented by virtual sources placed at [-0.725; 0; 0.725] 
mm laterally and 3.9mm axially)  at 5 MHz. Coherent compounding of the diverging waves 
emissions was applied as explained in 108 , in order to restore a synthetic focus in transmit. In 
receive a conventional dynamic beamforming algorithm implemented on GPU (cuda, nvidia 
geforce K5000) was used to compute the stack of ultrafast imaging acquisition. 35 
compounded images were obtained. A Butterworth temporal low-pass filter (cut-off 
frequency: 800Hz) was applied to each pixel to remove high frequency noise and a directional 
filter 250 was used to remove regressive shear-waves and improve the Signal-to-Noise Ratio 
(SNR). For each frame the spatial mean tissue velocity was also removed. The resulting 
imaging frame rate depended on the imaging depth – one compressional wave transmit and 
return time, and on the number of compounded divergent waves 108.  From 5 to 7 push and 
imaging sequences were used in order to increase the field of view and the SNR of the shear 
modulus maps 112, for a maximal total acquisition duration of 43ms. A time-of-flight 
algorithm 113 was used to track the shear-wave group velocity ct and the shear modulus map 
was obtained from (1.1) for each acquisition. Corresponding quality maps were obtained from 
the algorithm’s temporal 1-D cross-correlation. The final ‘stiffness map’ was obtained with a 
quality weighted average (least-squares mean) of all 5 to 7 acquisitions. A spatial median 
filter (in vivo: 1*1mm2; in vitro: 2.5*2.5mm2) was applied on the final maps. 
The time-of-flight algorithm estimates the shear-wave group velocity locally. It is 
based on a sliding window estimator for each pixel within a lateral line. In our study all 
imaging acquisitions were laterally resolved at 120µm; the velocity was averaged on 2mm of 
distance. Those values do not give but are related to the lateral resolution 210. 
2.1.3 In-vivo experimental setup 
This study was conducted with the approval of the Animal Care and Use Committee of 
the Hopital Européen Georges Pompidou (PARCC) according to the European Commission 
guiding principles (2010/63/EU). One sheep of 45kg was anesthetized with thiopentothal (0.5 
ml/kg), intubated and ventilated at 15 ml/kg with 2% isofluorane and oxygen. A sternotomy 
was performed and the thorax was filled with saline water. The TEE probe was placed in the 
thorax in front of the heart walls including the left and right ventricular free walls, and the left 
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and right atrial walls at a distance of 10 to 30 mm using the real-time Bmode guidance. After 
the procedure the animal was euthanized.  
In order to investigate the feasibility of in vivo cardiac SWE with a TEE probe, two 
types of sequences have been performed.  
First, the time variation of stiffness during the cardiac cycle was measured in the left 
atrium and in the right and left ventricles. Ten single-push 10-ms-long SWE sequences were 
performed in the myocardium at a rate of every 50ms, covering a whole cardiac cycle. Each 
push was centered laterally. The tissue velocity of each acquisition was averaged along 5mm 
in tissue’s depth providing two-dimensional spatiotemporal representations of the shear-wave 
propagation206, 249. The positions of the maxima of the waveform were fitted (least-squares 
linear regression) as a function of time to eventually obtain one shear-wave speed and shear 
modulus value per push. 
Second, stiffness maps were performed in the atrium, in the ventricular free walls and 
in the septum at end-diastole. Pushes were generated at a fixed depth between 20 and 30mm 
depending on the wall. The ventricular septum was imaged across the right or left ventricular 
wall with pushes generated up to 45mm in depth. Ultrafast imaging depth was fixed at 50mm 
in average, which resulted in a PRF of 9.8 kHz and a final frame rate of 4900 images/s after 
compounding (2 virtual sources).  
All acquisitions were performed within a single cardiac cycle. 
2.1.4 Ex-vivo experimental setup 
Shear-Wave Elastography and HIFU were performed in-vitro on chicken breast 
samples (n=3) and on two (n=2) entire ex-vivo porcine hearts for a total of seven (n=7) 
thermal lesions. The samples were fixed on a plastic stem and immerged in a degassed and 
thermostatic (37°C) water tank. In chicken breast large lesions were created by rotating the 
probe, in heart samples by varying the focusing depth of the HIFU beam such as the probe 
was immobile during the whole procedure. The whole HIFU/imaging prototype was cooled 
with 15°C water that was circulating inside a latex transducer cover fixed at the two 
extremities of the transducer. 
 111
For the heart samples, several tissues were targeted including the right ventricle, the 
left atrium, and the left auricle. Finally, an ex vivo esophagus was inserted around the 
transducers and a lesion was performed in the left ventricle with ablation and imaging 
performed through the esophagus (Figure 5-1b). 
 
Figure 5-2 : Schematic representation of the in-vitro therapy-imaging configuration. For the 
heart samples the probe was not moved during the whole procedure. (a) HIFU therapy is 
performed through the entire wall depth using the electronic steering along the central axis of 
the probe. (b) SWE imaging is realized before and after ablation.  Five to seven laterally 
steered pushes (focusing using the imaging probe) are performed to cover the whole field of 
view of the probe with shear-waves, of which propagation is acquired with diverging-waves 
ultrafast imaging. 
Imaging 
Figure 5-2 represents a schematic view of the therapy-imaging sequences performed 
in-vitro. The HIFU prototype was placed approximately 25 mm away from the sample’s 
surface (Figure 5-2a). A B-mode image was acquired and then SWE was performed – pushes 
were generated at an average depth of 30 mm (Figure 5-2b). In chicken breast, imaging depth 
was fixed at 50 mm which resulted in a PRF of 9.8 kHz and a final frame rate of 3300 
images/s after compounding (3 virtual sources). In the heart, imaging depth was fixed at 40 
mm which resulted in a PRF of 12.3 kHz and a final frame rate of 6200 images/s after 
compounding (2 virtual sources). The total processing time, including image beamforming 
and tissue velocity estimation was less than 1 minute. 
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Therapy 
In chicken breast HIFU ablation was performed using the prototype’s geometric 
focusing (40mm). One HIFU sequence consisted of 25 single exposures (4s on /6s off), with 
an emission acoustic intensity of 9W/cm2. Two to three sequences were performed per 
sample, for each of which, the probe was rotated by -2° or 2° relatively to the initial position 
and parallel to the imaging plane. 
In the heart HIFU ablation was performed without moving the prototype. Several 
HIFU sequences were performed, each at different depth by electronically moving the focal 
spot – typically from 35 to 25 mm with steps of 2mm. One HIFU sequence consisted of 2 
single exposures (15s on /10s off), with an emission acoustic intensity of 11W/cm2.  
Final B-mode images were taken and the same SWE mapping was performed after 
HIFU ablation.  
Gross pathology 
At the end of the experiments a gross pathology study was performed. More precisely, 
the samples were cut along the imaging plane of the ultrasound transducer, under control of 
the B-mode imaging, removed from water and photographed.  
Segmentation 
The dimension of SWE lesions were compared to the gross pathology. More 
specifically, depth and width of the lesions were compared between lesion-segmented images 
obtained for both techniques. Lesion’s boundaries were discriminated on the gross pathology 
photographs by identifying the variation in tissue color using a k-means clustering algorithm 
180
, by discriminating viable tissue (red) from ablated (white).  
Because the initial stiffness varies significantly across the different tissues and 
samples, we chose to set arbitrarily a threshold of relative stiffness increase to discriminate 
the ablated and normal tissue. A ratio of 1.7 was set based on previous results obtained by 
Sapin-de Brosses et al.176 and Mariani et al.201 which showed that the mean shear modulus 
increase was approximately twofold. The biggest and central discriminated region was 
identified as the lesion. Then the images underwent morphological opening by a 1mm-
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diameter disk, to smooth the obtained boundaries. Depth and width of the lesions were finally 
calculated with the extreme longitudinal and lateral boundaries of the remaining zone.  
2.2 Results 
2.2.1 In-vivo 
Myocardial stiffness and its temporal variation over one cardiac cycle were obtained in 
the atrial and the ventricular walls. In the right atrium stiffness was found to vary from 
0.5±0.1kPa to 6.0±0.3kPa during the cardiac cycle. Right ventricular stiffness ranged from 
1.3±0.3kPa in diastole to 13.5±9.1kPa in systole, whereas left ventricular stiffness varied 
between 1.3±0.2kPa and 12.5±5.1kPa. Figure 5-3 represents two examples of variations of the 
shear modulus, (a) in the right atrium, (b) in a left ventricle. The shape of the atrial stiffness’ 
variation (a) is in accordance with the one already observed by our group 249 : the shear 
modulus increases at the atrial systole (P-wave) and during the atrial blood filling (from the 
end of the QRS complex to the T-wave till the opening of the tricuspid valve). In contrast, 
ventricular stiffness’ variation is shown in Figure 5-3b. A strong increase of stiffness is found 
in systole (from the QRS complex to the T-wave) followed by a softening in diastole (from 
the T-wave to the QRS complex). 
Secondly, myocardial stiffness was mapped at end-diastole in atrial and ventricular 
walls. Figure 5-4 presents examples of shear modulus map acquired in (a) the right atrium, (b) 
right ventricle and (c) interventricular septum (acquired through the right ventricular wall). In 
the right atrium (a) the mean shear modulus within the sample is 1.3±0.3kPa; in the right 
ventricle (b) 1.7±0.5kPa; in the interventricular septum (c) 1.9±0.6kPa. Over the ventricular 
stiffness’ maps, performed between the P-wave and the beginning of the QRS complex, the 
average shear modulus was: 1.8±0.2kPa (right ventricle), 2.3±0.4kPa (left ventricle), 
1.8±0.2kPa (interventricular septum). 
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Figure 5-3 : Time variation of stiffness in a (a) right atrium and (b) left ventricle free wall. On 
each tissue 15 acquisitions were performed, at a rate of every 50ms, corresponding to ten 
acquisitions per heart cycle. Positions of pushes are represented on corresponding Bmode 
images (left) with the areas where the shear-wave propagation was considered. The obtained 
shear modulus values (right up) are represented for each acquisition with the corresponding 
ECG signal (right down). Error bars correspond to the standard error obtained for each shear 
modulus value, when operating the linear regression on the shear-wave’s slope position. (a) 
The shear modulus varied in the right atrium from 0.5±0.1kPa to 6.0±0.3kPa with a mean 
value of 2.5±1.7kPa. The peak at push no.4 corresponds to the atrial systole, at push no.10 to 
the end of atrial blood filling followed by the opening of the tricuspid valve and atrial 
emptying. (b) In the left ventricle the shear modulus varied from 0.8±0.1kPa to 15.5±0.4kPa 
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for a mean value of 7.4±6.3kPa. The important increase in stiffness corresponds to the 
ventricular systole. 
 
Figure 5-4 : Shear modulus maps of a (a) right atrium, (b) right ventricle free wall and (c) the 
interventricular septum, superimposed on Bmode images. The mean shear modulus within: 
(a) the atrial wall, acquired 50ms before the P-wave (atrial systole), is 1.3±0.3kPa; (b) the 
right ventricle, acquired between the P-wave and the beginning of the QRS complex 
(ventricular diastole), is 1.7±0.5kPa; (c) the interventricular septum, acquired between the P-
wave and QRS complex (ventricular diastole), is 1.9±0.6kPa. 
2.2.2 Stiffness mapping of ablated tissues 
Figure 5-5 shows the maps of the shear modulus in three different tissues (respectively 
chicken breast, left ventricle and left atrium before and after HIFU ablation, as well as the 
corresponding gross pathology pictures. On Figure 5-5a stiffness appears to be relatively 
homogeneous over the sample, with a mean shear modulus µ of 4.8±1.1 kPa in the central 
zone, before ablation. In contrast, a stiff region associated to the ablated tissue, is visible after 
treatment, with an average µ of 20.5±10.0 kPa (corresponding to a ratio of the shear modulus 
before/after ablation of 5.0±3.2) in the same central zone. Figure 5-5b shows the stiffening of 
a left ventricular wall when both ablation and SWE were performed through the wall of an 
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esophagus. The ablated zone appears as a hyperechogenic region at an approximate depth of 
1cm in the tissue. No imaging parameters were changed for this acquisition. The mean 
stiffness increased from 21.2±3.3kPa to 73.8±13.9kPa in the central region of the tissue (ratio 
of 3.7±1.2). In contrast, on B-mode images, no clear echogenic borders were visible after 
ablation. The little left atrial lesion on Figure 5-5c appears as highly contrasted; it increases 
from a mean value of 12.2±4.3 kPa to 30.3±10.3 in the center of the lesion (ratio of 3.2±2.0). 
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Figure 5-5 : Shear modulus maps in normal (down left), ablated (down middle) in vitro 
tissues, with corresponding Bmode images before and after ablation (respectively up left and 
up right) and a photography of the gross pathology section (down right). The mean shear 
modulus increased from 4.8±1.1 kPa before ablation to 20.5±10.0 kPa in the central-8mm-
diamater zone of the chicken breast tissue (a), from 21.2±3.3kPa to 73.8±13.9kPa in the 
central-8mm-diameter zone of the left ventricle with SWE and HIFU performed through an 
esophagus (b), from 12.2±4.3 kPa to 30.3±10.3 in the central-5mm-diameter zone of the right 
atrium (c). 
In total 7 HIFU ablations were performed and mapped with SWE. The presence of a 
lesion was clearly seen on all stiffness maps. Table 5-1 summarizes the treatment procedures 
and the mean shear moduli found for all samples before and after ablation. The mean stiffness 
ratios pre and post treatment calculated in an 8mm-diameter area in chicken breast and 
ventricles and in a 5mm-diameter in atria were respectively approximately 3.8, 3.0 and 2.2. 
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Table 5-1: Summary of all SWE and HIFU procedures 
 
2.2.3 SWE agreement with gross pathology 
Figure 5-6 shows (a) the segmentations performed on the gross pathology samples 
presented on Figure 5-5 and (b) an example of segmentation performed on a SWE stiffness 
map with the measurement of the lesion’s dimensions.  
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Figure 5-6 : (a) Examples of automatic segmentation on images of gross pathology sections of 
ablated tissues (respectively from left to right: chicken breast, porcine left ventricle, porcine 
right atrium). (b) Example of the automated treatment of a segmented chicken breast stiffness 
map after ablation. A threshold is first applied on the shear modulus map (left), the biggest 
surface is kept (middle), then a morphological (1mm diameter disk) opening is applied to 
smooth the boundaries, finally such obtained lateral and axial extremities are considered as 
lesion’s width and depth (right).   
The agreement of lesions’ depths and widths determined with gross pathology and 
SWE is represented on Figure 5-7. The median difference between both techniques found in 
depth was 0.2mm, with first and third quartiles ranging from -0.8 to 2.6mm. In width a 
median difference of 0.2mm was found with first and third quartiles ranging from -2.7 to 
2.7mm for a mean depth of 10.6±6.0mm and width of 11.1±6.2mm found with gross 
pathology. 
 
Figure 5-7 : Difference of lesions’ depth and width determined with gross pathology against 
SWE, represented on boxplots. In depth a median difference of 0.2mm was found with first 
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and third quartiles ranging from -0.8 to 2.6mm. In width a median difference of 0.2mm was 
found with first and third quartiles ranging from -2.7 to 2.7mm. 
2.3 Discussion 
In this study we have investigated the feasibility of using shear wave elastography for 
the evaluation of HIFU induced thermal lesions in a transesophageal setup. We verified, first, 
the feasibility of performing cardiac SWE with a conventional imaging TEE probe in vivo, in 
an open chest setup. We successfully performed SWE mapping in the atrium and in the 
ventricles at the ventricular end-diastole. Additionally we investigated the time variation of 
stiffness in the atrium and in the ventricles.  The measured stiffness values are in accordance 
with previous in vivo studies on a beating heart in open chest 206, 212,  transthoracic 256  or 
intracardiac setup 208, 249. 
Second, we combined, in a single transesophageal device, an imaging and a 
therapeutic transducer to perform ultrasound-guided HIFU on ex vivo cardiac and muscular 
tissues. We have demonstrated that shear wave elastography can map the thermal lesions with 
a high contrast. Whereas TEE B-mode imaging was unable to observe the thermal lesions, it 
appeared clearly on post-treatment shear modulus maps. Moreover, the dimensions of the 
lesions measured on the maps agreed well with the dimensions of the lesions observed on 
gross pathology. This agreement was particularly good along depth of the TEE image, in the 
transmural direction of the ablated wall which is a crucial aspect of an effective ablation 
procedure. 
Despite the small dimension of the TEE imaging transducer, shear waves were 
generated and imaged successively at a depth up to 50 mm. Ultrafast imaging was performed 
over a large field of view using the emission of diverging waves at very high frame rates. To 
increase the imaging quality, coherent compounding of 2 to 3 diverging waves was used. 
Beyond the evaluation of HIFU lesions, our results suggest that TEE may be an interesting 
way to provide myocardial stiffness which is challenging in transthoracic imaging on some 
patients. To our knowledge, this study reports the first implementation of shear wave 
elastography on a transesophageal transducer. The absence of other studies may be justified 
by the difficulty to implement TEE on animal models. Indeed, quadrupeds, the most common 
subjects, present anatomical differences in the vicinity of the heart and esophagus with 
bipeds. The area between those organs is occupied by bronchi and lungs which degrade 
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significantly the quality of cardiac TEE imaging and compromise potential transesophageal 
HIFU. Thus the following step of our study would be the use of the USgHIFU 
transesophageal device on biped non-human subjects. It is important to note that the presence 
of other tissues between the probe and the studied samples was not precluding for obtaining 
shear modulus maps of a good quality: SWE has been successfully performed in the 
interventricular septum through a left or right ventricular wall in-vivo and in the left ventricle 
through an esophagus and the cooling balloon in-vitro. 
One limitation in this study is the fact that there was no absolute threshold of stiffness 
for ablated tissues, within their different types (breast, atrial, ventricular muscle). This comes 
from the various conservation conditions of the tissues which resulted in very different initial 
stiffness. Moreover, in some of the samples, the measured shear velocity may not be directly 
linked to the shear modulus in thin tissues such as the atrial wall. In such small layers, shear 
waves are guided which results in dispersive propagation. As the assumption of infinite 
medium is not true anymore it limits the validity of the quantitative stiffness measurement. 
However, we showed here that the stiffness contrast on the post treatment map was high 
enough to delineate the lesion. Moreover, previous work indicated that the elasticity contrast 
changes (ie. Ratio between shear modulus during the treatment and the initial shear modulus 
before treatment) is a very sensitive marker for thermal necrosis independently from the 
initial tissue stiffness value 176. Furthermore the precision of SWE on HIFU lesions with the 
TEE probe has to be further investigated, a limited number of samples are presented here, yet 
their variety demonstrate the flexibility of the technique. SWE determined lesions were 
compared to measurements operated on gross pathology sections. Those sections were 
realized approximately within 1mm of the ultrasonic imaging plane implying an error on the 
effective lesions’ sizes. 
Another limitation is the need to improve processing time to obtain shear modulus 
maps. The beamforming and stiffness map calculations were performed respectively on the 
scanner and a laptop using Matlab® and were performed within one minute. Nevertheless all 
acquisitions were performed within a single heartbeat thus SWE based on diverging waves 
ultrafast imaging can potentially be real-time, as it is already clinically with plane wave 
imaging. However this technical optimization was not the goal of the study. 
As a final point, the combination of transesophageal SWE and HIFU on a same device 
could present some advantages over intracardiac Radio-Frequency Catheter Ablation. The 
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system is potentially capable of creating transmural lesions in the atria and in the ventricles 91 
or possibly, by extension, select the ventricular layer (epicardium, myocardium, endocardium) 
to ablate. This need is encountered during ablation procedures for ventricular tachycardia and, 
to our knowledge, no minimally invasive technique is capable to do so 8. The system presents 
an imaging transducer, perfectly aligned with the therapy probe. The lesion can be precisely 
imaged at its center, which is particularly important to evaluate the transmurality of the 
ablation. Thanks to the wide TEE beam, guidance within the heart is also facilitated and 
potentially no fluoroscopy would be needed for the procedure. The HIFU technique requires 
no contact with the targeted tissue while this is problematic with RFCA 251. Finally as the 
probe is not in the vascular and particularly cardiac system, the thrombogenic risk could be 
significantly reduced. 
On the other hand the use of a transesophageal access implies some other risks. TEE-
associated morbidity is reported to be uncommon: from 0.2% to 0.5% in non-operatory and 
from 0.2% to 1.2% in operatory settings257. The anatomy of the USgHIFU device is different 
from a classical TEE probe thus the injury risks will have to be carefully evaluated. During 
therapy the HIFU probe heats (up to 65°C at its surface) but the temperature of the external 
balloon, containing the cooling liquid, did not exceed 37°C even with the presence of an 
esophagus. Finally preoperative TEE is already routinely performed before RFCA procedures 
(50% of a systematic usage is reported for VT RFCA 8). To perform intraoperative TEE with 
transesophageal HIFU a general anesthesia would be needed, however general anesthesia is 
already frequently performed during RFCA (approximately 50% of the procedures 8).  
3 Conclusion 
In this study we have shown the feasibility of shear-wave elastography with a 
transesophageal ultrasound-guided HIFU probe to map cardiac stiffness in vivo and to map 
thermal HIFU-induced lesions in cardiac tissues in vitro. Transesophageal SWE is a 
promising technique to improve the ablation control and predict thermal lesions extent. This 
endoscopic HIFU-SWE combination in-vivo would be the upcoming step of the study. 
Furthermore, beyond the main scope of this study, transesophageal SWE could be proven as a 
promising elastographic modality for cardiac diagnostics. 
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The transesophageal approach presents as a very interesting alternative to the 
intracardiac dual-mode system. While those systems are at an early stadium of development 
and some technical uncertainties have to be resolved, the main advantage of the intracardiac 
system may be its proximity with the tissue, resulting in fine in better imaging resolution and 
potentially a more localized ablation. On the other hand the transesophageal approach benefits 
from a large field of view and potentially a better capacity to ablate larger cardiac zones. As 
the intracardiac dual-mode system has already been validated in-vivo and similar therapeutic 
approaches have already existed in clinics, the implementation of this approach may seem 
more straightforward than the transesophageal one. Nevertheless more studies will have to 
determine whether one of these approaches could have a better clinical viability or, in 
contrary, whether they could become complementary. 
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Chapter 6. Other imaging perspectives 
and general conclusion 
1 Other imaging perspectives: Ultrafast acoustoelectric 
tomography 
1.1 Introduction 
1.1.1 State-of-the-art and concepts 
Imaging the electrical activity of the body is central to the diagnosis of and treatment 
planning for some of our most pressing healthcare challenges, including heart and brain 
diseases. However, there exists no clinical imaging modality yet in which the contrast 
originates directly from voltage or current.  Indeed, technologies aimed at mapping the brain 
activity such as, e.g., functional magnetic resonance imaging 258, 259, diffuse optical imaging 
260
, and functional ultrasound 225 rely on slow physiological correlates such as the blood-
oxygen-level dependent (BOLD) effect, blood oxygenation, or blood flow. While action 
potentials travel at speeds on the order of meters per second, the hemodynamic response acts 
as a filter that blurs electrical phenomena above the Hz range and therefore greatly limits the 
non-invasive study of brain activity. Physiological correlates have also been used in the heart, 
such as the transient mechanical response to electrical activation, i.e., the Electromechanical 
Wave, and recent studies suggest they can reflect in a one-to-one fashion the electrical 
activity261, 262.  However, as with all physiological correlates, uncertainty arises regarding the 
strength of that correlation in diseased tissues 263.   
In the context of RFCA for atrial and ventricular arrhythmias electrical current and 
action potentials imaging in the heart are performed with mono or multi electrode intracardiac 
systems 9; new non-invasive systems were also implemented in clinics 20. Despite the 
undeniable utility and functionality of these systems, it is not possible to map the electrical 
current density with spatial resolution under 5mm 264, 265, which could help to identify 
unablated, conducting regions or other depolarization sources participating or originating the 
arrhythmia. 
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The acoustoelectric effect 266, 267 has recently been shown to provide contrast directly 
from current densities by measuring ultrasound-modulated electrical impedance 268.  Multiple 
studies have been conducted and demonstrated the potency of the approach, e.g., by mapping 
the electrical activity in nerves ex vivo 269 and in the heart ex vivo 270.  More specifically, the 
technique consists in insonifying a tissue with a focused ultrasound beam while 
simultaneously measuring high-frequency differences of potentials.  When the ultrasound 
wave reaches a region in which an electrical current flows, a high-frequency difference of 
potential can be detected.  Proper synchronization and knowledge of the speed of sound in 
tissue can then be used to form image lines with lateral resolution and signal-to-noise ratios 
that vary with depth. Many such lines can then be obtained by moving the focal region 
laterally and in turn concatenated to form an image.  The main limitation of such an approach 
is the limited signal-to-noise ratio (SNR) of the detected differences of potential.  Indeed, 
averaging over multiple acquisitions is usually necessary.  To palliate this issue, the length of 
the ultrasound pulse can be increased, but such an approach lowers both the axial and lateral 
resolutions. Finally, to achieve sufficient frame rates to track the electrical activation, low line 
densities are required.    
1.1.2 New potential for intracardiac imaging 
In this work, first, an experimental proof of concept study has been conducted in a 
simple setup to demonstrate the acoustoelectric interaction in ionic solutions, beginning with 
a single-element focalized transducer, then by focalizing ultrasound with an imaging probe. 
This part underlines the weaknesses of focal acoustoelectric imaging, even though a solution 
for signal SNR increasing is proposed. 
Second, we developed Ultrafast Acoustoelectric Tomography (UAT), based on plane 
wave emissions. Reconstruction strategies based on the Radon transform were devised to 
increase the frame rate and provide uniformly high spatial and temporal resolutions while 
respecting FDA standards for human use. Validation in phantoms was conducted, showing the 
viability of the approach with a standard imaging probe. 
1.2 Focused acoustoelectric imaging 
In this first part the acoustoelectric (AE) effect was studied in ionic (saline) solutions, 
by using focalized ultrasound. The current was generated externally and injected into the 
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environment. Ultrasound was send through an acoustic window and the AE effect was 
measured with electrodes within the environment. 
1.2.1 Single-element transducer 
Methods 
The experimental setup was composed of four parts (Figure 6-1a):  
- The study environment (Figure 6-1b), composed of an 18.5*4.5*2mm3 saline 
solution (0.9% NaCl) in an open silicon cavity. The alternative current was 
uniformly injected at the extremities of the cavity with cylindrical steel 
electrodes. The environment was set in a box with an acoustic window at its 
bottom. 
- The current injection electronics. A 500Hz sinusoidal current was amplified, 
low pass filtered (2nd order RC filter, 10.6kHz cutoff frequency) and injected to 
the saline environment through a transformer (Z218A6C, OEP, UK) in order to 
create a floating mass injection. The current within the saline solution, in order 
of dozens of mA, was measured at the extremities of a 10Ω resistance between 
the transformer and the solution. 
- The reception electronics. Measurement was performed with the injection 
electrodes, to filter the current out, the signal was high-pas filtered (2nd order 
RC filters, 30kHz cutoff frequency), amplified with a differential amplifier 
(Lecroy, Chestnut Ridge, NY), averaged 512 times and sampled with an 
oscilloscope (Tektronix, Beaverton, OR) and registered on a laptop. 
- The ultrasound transducer. In this part it was a single-element transducer 
(2.5MHz, 25mm geometrical focus, F/D 1, Imasonic, France) fixed on a 2D 
motorized setup to scan the entire saline environment. 
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Figure 6-1 : Acoustoelectric setup with a single-element transducer. (a) Schematics of the 
whole setup, showing (left) the current injection electronics, (middle) the transducer and the 
saline environment (box), (right) the measure and registering electronics. (b) Photograph of 
the ionic environment seen from above. The saline solution lies within a rectangular cavity 
made with silicon. The current injecting and measure electrodes are on both sides of the 
cavity. An acoustic window let pass the ultrasound. 
In this setup the ultrasonic beam (2 cycles, 2.5MHz, 5MPa peak positive pressure, -
4.5MPa peak negative) was focalized within the saline solution (injected current: 13.5mA) on 
the negative peaks of the current. and the whole environment was scanned by a motorized 
displacement of the transducer (500µm steps). 
Results 
Figure 6-2a shows an example of an impedance modulation (AE effect) on a temporal 
signal acquired in the middle of the cavity. The 512-times averaged signal has an amplitude of 
90µV. Figure 6-2b the amplitude of the effect in the whole cavity, the effect presents a higher 
amplitude near the electrodes (left and right) and is uniform between. 
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Figure 6-2 : Examples of the AE effect in the saline solution (after suppression of the 
amplification). (a) Temporal signal acquired in the middle of the cavity (averaged 512 times). 
Before 5µs the ultrasonic emission can be seen as a very high amplitude perturbation. 
Between 15µs and 20µs the low-frequency (approx. 300kHz) AE effect appears (90µV peak-
to-peak amplitude). Between 30µs and 35µs a new perturbation appears, corresponding to the 
come and return of the ultrasonic wave which re-excites the transducer. (b) 2D scan of the 
saline cavity, showing the amplitude of the AE effect as on (a). The signal is stronger near the 
electrodes (left and right) and is more uniform between.  
Discussion 
With this setup the AE effect could be clearly demonstrated. However it presented 
several limitations. First, the signal had to be averaged 512 times because of a very weak SNR 
caused by the limited efficiency of the reception electronics and the low amplitude of the 
effect itself. Second, a mechanical scan had to be performed to obtain a 2D map of the saline 
environment. With approx. 4s of measurement (with averaging and registering) per spatial 
point, the whole scan duration was of approx. 25min. Finally because of the low SNR, the 
pressures induced in the solution were high (-4.5MPa of peak negative pressure), resulting in 
a MI of 2.8 which is above the accepted limit of 1.9.  
To increase the SNR, we have improved the reception electronics, which gave us the 
possibility to decrease the pressure needed to measure the AE effect and perform a study by 
using a linear imaging array. 
1.2.2 Imaging array 
Modified setup 
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In the second setup the reception electronics have been improved. A 40dB amplifier 
has been added on the output of the differential one (Figure 6-3) and a low-pass filter (1st 
order RC, 1MHz cutoff frequency). As a consequence the SNR was significantly improved 
and the single-element transducer was replaced with a linear imaging array (4MHz center 
frequency, 128 elements, 0.33mm pitch, Vermon, France). The AE effect was measured by 
focusing with the array at 37mm through a coupling gel (polyvinyl alcohol). 
 
Figure 6-3 : Modifed part of the setup. Ultrasonic modulation of impedance in the saline 
solution was induced with an imaging linear array through a coupling gel. An amplifier and a 
low-pass filter have been added to increase the SNR of the AE effect. 
Multiple focusing 
Thanks to these modifications the SNR was significantly improved and AE effects 
down to 15µV could be detected. However, the linear probe had a large aperture (42.2mm) 
and focusing at 37mm with all the elements to create one focal spot was not profitable 
because of the directivity of the elements.  
Taking this to account and for the constant sake to improve the SNR as well as the 
amplitude of the AE effect a compromise has been chosen. The elements of the probe were 
divided in four parts to create up to four focal spots simultaneously with a spatial distance of 
3.3mm (1cm in total) between each. More specifically an emission pattern based on the 
Hadamard matrix has been chosen: 
Given the Hadamard matrix HAE = (1 11 −1 1 11 −11 11 −1 −1 −1−1 1 * 
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An emission pattern has been chosen as: H = (HAE + 1)/2 = (1 11 0 1 11 01 11 0 0 00 1* 
If F = (+,-.* are the different focal spots, 
The final received signal is: S = H * F = /+ + , + - + .+ + -+ + ,+ + . 1 
And the signal corresponding to each focal spot can be retrieved with: F = H-1 * S 
An acquisition was made using this technique, i.e. four emissions were performed 
corresponding to each line of H. The retrieved AE effect corresponding to each focal spot was 
confronted to a supplementary measure, were each focal spot was generated independently 
using the corresponding part of the array.  
Results 
Figure 6-4 shows the results obtained in the saline solution when performing the 
Hadamard emission pattern and the retrieved AE effect corresponding to each focal spot. 
When focusing with 4 simultaneous focal spots the AE effect had an amplitude of 180µV, 
down to 64µV with two extreme spots, whereas when focalizing with one spot it had 28-
48µV at the extremities and 80µV in the center. This latter difference is due to the fact that 
the extreme foci were performed with a high steering and the pressure pattern was not 
uniform between the foci. The global amplitudes and thus the SNR were improved with 
multiple foci. 
Finally the confrontation between the signals retrieved by matrix inversion or by 
independent measurement was very promising. The amplitude pattern was respected (high 
amplitude in the center and low at the extremities) with differences on the range of 5-35%. 
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Figure 6-4 : Resume of the Hadamard technique with the obtained results. 1st column: matrix 
representation of the reception signal (up) and the retrieved signal (down). 2nd column: 
schematic representation of the induced (up) and corresponding retrieved (down) focal spots. 
3rd column: received temporal signal centered on the AE effect (up), retrieved AE temporal 
signal (down). 4th column: peak-to-peak amplitude of the measured AE effect (up) and the 
retrieved AE effect (down). 5th column: comparison to the AE effect measure with the 
corresponding single focus. 
Discussion 
While the results shown with Hadamard matrix were interesting and show a potential 
way to improve the quality of the AE effect measures with an imaging array, an important 
limitation was not addressed. Regarding a cardiac application, imaging based on focalized 
beams present an insufficient temporal resolution to observe and image many transient events 
that occur in the heart. In this study an important temporal averaging was needed to observe 
the signal. However there was a very important way for improvement by designing dedicated, 
low-noise electronics. Still, 128 single emissions would be necessary to create a whole image 
with a good resolution. In order to answer to this limitation a completely new setup has been 
designed with novel Ultrafast plane-wave imaging of the current density. 
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1.3 Ultrafast Acoustoelectric Tomography 
1.3.1 Methods 
1.3.1.1 Image Formation 
Forward problem 
Figure 6-5 shows a typical acoustoelectric imaging setup. An ultrasound transducer 
and a pair of electrodes are placed onto the object to image. The emission of an ultrasound 
wave triggers the recording of highly amplified, high-frequency biopotentials. The 
biopotentials V detected by the pair of electrodes can be modelled as follows: 
2′ = 	4 567(8)9:;<=> ∆@(8).8   (3.1) 
Where K is a constant of interaction of approximately 10−9 Pa−1 in a 0.9% NaCl 
solution 267, ρ is the resistivity of the medium, ∆P is the pressure variation, and J(x) is the 
detected current density distribution, i.e., the scalar product of the current density in the 
medium and the sensitivity vector of the electrodes. When the variation in pressure is caused 
by a transducer array emitting a plane wave, ∆P(x,y,z,t) can be parametrized as a function of 
the emission angle θ and time t.  Ignoring the elevational direction z, we have: ∆P(x,y) = 
∆P(qsinθ + ctcosθ, qcosθ + ctsinθ), where q and ct indicate the direction parallel and 
perpendicular to the wavefront, respectively (Figure 6-6).  
 
Figure 6-5 : Typical Acoustoelectric Imaging experimental setup.  An ultrasound probe is 
used to create a pressure variation in a medium undergoing a current density. Electrodes are 
used to detect this variation and the amplified biopotentials can be used to reconstruct images, 
given a known sound velocity c. 
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Consider the ideal case of a Dirac delta distribution emission, i.e., that the ultrasound 
transducer can emit an infinitely short pulse (i.e., with infinite bandwidth); the acoustoelectric 
signal then becomes:  
2(A, 	) = 4 7(B sin A + -	 cos A, B cos A + -	 sin A).BGHH V(θ, t) = 4 J(q sin θ +GH-H
ct cos θ, q cos θ + ct sin θ)dqV(θ, t) = 4 J(q sin θ + ct cos θ, q cos θ + ct sin θ)dqGH-H , 
or, equivalenty, 
2(A, 	) = [7](A, -	)
= R R 7(S, T)U(S sin A +y cos A − -	).S.TGH
H
GH
H
 
where V = V’/K6 and R[J] denotes the Radon transform.  In practice, however, a finite 
bandwidth will be emitted by the ultrasound array, resulting in the convolution in the ct 
variable of the Radon Transform: 
2(A, 	) = W(-	) ∗ [7](A, -	), 
where W(ct) is the emitted waveform.  For example, a standard pulse excitation results 
in the following convolution kernel: 
W(-	) = Y %(Z[)\%(]^)\ sin _=`  , 
where n and m can be tuned within the bandwidth of the ultrasound transducer. Note 
that this convolution kernel is equivalent to a ridgelets transform 271 of the current density 
distribution. Indeed, in the previous example, setting m = n and ignoring the z dimension, this 
kernel consists of a ridgelets decomposition with parameters a = nλ, b = ct and θ.  The 
ridgelets decomposition benefits from a number of mathematical properties, such as a 
Parseval-Plancherel relationship, a reconstruction formula, sparse representation of objects 
that are smooth away from line discontinuities, and can be expressed as a composition of a 
wavelets transform and a Radon transform.  More specifically, denoting the wavelet and 
ridgelet transforms by WT[.], and RT[.] respectively, it can be shown that 
2 = [7] = W[[7]], 
 135
Inverse problem 
Both the wavelets and Radon transform have well known inversions, and, therefore, 
we have, 
7 = [W[2]]. 
In practice, however, both the emission angles and the bandwidth available will be 
limited.  Typically, emission angles will be constrained within ±20° and the bandwidth to 
50% of the central emission frequency. These limitations transform a fully sampled k-space 
into a limited-angle annulus, resulting in an axial resolution proportional to the pulse width 
and a lateral resolution approximately 3 times bigger, i.e., worse, since sin(20°) = 0.342.     
The inversion process is two-fold: first invert the wavelets transform, and then invert 
the Radon transform.  Numerous strategies exist to invert the angle-limited Radon transform.  
The most common is probably filtered back-projection, which consists in applying a ramp 
filter to the Radon projection prior to back-projection, which itself is equivalent to 
beamforming. 
 
Figure 6-6 : Ultrafast acoustoelectric imaging direct problem.  (A) In the ideal case of a Dirac 
pulse emission, the biopotentials measured correspond to the integration of the detected 
current density over an infinitely narroy wavefront, which is defined as a Radon transform 
when performed over 180°. (B) In reality, the wavefront will be constrained to a limited 
bandwidth in k-space due to the limited bandwidth of the ultrasound probe and to the limited 
emission angles that can be produced with a linear array. The different regions sampled by the 
angle-limited Radon transform R[J] and the emitted waveform W(ct) are indicated in different 
colors, along with their intersections. 
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Ideally, we would like to maximize the signal-to-noise ratio (SNR), which is notably 
low due to the weakness of the acoustoelectric effect. SNR can be improved by limiting the 
level of noise. Given that the ridgelet transform is a sparsifying basis that will represent the 
current density distribution with a small number of very large coefficients and a large number 
of small coefficients, denoising can be performed by thresholding the biopotential values 272, 
273
.  This thresholding can be carried out by simply removing ‘small’ values, but we can also 
include a priori knowledge to perform that task.  More specifically, it is beneficial to emit 
twice at the same angle but with an inverted waveform since by subtracting the resulting 
signals V+ and V-, any systemic artifact is rejected.  Additionally, since we know that both V+ 
and V- are sparse, i.e., they contain a few large values but mostly values below the noise level 
that can be eliminated without altering significantly the resulting reconstruction,  we 
conducted a normalized cross-correlation between corresponding windows in V+ and V-.  This 
results in a value close to zero in noisy regions and -1 in presence of signal, indicating which 
regions to threshold.  This approach was carried out to limit the level of noise in all the results 
shown herein. 
1.3.1.2 Experimental Setup  
Plane waves between -20 and 20 degrees were emitted using an Aixplorer system 
(Supersonic Imagine, France) with a 6-MHz linear array probe (MI < 1.9). For images of 
Figure 6-7, electrodes potentials were high-passed filtered before entering a 1-MHz 
bandwidth differential preamplifier (Lecroy, Chestnut Ridge, NY), an amplifier (Olympus 
NDT, Waltham, MA), and then averaged up to 512 times and sampled on an oscilloscope 
(Tektronix, Beaverton, OR). Currents were applied and imaged in two phantoms containing a 
0.9% NaCl solution: 1) a Tygon tube with an inner diameter of 0.87 mm, and 2) a triangular-
prism-shaped container with a base of 2 mm and a height of 5 mm.  Results of Figure 6-8 
were obtained using customized active electrodes based on an ultralow noise biopotential 
amplifier (G = 2000, AD8428, Analog instruments) with very high common-mode rejection 
ratio (140 dB) and a 3.5-MHz bandwidth. Currents were generated using a 9V battery. No 
averaging was necessary. The phantom used consisted in a 2-mm wide box containing a 
0.9%-NaCl solution. 
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1.3.2 Results 
Figure 6-7 A and B show the reconstructions using 51 projections from -20 to 20° at  
1-MHz bandwidth, of phantom 1 and 2, respectively.  Phantom 1 reveals the typical 
resolution that can be achieved using UAT, i.e., approximately 1 mm.  The signal originates 
solely from the region undergoing the current.  The oscillating signal obtained in that region is 
also consistent with theory and corresponds approximately to the impulse function of the 
system.  Phantom 2 shows that UAT can be used to reconstruct quantitatively complicated 
structures.  Indeed, one can observe that the reconstructed current density increases linearly 
from the base of the triangle to its apex, as the cross-sectional area decreases, as expected in 
theory.  Moreover, because of the band-limited nature of the image, the signal is stronger near 
variations in the image.  For example, near the upper boundary of the container, the current 
transitions from a region not undergoing any current density to a region undergoing negative 
current density, which is reflected by the blue color on the image.  Symmetrically, when the 
current density transitions from a negative value to a null value in the lower region of the 
container, the signal obtained is positive.   
 
Figure 6-7 : Ultrafast Acoustoelectric Imaging in 0.9% NaCl phantoms.  (A) Reconstruction 
of the current density inside a tygon tube. (B) Triangular-prism-shaped container.  The 
intensity of the reconstructed current density increases near the apex, as expected due to the 
reduction in the conductor cross-section.   
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Figure 6-8 : Acoustoelectric Imaging of a 2-mm wide box filled with a 0.9%-NaCl solution.  
(A) Plane wave reconstruction using 21 plane-waves between -10 and 10 degrees.  (B) 21-
focused emissions image.  (C) K-space of the reconstruction in A. 
Figure 6-8 shows a comparison of acoustoelectric images obtained using plane waves 
(Figure 6-8A) and focused emissions (Figure 6-8B).  In both cases, 21 emissions were used.  
One can observe that the image obtained using plane wave is of better quality and less 
pixelated, indicating that a better image quality can be obtained for a given number of 
emission, or, inversely, that the frame rate can be increased (as the frame rate is dictated by 
the number of emissions necessary to generate an image). Figure 6-8C shows the k-space of 
the reconstruction of Figure 6-8A, and clearly showing the cropped-annulus shape predicted 
by our reconstruction model. 
1.3.3 Discussion 
The objective of this study was to determine the feasibility of performing high frame 
rate current density imaging while preserving high spatial resolution.  We have shown that by 
using plane wave emissions, the inverse problem becomes easily tractable as it can be 
decomposed into well-known inverse problems and provides high frame rates and uniformly 
high axial and lateral resolution.  Examples provided in phantoms demonstrated the feasibility 
of the method.    
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Achieving high frame rates in acoustoelectric imaging is crucial for future applications 
as action potentials are propagating rapidly.  For example, the heart can depolarize completely 
in less than 60 ms.  To track this activation sequence, it is necessary to achieve frame rates on 
the order of hundreds of hertz. A typical approach consisting of imaging a 20-cm deep heart 
with 64 emissions leads to a frame rate of 120 Hz, or, only 7 images during the activation 
sequence, assuming no averaging is necessary. Plane wave approaches could significantly 
reduce the number of emissions needed for a given image quality, as has been shown in 
ultrasound imaging 107, therefore expanding possible applications of acoustoelectric imaging.    
Similarly to approaches based on focused emissions, UAT suffers from small signal to 
noise ratios. This issue can be addressed via improved instrumentation, as we have 
demonstrated in this study using active electrodes.  Moreover, improved sequences and signal 
processing strategies could be used to limit the influence of noise. One approach would 
consist in performing pulse compression 274 by emitting a chirp that covers the entire available 
ultrasound bandwidth. In that case, we replace the truncated wavelets transform by a 
convolution with a chirp, which can be inverted using a matched filter.  This strategy should, 
in theory, maximize the SNR without altering the imaging frame rate.  In the case of the 
inversion of the Radon transform, strategies such as compressed sensing could also be 
considered 275–277. 
Potential clinical applications of UAT are numerous as the simplicity of the required 
instrumentation makes this approach highly translational. Indeed, low frequency 
electrocardiograms (ECG) are already recorded with virtually every echocardiographic exam.  
By simply replacing the current ECG acquisition systems by high frequency amplification, 
one could detect the acoustoelectric potentials and perform UAT without modifying currently 
existing clinical protocols and with most commercially-available ultrasound scanners. 
By using an intracardiac approach, this technique could potentially provide images of 
cardiac electrical currents with an unachieved sub-millimetric resolution, which would help to 
find or diagnose arrhythmogenic or unwanted electrical pathways. 
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2 General Conclusion 
This thesis was an opportunity to take benefit from the more and more various 
possibilities ultrasound can offer in the field of medical imaging and therapy and apply them 
to a particular need: the treatment of cardiac arrhythmias. By choosing an all-ultrasound 
approach for both therapy and imaging, our collaborators and us, have developed two 
interstitial devices, an intracardiac dual-mode catheter and an ultrasound-guided-HIFU 
transesophageal endoscope, both adapted for the cardiac environment. 
More specifically during this work we have adapted and validated on the two systems 
many ultrasound imaging modalities (Ultrafast imaging, Shear-Wave Elastography, Ultrafast 
Doppler and Acousto-Electric Imaging) which have been developed at the Institut Langevin 
during recent years, in order to guide and control therapy, as well as provide new diagnostic 
possibilities. We have also participated in the development and validated the intracardiac 
device for HIFU thermal therapy to obtain finally a miniaturized all-ultrasound theranostic 
system. 
In order to achieve these goals, first, we validated the accuracy of SWE to monitor 
thermal therapies, RFA and HIFU, in-vivo in the liver, an organ that is an easier environment 
than the heart: more homogeneous and less affected by motion. The obtained results were 
very promising, giving high sensitivity and positive predictive values for ablated tissue 
detection, and confirmed the previous results on the link of thermally coagulated tissue and 
elastographic images. While this study could have impacts in cancer ablation in the liver, to 
us it showed also the robustness of the SWE technique and confirmed the pertinence to apply 
it for thermal ablation monitoring in the heart. 
Second, we implemented SWE and other imaging modalities on the intracardiac 
transducer and tested the system in-vivo. In particular we validated the feasibility of SWE to 
evaluate classical RFCA in the heart and showed the potential for other diagnostic imaging 
(e.g. the coronary detection with Ultrafast Doppler).  
Third, we implemented HIFU therapy on the same transducer to obtain a device 
capable to perform image-controlled therapy with the same aperture. Such a dual-mode 
system presents a very interesting flexibility for the procedures of ablation for atrial 
fibrillation as well as for ventricular tachycardia. Thanks to the numerous imaging and 
 141
therapeutic possibilities it offers its applications could be various in the heart as well as in 
other organs. 
Finally we participated to the development of the second heart dedicated ultrasonic 
system by implementing and validating SWE for the evaluation of HIFU ablation. For this, 
we have tested the previously developed SWE based on diverging-waves ultrafast imaging, 
with a transesophageal probe. We showed the feasibility of stiffness mapping with the system 
in-vivo on a normal beating heart and in vitro on cardiac tissues with HIFU induced lesions 
by the same probe. Beyond the scope of thermal ablation control the SWE transesophageal 
approach could be proven as a promising elastographic modality for cardiac diagnostics. 
By its applicative nature, the main tasks of this thesis were based on system 
development and the adaptation of already existing ultrasonic modalities and techniques on 
miniaturized devices, for the demanding cardiac environment. Thanks to the scientific 
knowledge, experience, enthusiasm and very rich environment within the Institut Langevin as 
well as among all the other partners the project resulted in two new and very promising 
devices to address one of the most prevalent cardiac disorder. The so far very promising 
results show a product of a very positive collaboration among several partners. By providing a 
concrete therapeutic and potentially diagnostic solution this work could help ultrasound to 
propagate and gain recognition in the medical field for cardiac but also non-cardiac 
applications. From my point of view, ultrasound is the most promising medical imaging and 
therapy modality and has still the biggest room for improvement. It was very exciting to work 
and participate to the world of these translational physics and to be a part of a chain 
connecting public research with industry and the hospital world. 
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